{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Miniscule sample of production code\n",
    "---\n",
    "This notebook is mainly used as a sandbox and to visualize results of code fragments before adding them to the production pipeline"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<br>\n",
    "<hr>\n",
    "<br>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='toc'></a>\n",
    "### Table of Contents\n",
    "[1. Convert PDFs to images](#section-1)<br>\n",
    "[2. Use PyTesseract for page segmentation](#section-2)<br>\n",
    "[3. Image preprocessing](#section-3)<br>\n",
    "[4. Text extraction using OCR](#section-4)<br>\n",
    "[5. Text segmentation using RegEx](#section-5)<br>\n",
    "<br>\n",
    "<hr>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a id='section-1'></a>\n",
    "### - Convert PDFs to images"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Loading dependencies\n",
    "from pdf2image import convert_from_path\n",
    "from pdf2image.exceptions import (\n",
    "    PDFInfoNotInstalledError,\n",
    "    PDFPageCountError,\n",
    "    PDFSyntaxError\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Start converting pdf pages into separate images\n",
    "pages = convert_from_path('../PDFs/US20190030051.pdf', dpi=600, fmt='png',\n",
    "                         output_folder='./sandbox/images/pdf_to_img')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<hr>\n",
    "<br>\n",
    "\n",
    "<a id='section-2'></a>\n",
    "\n",
    "### - Use PyTesseract for page segmentation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Loading dependencies\n",
    "try:\n",
    "    from PIL import Image\n",
    "except ImportError:\n",
    "    import Image\n",
    "import pytesseract\n",
    "import cv2\n",
    "from matplotlib import pyplot as plt\n",
    "import numpy as np\n",
    "import glob"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1080x2160 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Loop through all images in the folder\n",
    "for image in glob.glob('sandbox/images/pdf_to_img/*.png'):\n",
    "    # Read the image and get the dimensions\n",
    "    img = cv2.imread(image)\n",
    "    h, w, _ = img.shape\n",
    "\n",
    "    # Run tesseract method to get bounding boxes around recognized characters\n",
    "    boxes = pytesseract.image_to_boxes(\n",
    "        Image.open(image))\n",
    "\n",
    "    # Draw the bounding boxes on the image\n",
    "    for b in boxes.splitlines():\n",
    "        b = b.split(' ')\n",
    "        img = cv2.rectangle(img, (int(b[1]), h - int(b[2])), (int(b[3]), h - int(b[4])), (0, 255, 0), 2)\n",
    "\n",
    "    # Save image with bounding boxes\n",
    "    plt.imsave('sandbox/images/img_segmentation/' + image[27:-3] + 'png', img)\n",
    "    \n",
    "# Show page with bounding boxes\n",
    "fig = plt.figure(figsize = (15,30))\n",
    "plt.imshow(img)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1080x2160 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Loop through all images in the folder\n",
    "for image in glob.glob('sandbox/images/pdf_to_img/*.png'):\n",
    "    \n",
    "    # Read the image and get the dimensions\n",
    "    img2 = cv2.imread(image)\n",
    "    h, w, _ = img2.shape\n",
    "\n",
    "    # Run tesseract method to get bounding boxes around recognized characters\n",
    "    boxes = pytesseract.image_to_boxes(\n",
    "        Image.open(image))\n",
    "\n",
    "    # Loop through all bounding boxes\n",
    "    for b in boxes.splitlines():\n",
    "        b = b.split(' ')\n",
    "        \n",
    "        # Extract figures from a page and save them\n",
    "        images = []\n",
    "    \n",
    "        # Check for dimensions of bound box, if they exceed 800px for width and height\n",
    "        # consider the box containing a figure and crop it out\n",
    "        if (int(b[3]) - int(b[1]) > 800) and ((h - int(b[2])) - (h - int(b[4])) > 800):\n",
    "            images.append([int(b[2]), int(b[4]), int(b[1]), int(b[3])])\n",
    "            crop = img2[images[0][0]:images[0][1], images[0][2]:images[0][3]]\n",
    "            plt.imsave('./sandbox/images/figure_extraction/' + image[27:-3] + 'png', crop)\n",
    "\n",
    "# Show extracted figure\n",
    "fig2 = plt.figure(figsize = (15,30))\n",
    "plt.imshow(crop)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<hr>\n",
    "<br>\n",
    "\n",
    "<a id='section-3'></a>\n",
    "\n",
    "### - Image preprocessing"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Loading dependencies\n",
    "\n",
    "import glob\n",
    "import os\n",
    "from PIL import Image\n",
    "import cv2 as cv\n",
    "import numpy as np"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1080x2160 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Loop through all images in the folder\n",
    "for image in glob.glob('sandbox/images/pdf_to_img/*.png'):\n",
    "\n",
    "    # Apply thresholding to increase constrast of black characters\n",
    "    # and increase tesseract reading accuracy\n",
    "    img3 = cv.imread(image, 0)\n",
    "    ret, thresh1 = cv.threshold(img3, 127, 255, cv.THRESH_BINARY)\n",
    "\n",
    "    # Crop header and footer of each page and\n",
    "    # remove white borders on the sides\n",
    "    crop_img = img3[800:6300, 500:4600]\n",
    "\n",
    "    # Change color space to be compatible with the format to save\n",
    "    crop_img = cv.cvtColor(crop_img, cv.COLOR_BGR2RGB)\n",
    "\n",
    "    # Save images of the current document\n",
    "    cv.imwrite('sandbox/images/img_preprocessing/' + image[28:-3] + 'png', crop_img)\n",
    "\n",
    "# Show preprocessed image\n",
    "fig3 = plt.figure(figsize = (15,30))\n",
    "plt.imshow(crop_img)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<hr>\n",
    "<br>\n",
    "\n",
    "<a id='section-4'></a>\n",
    "\n",
    "### - Text extraction using OCR"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Loading dependencies\n",
    "import glob\n",
    "import os\n",
    "from PIL import Image\n",
    "import pytesseract"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Reading from image 12\n",
      "Reading from image 20\n",
      "Reading from image 03\n",
      "Reading from image 51\n",
      "Reading from image 60\n",
      "Reading from image 32\n",
      "Reading from image 58\n",
      "Reading from image 47\n",
      "Reading from image 50\n",
      "Reading from image 06\n",
      "Reading from image 53\n",
      "Reading from image 23\n",
      "Reading from image 35\n",
      "Reading from image 24\n",
      "Reading from image 10\n",
      "Reading from image 38\n",
      "Reading from image 72\n",
      "Reading from image 70\n",
      "Reading from image 39\n",
      "Reading from image 30\n",
      "Reading from image 36\n",
      "Reading from image 13\n",
      "Reading from image 48\n",
      "Reading from image 46\n",
      "Reading from image 31\n",
      "Reading from image 22\n",
      "Reading from image 49\n",
      "Reading from image 55\n",
      "Reading from image 16\n",
      "Reading from image 02\n",
      "Reading from image 11\n",
      "Reading from image 08\n",
      "Reading from image 61\n",
      "Reading from image 37\n",
      "Reading from image 44\n",
      "Reading from image 18\n",
      "Reading from image 54\n",
      "Reading from image 65\n",
      "Reading from image 62\n",
      "Reading from image 09\n",
      "Reading from image 27\n",
      "Reading from image 66\n",
      "Reading from image 41\n",
      "Reading from image 67\n",
      "Reading from image 34\n",
      "Reading from image 19\n",
      "Reading from image 45\n",
      "Reading from image 25\n",
      "Reading from image 15\n",
      "Reading from image 52\n",
      "Reading from image 42\n",
      "Reading from image 21\n",
      "Reading from image 68\n",
      "Reading from image 04\n",
      "Reading from image 56\n",
      "Reading from image 05\n",
      "Reading from image 14\n",
      "Reading from image 29\n",
      "Reading from image 28\n",
      "Reading from image 43\n",
      "Reading from image 71\n",
      "Reading from image 17\n",
      "Reading from image 33\n",
      "Reading from image 64\n",
      "Reading from image 01\n",
      "Reading from image 40\n",
      "Reading from image 69\n",
      "Reading from image 57\n",
      "Reading from image 59\n",
      "Reading from image 07\n",
      "Reading from image 63\n",
      "Reading from image 26\n",
      "ates\n",
      "\n",
      " \n",
      "\n",
      "pes\n",
      "\n",
      "=\n",
      "\n",
      " \n",
      "\n",
      "VAS Change vs. Placebo (mm)\n",
      "\n",
      "-12\n",
      "\n",
      "\n",
      "\n",
      ".\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "     \n",
      "\n",
      "Change in VAS Pain Score Compared to Placebo\n",
      "with Zoledronic Acid Treatment\n",
      "\n",
      "OARS! Grade 0 OARSI Grade 1-2.\n",
      "\n",
      "A A ys (Me EN[0019] In some embodiments, about 300 mg/m* to about\n",
      "600 mg/m? of zoledronic acid is administered per month,\n",
      "based upon the body surface area of the mammal.\n",
      "\n",
      "[0020] In some embodiments, about 50 mg/m? to about\n",
      "600 mg/m* of zoledronic acid is administered per month,\n",
      "based upon the body surface area of the mammal.\n",
      "\n",
      "[0021] Some embodiments include administering an\n",
      "osteoclast inhibitor, such as a bisphosphonate, including\n",
      "zoledronic acid, neridronic acid, etc. to inhibit the develop-\n",
      "ment of pain, unweighting, and edema when administered\n",
      "early such as when a precipitating event such as fracture\n",
      "occurs, wherein the precipitating event is associated with\n",
      "CRPS.\n",
      "\n",
      "[0022] Some embodiments include administering an\n",
      "osteoclast inhibitor, such as a bisphosphonate, including\n",
      "zoledronic acid, neridronic acid, etc. to reverse established\n",
      "allodynia and unweighting when administered at least 4\n",
      "weeks after a precipitating event such as fracture that is\n",
      "associated with CRPS.\n",
      "\n",
      "BRIEF DESCRIPTION OF DRAWINGS\n",
      "\n",
      "[0023] FIG. 1 1s a plot of pain compression thresholds in\n",
      "a rat model of inflammatory pain using three different doses\n",
      "of zoledronic acid. Measurements were taken at baseline\n",
      "(BL) and at various time points after dosing on the days\n",
      "indicated.\n",
      "\n",
      "[0024] FIG. 2A is a graph depicting reversal of arthritis\n",
      "pain for two different doses of zoledronic acid in a rat model\n",
      "of arthritis pain.\n",
      "\n",
      "[0025] FIG. 2B is a graph depicting pain thresholds for\n",
      "two different doses of zoledronic acid in a rat model of\n",
      "arthritis pain.\n",
      "\n",
      "[0026] FIG. 3 is a graph summarizing the results for\n",
      "vehicle and zoledronic acid treated rats in a rat model of\n",
      "complex regional pain syndrome.\n",
      "\n",
      "[0027] FIG. 4 depicts hindpaw pain thresholds for vehicle\n",
      "and zoledronic acid treated rats in a rat model of complex\n",
      "regional pain syndrome.\n",
      "\n",
      "[0028] FIG. 5 depicts weight bearing for vehicle and\n",
      "zoledronic acid treated rats in a rat model of complex\n",
      "regional pain syndrome.\n",
      "\n",
      "[0029] FIG. 6 depicts paw thickness change for vehicle\n",
      "and zoledronic acid treated rats in a rat model of complex\n",
      "regional pain syndrome.\n",
      "\n",
      "[0030] FIG. 7 depicts the aqueous solubility of disodium\n",
      "zoledronate tetrahydrate as compared to the diacid form of\n",
      "zoledronic acid.\n",
      "\n",
      "[0031] FIG. 8 depicts the plasma concentration of zole-\n",
      "dronic acid in dogs over time after administration of 150 mg\n",
      "of the disodium salt form of zoledronic acid and the diacid\n",
      "form of zoledronic acid.\n",
      "\n",
      "[0032] FIG. 9 depicts the compressibility of dosage forms\n",
      "containing zoledronic acid in the disodium salt form as\n",
      "compared to the diacid form.\n",
      "\n",
      "[0033] FIG. 10 depicts the change in VAS pain score\n",
      "compared to placebo at three months with zoledronic acid\n",
      "treatment in patients with osteoarthritis of the knee, bone\n",
      "marrow lesions, and different degrees of joint space narrow-\n",
      "ing.\n",
      "\n",
      "[0034] FIG. 11 depicts the change in VAS pain score\n",
      "compared to baseline at three months with zoledronic acid\n",
      "treatment in patients with osteoarthritis of the knee, bone\n",
      "marrow lesions, and different degrees of joint space narrow-\n",
      "ing.\n",
      "\n",
      "[0035] FIG. 12 depicts the change in VAS pain score\n",
      "compared to placebo at three months with zoledronic acid\n",
      "treatment in different subgroups of patients with osteoar-\n",
      "thritis of the knee and bone marrow lesions.\n",
      "\n",
      "[0036] FIG. 13 depicts the change in BML lesion size\n",
      "compared to placebo at six months with zoledronic acid\n",
      "treatment in patients with osteoarthritis of the knee, bone\n",
      "marrow lesions, and different degrees of joint space narrow-\n",
      "ing.\n",
      "\n",
      "[0037] FIG. 14 depicts hindpaw pain thresholds for\n",
      "vehicle and zoledronic acid treated rats in a rat model of\n",
      "complex regional pain syndrome.\n",
      "\n",
      "[0038] FIG. 15 depicts weight bearing for vehicle and\n",
      "zoledronic acid treated rats in a rat model of complex\n",
      "regional pain syndrome.\n",
      "\n",
      "[0039] FIG. 16 depicts hindpaw pain thresholds for rats\n",
      "administered zoledronic acid at the time of fracture as\n",
      "compared to rats administered zoledronic acid four weeks\n",
      "after fracture.\n",
      "\n",
      "DETAILED DESCRIPTION\n",
      "\n",
      "[0040] Inhibitors of osteoclast activity include bisphos-\n",
      "phonate compounds such as pamidronate or pamidronic\n",
      "acid, neridronate or neridronic acid, olpadronate or olpad-\n",
      "ronic acid, alendronate or alendronic acid, incadronate or\n",
      "incadronic acid, ibandronate or ibandronic acid, risedronate\n",
      "or risedronic acid, cimadronate or cimadronic acid, zoledro-\n",
      "nate or zoledronic acid, etidronate or etidronic acid, clodro-\n",
      "nate or clodronic acid, tiludronate or tiludronic acid, etc.\n",
      "\n",
      "[0041] RANK/RANKL antagonists may be inhibitors of\n",
      "osteoclast activity. RANK/RANKL antagonists include but\n",
      "are not limited to OPG (osteoprotegerin) or a variant thereof,\n",
      "an anti-RANKL antibody such as denosumab, a monoclonal\n",
      "anti-RANKL antibody, a small interfering RNA, a micro-\n",
      "RNA, a precursor molecule, a nbozyme, an antisense\n",
      "nucleic acid, or an aptamer targeting RANKL. Antibodies\n",
      "such as AB-25E9, small molecules, small interfering RNAs,\n",
      "microRNAs, precursor molecules, ribozymes, antisense\n",
      "nucleic acids, or aptamers that target the cell-surface protein\n",
      "Siglec-15 may be osteoclast inhibitors.\n",
      "\n",
      "[0042] Some Brutons tyrosine kinase (BTK) inhibitors\n",
      "may be inhibitors of osteoclast activity. BTK inhibitors can\n",
      "include ONO-4059; ibrutinib; Benzo[b]thiophene-2-carbox-\n",
      "amide, N-[3-[6-[[4-[(2R)-1,4-dimethyl-3-oxo-2-piperazi-\n",
      "nyl|phenyl]amino]-4,5-dihydro-4-methyl-5-oxo-2-pyrazi-\n",
      "nyl]-2-methylpheny] |-4,5,6,7-tetrahydro- (GDC-0834);\n",
      "RN-486; Benzamide, 4-(1,1-dimethylethyl)-N-[3-[8-(phe-\n",
      "nylamino)imidazo[ 1,2-a]pyrazin-6-yl|pheny1]-(CGI-560);\n",
      "Benzamide, N-[3-[4,5-dihydro-4-methy1-6-[[4-(4-morpholi-\n",
      "nylcarbonyl)pheny]l amino |-5-oxo-2-pyraziny1]-2-methyl-\n",
      "phenyl ]-4-(1,1-dimethylethyl)- (CGI-1746CAS Registry\n",
      "No. 910232-84-7); HM-71224; 2-Propenamide, N-[3-[[5-\n",
      "fluoro-2-[[4-(2-methoxyethoxy) phenyl ]amino]-4-pyrimidi-\n",
      "nylJamino|phenyl]- (CC-292, CAS Registry No. 1202757-\n",
      "89-8); 2-Pyridinecarboxamide, 4-[4-[[5-fluoro-4-[[3-[(1-\n",
      "oxo-2-propen-1-yl)amino]phenyl amino |-2-pyrimidiny]]\n",
      "amino|phenoxy |-N-methyl- (CNX-774, CAS Registry No.\n",
      "1202759-32-7), AVL-101 (CAS Registry No. 1552307-34-\n",
      "2), AVL-291 (CAS Registry No. 1552307-35-3), and AVL-\n",
      "292 (CAS Registry No. 1552307-36-4), [N-(2-chloro-6-\n",
      "methylpheny1)-2-(6-(4-(2-hydroxyethyl) piperazin-1-yl)-2-\n",
      "methylpyrimidin-4-ylamino )thiazole-5-carboxamide]30% *\n",
      "\n",
      "20% 4\n",
      "\n",
      "% Reversal of Arthritis Pain\n",
      "\n",
      "10% 4\n",
      "\n",
      " \n",
      "\n",
      "ZO led ronic\n",
      "acid 360\n",
      "\n",
      "FIG. 2A-continued\n",
      "\n",
      "PO;\n",
      "PO3;H\n",
      "\n",
      "Rohe\n",
      "\n",
      "OH\n",
      "HO\n",
      "\n",
      "aa\n",
      "\n",
      "HOP\n",
      "\n",
      "Na salt of Compound 2\n",
      "\n",
      "1,3-Bis(2-methoxy-2-oxoethy]l)-1H-imidazol-3-1um\n",
      "chloride (9)\n",
      "\n",
      "[0303] Methyl chloroacetate (29.8 mL, 338.6 mmol, 2.0\n",
      "eq) was added drop-wise to 1-(trimethylsilyl)-1H-imidazole\n",
      "(8; 25.0 mL, 169.3 mmol). The mixture was heated at 60 C.\n",
      "for 24 hours. The mixture was cooled to room temperature,\n",
      "washed with Et,O (3x500 mL) and dried in vacuo yielding\n",
      "9 (41.97 g, 168.8 mmol, 99.7%) as a white solid.\n",
      "\n",
      "1,3-Bis(carboxymethy1)1H-imidazol-3-1um chloride\n",
      "(10)\n",
      "\n",
      "[0304] To 1,3-bis(2-methoxy-2-oxoethyl)-1H-imidazol-3-\n",
      "tum chloride (9; 41.00 g, 164.88 mmol, 1 eq.) was added\n",
      "37% aq. HCI (30.03 mL, 362.74 mmol, 2.2 eq.). The mixture\n",
      "was stirred under reflux for 0.5 hour. The mixture was\n",
      "concentrated and the remaining solid was washed with\n",
      "acetone (2x200 mL) and Et,O (3x200 mL). Drying in vacuo\n",
      "gave 10 (31.89 g, 144.55 mmol, 87.7%) as a white solid.\n",
      "[0305] Compound 1:\n",
      "\n",
      "[0306] Compound 10 is reacted with an equimolar amount\n",
      "of phosphorous acid, followed by an equimolar amount of\n",
      "phosphorous trichloride, and an excess of water to form\n",
      "Compound 1, which is precipitated from ethanol.\n",
      "\n",
      "[0307] Compound 2:\n",
      "\n",
      "[0308] 1,3-Bis(carboxymethyl)-1H-imidazol-3-1um_ chlo-\n",
      "ride (10, 2.00 g, 9 mmol, 1.0 eq) and H3;PO, (7.37 g, 90\n",
      "mmol, 10 eq) were dissolved in toluene (10 mL) and heated\n",
      "to 70 C. The reaction mixture was stirred at this tempera-\n",
      "ture for 20 min before PCI, (16 mL, 180 mmol, 20 eq) was\n",
      "added within 30 min. The reaction mixture was then heated\n",
      "to 95 C. and stirred at this temperature for 2 h. Then, aq.\n",
      "HCl (30 mL, 37% HCl and 5 mL H,O) was added. The\n",
      "reaction mixture was heated to 100 C. and stirred at this\n",
      "temperature for 7 h, then stirred at room temperature for 2\n",
      "days and filtered. The filtrate was cooled in an ice bath and\n",
      "added within 45 min to absolute EtOH (90 mL). The\n",
      "resulting turbid solution was stirred for 1 h at room tem-\n",
      "perature before the solid was filtered off. The filter cake\n",
      "(Compound 2) was isolated and analyzed by 2D-NMR\n",
      "spectroscopy and mass spectrometry (m/z=477). The filtrate\n",
      "was concentrated in vacuo to give a residue. This residue\n",
      "(500 mg) was treated with ag. NaOH (150 mg in 3.5 mL of\n",
      "H,O) and EtOH (7 mL). After standing overnight the liquid\n",
      "was decanted and the resulting solid (Na salt of Compound\n",
      "2) was obtained and analyzed by NMR and mass spectrom-\n",
      "etry (m/z=477).\n",
      "\n",
      "[0309] The following embodiments are specifically con-\n",
      "templated:\n",
      "\n",
      "Embodiment 1\n",
      "[0310] A method of relieving inflammatory pain compris-\n",
      "\n",
      "ing administering an oral dosage form containing zoledronic\n",
      "\n",
      "Na*\n",
      "\n",
      "NaOH\n",
      "HO\n",
      "\n",
      "Compound 2\n",
      "\n",
      "acid to a mammal in need thereof, wherein the mammal\n",
      "receives a total monthly dose of zoledronic acid that is about\n",
      "800 mg/m? or less based upon the body surface area of the\n",
      "mammal.\n",
      "\n",
      "Embodiment 2\n",
      "\n",
      "[0311] The method of embodiment 1, wherein the mam-\n",
      "mal is a human being that receives a total monthly dose of\n",
      "zoledronic acid that is about 30 mg/m? to about 700 mg/m.\n",
      "\n",
      "Embodiment 3\n",
      "\n",
      "[0312] The method of embodiment 2, wherein the total\n",
      "monthly dose is administered in 4 or 5 weekly doses.\n",
      "\n",
      "Embodiment 4\n",
      "\n",
      "[0313] The method of embodiment 2, wherein the total\n",
      "monthly dose is administered in 28 to 31 daily doses.\n",
      "\n",
      "Embodiment 5\n",
      "[0314] The method of embodiment 2, wherein the total\n",
      "\n",
      "monthly dose is administered in 5 to 10 individual doses\n",
      "during the month.\n",
      "\n",
      "Embodiment 6\n",
      "\n",
      "[0315] The method of embodiment 1, wherein the mam-\n",
      "mal is a human being that receives a total weekly dose of\n",
      "zoledronic acid that is about 10 mg to about 300 mg.\n",
      "\n",
      "Embodiment 7\n",
      "\n",
      "[0316] The method of embodiment 6, wherein the total\n",
      "weekly dose is a single dose, administered once a week.\n",
      "\n",
      "Embodiment 8\n",
      "\n",
      "[0317] The method of embodiment 6, wherein the total\n",
      "weekly dose is administered in 2 to 7 individual doses during\n",
      "the week.\n",
      "\n",
      "Embodiment 9\n",
      "\n",
      "[0318] The method of embodiment 1, wherein the mam-\n",
      "mal is a human being that receives a total weekly dose of\n",
      "zoledronic acid that is about 10 mg to about 150 mg.\n",
      "\n",
      "Embodiment 10\n",
      "\n",
      "[0319] The method of any preceding embodiment,\n",
      "wherein the mammal experiences significant pain relief\n",
      "more than 3 hours after administration of the dosage form.\n",
      "\n",
      "Embodiment 11\n",
      "\n",
      "[0320] The method of embodiment 10, wherein the mam-\n",
      "mal experiences significant pain relief during at least a partEmbodiment 178\n",
      "\n",
      "[0494] The method of any one of embodiments 167-170,\n",
      "wherein the inhibitor of osteoclast activity is or comprises\n",
      "risedronic acid.\n",
      "\n",
      "Embodiment 179\n",
      "\n",
      "[0495] The method of any one of embodiments 167-178,\n",
      "wherein the inhibitor of osteoclast activity is administered\n",
      "orally.\n",
      "\n",
      "Embodiment 180\n",
      "\n",
      "[0496] The method of any one of embodiments 167-178,\n",
      "wherein the inhibitor of osteoclast activity is administered\n",
      "intravenously.\n",
      "\n",
      "Embodiment 181\n",
      "\n",
      "[0497] The method of any one of embodiments 167-180,\n",
      "wherein the patient experiences a reduction in bone marrow\n",
      "lesion size that is at least about 100% greater than a\n",
      "reduction in bone marrow lesion size achieved with a\n",
      "placebo.\n",
      "\n",
      "Embodiment 182\n",
      "\n",
      "[0498] The method of any one of embodiments 167-180,\n",
      "wherein the patient experiences a reduction in bone marrow\n",
      "lesion size that is at least about 150% greater than a\n",
      "reduction in bone marrow lesion size achieved with a\n",
      "placebo.\n",
      "\n",
      "Embodiment 183\n",
      "\n",
      "[0499] The method of any one of embodiments 167-182,\n",
      "wherein the inhibitor of osteoclast activity is administered at\n",
      "least twice over a period of at least four weeks.\n",
      "\n",
      "Embodiment 184\n",
      "\n",
      "[0500] The method of any one of embodiments 167-183,\n",
      "wherein the inhibitor of osteoclast activity is administered\n",
      "once weekly for a period of six weeks.\n",
      "\n",
      "Embodiment 185\n",
      "\n",
      "[0501] The method of any one of embodiments 167-184,\n",
      "wherein the inhibitor of osteoclast activity comprises zole-\n",
      "dronic acid, and the weekly dose is between about 25 mg and\n",
      "about 75 mg.\n",
      "\n",
      "Embodiment 186\n",
      "\n",
      "[0502] A method of treating knee pain comprising: select-\n",
      "ing a patient having knee pain and OARSI grade 0 of joint\n",
      "space narrowing, and administering an inhibitor of osteo-\n",
      "clast activity to the patient for the treatment of the knee pain.\n",
      "\n",
      "Embodiment 187\n",
      "\n",
      "[0503] The method of embodiment 186, wherein the\n",
      "inhibitor of osteoclast activity is administered at least twice.\n",
      "\n",
      "Embodiment 188\n",
      "\n",
      "[0504] The method of any one of embodiments 186-187,\n",
      "wherein the inhibitor of osteoclast activity is administered\n",
      "about every three months, or more frequently.\n",
      "\n",
      "Embodiment 189\n",
      "\n",
      "[0505] The method of any one of embodiments 186-188,\n",
      "wherein the inhibitor of osteoclast activity comprises a\n",
      "nitrogen-containing bisphosphonate.\n",
      "\n",
      "Embodiment 190\n",
      "\n",
      "[0506] The method of any one of embodiments 186-189,\n",
      "wherein the patient experiences pain relief three months\n",
      "after administration of the inhibitor of osteoclast activity.\n",
      "\n",
      "Embodiment 191\n",
      "\n",
      "[0507] The method of any one of embodiments 186-190,\n",
      "wherein the inhibitor of osteoclast activity is or comprises\n",
      "zoledronic acid.\n",
      "\n",
      "Embodiment 192\n",
      "\n",
      "[0508] The method of any one of embodiments 186-190,\n",
      "wherein the inhibitor of osteoclast activity is or comprises\n",
      "pamidronic acid.\n",
      "\n",
      "Embodiment 193\n",
      "\n",
      "[0509] The method of any one of embodiments 186-190,\n",
      "wherein the inhibitor of osteoclast activity is or comprises\n",
      "neridronic acid.\n",
      "\n",
      "Embodiment 194\n",
      "\n",
      "[0510] The method of any one of embodiments 186-190,\n",
      "wherein the inhibitor of osteoclast activity is or comprises\n",
      "olpadronic acid.\n",
      "\n",
      "Embodiment 195\n",
      "\n",
      "[0511] The method of any one of embodiments 186-190,\n",
      "wherein the inhibitor of osteoclast activity is or comprises\n",
      "alendronic acid.\n",
      "\n",
      "Embodiment 196\n",
      "\n",
      "[0512] The method of any one of embodiments 186-190,\n",
      "wherein the inhibitor of osteoclast activity is or comprises\n",
      "incadronic acid.\n",
      "\n",
      "Embodiment 197\n",
      "\n",
      "[0513] The method of any one of embodiments 186-190,\n",
      "wherein the inhibitor of osteoclast activity is or comprises\n",
      "ibandronic acid.\n",
      "\n",
      "Embodiment 198\n",
      "\n",
      "[0514] The method of any one of embodiments 186-190,\n",
      "wherein the inhibitor of osteoclast activity is or comprises\n",
      "risedronic acid.\n",
      "\n",
      "Embodiment 199\n",
      "\n",
      "[0515] The method of any one of embodiments 186-198,\n",
      "wherein the patient experiences a reduction in pain inten-\n",
      "sitywhen using a 100 mm visual analog scaleof at least\n",
      "about 20.\n",
      "\n",
      "Embodiment 200\n",
      "\n",
      "[0516] A method of treating a bone marrow lesion of the\n",
      "knee comprising: selecting a patient having a bone marrowfactor of about 10 to about 30, about 10 to about 20, about\n",
      "10 to about 15, about 12 to about 15 or 16, about 15 to about\n",
      "20, about 14, about 12, about 15, or any 24 hour sustained\n",
      "plasma level factor in a range bounded by, or between, any\n",
      "of these values, for the particular species of mammal.\n",
      "\n",
      "[0152] An oral dosage form comprising zoledronic acid\n",
      "having a dose of zoledronic acid and a configuration suitable\n",
      "for a particular species of mammal may be configured so that\n",
      "the zoledronic acid has a 36 hour sustained plasma level\n",
      "factor of about 6 to about 20, about 8 to about 15, about 9\n",
      "to about 12 or 13, about 8 to about 10, about 11 to about 13,\n",
      "about 9, about 13, or any 24 hour sustained plasma level\n",
      "factor in a range bounded by, or between, any of these\n",
      "values, for the particular species of mammal.\n",
      "\n",
      "[0153] An oral dosage form comprising zoledronic acid\n",
      "having a dose of zoledronic acid and a configuration suitable\n",
      "for a particular species of mammal may be configured so that\n",
      "the zoledronic acid has a 48 hour sustained plasma level\n",
      "factor of about 5 to about 20, about 6 to about 15, about 7\n",
      "or 8 to about 12 or 13, about 8 to about 10, about 11 to about\n",
      "13, about 8, about 12, or any 48 hour sustained plasma level\n",
      "factor in a range bounded by, or between, any of these\n",
      "values, for the particular species of mammal.\n",
      "\n",
      "[0154] An oral dosage form comprising zoledronic acid\n",
      "having a dose of zoledronic acid and a configuration suitable\n",
      "for a particular species of mammal may be configured so that\n",
      "the zoledronic acid has a 72 hour sustained plasma level\n",
      "factor of about 4 to about 20, about 5 to about 10, about 5\n",
      "or 6 to about 10 or 11, about 5 to about 6, about 9 to about\n",
      "10, about 6, about 10, or any 72 hour sustained plasma level\n",
      "factor in a range bounded by, or between, any of these\n",
      "values, for the particular species of mammal.\n",
      "\n",
      "[0155] An oral dosage form comprising zoledronic acid\n",
      "having a dose of zoledronic acid and a configuration suitable\n",
      "for a particular species of mammal may be configured so that\n",
      "the particular species of mammal has a plasma concentration\n",
      "of zoledronic acid at 12 hours that is about 0.5 ng/mL to\n",
      "about 5 ng/mL, about 1 ng/mL to about 3 ng/mL, about 1\n",
      "ng/mL to about 2 ng/mL, about 2 ng/mL to about 3 ng/mL,\n",
      "about 3 ng/mL to about 4 ng/mL, about 1.2 ng/mL, about 2.6\n",
      "ng/mL, about 3.2 ng/mL, or any plasma concentration in a\n",
      "range bounded by, or between, any of these values.\n",
      "\n",
      "[0156] An oral dosage form comprising zoledronic acid\n",
      "having a dose of zoledronic acid and a configuration suitable\n",
      "for a particular species of mammal may be configured so that\n",
      "the particular species of mammal has a plasma concentration\n",
      "of zoledronic acid at 24 hours that is about 0.2 ng/mL to\n",
      "about 2 ng/mL, about 0.5 ng/mL to about 1.5 ng/mL, about\n",
      "0.5 ng/mL to about 1 ng/mL, about 1 ng/mL to about 1.5\n",
      "ng/mL, about 0.5 ng/mL, about 1.0 ng/mL, about 1.4 ng/mL,\n",
      "or any plasma concentration in a range bounded by, or\n",
      "between, any of these values.\n",
      "\n",
      "[0157] An oral dosage form comprising zoledronic acid\n",
      "having a dose of zoledronic acid and a configuration suitable\n",
      "for a particular species of mammal may be configured so that\n",
      "the particular species of mammal has a plasma concentration\n",
      "of zoledronic acid at 36 hours that is about 0.1 ng/mL to\n",
      "about 2 ng/mL, about 0.2 ng/mL to about 1.5 ng/mL, about\n",
      "0.2 ng/mL to about 0.5 ng/mL, about 0.5 ng/mL to about 1\n",
      "ng/mL, about 1 ng/mL to about 1.3 ng/mL, about 0.3 ng/mL,\n",
      "about 0.8 ng/mL, about 1.1 ng/mL, or any plasma concen-\n",
      "tration in a range bounded by, or between, any of these\n",
      "values.\n",
      "\n",
      "[0158] An oral dosage form comprising zoledronic acid\n",
      "having a dose of zoledronic acid and a configuration suitable\n",
      "for a particular species of mammal may be configured so that\n",
      "the particular species of mammal has a plasma concentration\n",
      "of zoledronic acid at 48 hours that is about 0.1 ng/mL to\n",
      "about 2 ng/mL, about 0.2 ng/mL to about 1.5 ng/mL, about\n",
      "0.2 ng/mL to about 0.5 ng/mL, about 0.5 ng/mL to about 0.9\n",
      "ng/mL, about 0.9 ng/mL to about 1.3 ng/mL, about 0.3\n",
      "ng/mL, about 0.7 ng/mL, about 1.1 ng/mL, or any plasma\n",
      "concentration in a range bounded by, or between, any of\n",
      "these values.\n",
      "\n",
      "[0159] An oral dosage form comprising zoledronic acid\n",
      "having a dose of zoledronic acid and a configuration suitable\n",
      "for a particular species of mammal may be configured so that\n",
      "the particular species of mammal has a plasma concentration\n",
      "of zoledronic acid at 72 hours that is about 0.2 ng/mL to\n",
      "about 1 ng/mL, about 0.2 ng/mL to about 1.5 ng/mL, about\n",
      "0.1 ng/mL to about 0.3 ng/mL, about 0.3 ng/mL to about 0.6\n",
      "ng/mL, about 0.6 ng/mL to about 1 ng/mL, about 0.2 ng/mL,\n",
      "about 0.5 ng/mL, about 0.9 ng/mL, or any plasma concen-\n",
      "tration in a range bounded by, or between, any of these\n",
      "values.\n",
      "\n",
      "[0160] An oral dosage form comprising zoledronic acid\n",
      "having a dose of zoledronic acid and a configuration suitable\n",
      "for a particular species of mammal may be configured so that\n",
      "the elimination half-life of zoledronic acid in the particular\n",
      "species of mammal is about 30 hours to about 100 hours,\n",
      "about 40 hours to about 60 hours, about 40 hours to about\n",
      "50 hours, about 50 hours to about 60 hours, about 42 hours,\n",
      "about 51 hours, about 59 hours, or any half-life in a range\n",
      "bounded by, or between, any of these values.\n",
      "\n",
      "[0161] As used herein, the elimination half-life refers to\n",
      "the apparent first-order terminal plasma elimination half-\n",
      "life, obtained by non-compartmental analysis using Win-\n",
      "Nonlin. A terminal plasma elimination half-life is the time\n",
      "required to reduce the plasma concentration to half after\n",
      "reaching pseudo-equilibrium, and not the time required to\n",
      "eliminate half the administered dose. For orally adminis-\n",
      "tered drugs, terminal plasma elimination half-life can be\n",
      "affected by absorption of the drug, as well as plasma\n",
      "clearance and extent of distribution.\n",
      "\n",
      "[0162] In some embodiments, the disodium salt form of\n",
      "zoledronic acid provides an enhancement to bioavailability,\n",
      "as compared to the diacid form of zoledronic acid, which\n",
      "adds to any enhancement to bioavailability provided by any\n",
      "bioavailability-enhancing agents in the dosage form. In\n",
      "some embodiments, the disodium salt form of zoledronic\n",
      "acid provides an enhancement to bioavailability, as com-\n",
      "pared to the diacid form of zoledronic acid, which is greater\n",
      "than any enhancement to bioavailability provided by any\n",
      "bioavailability-enhancing agents in the dosage form. In\n",
      "some embodiments, the disodium salt form of zoledronic\n",
      "acid may be administered in a dosage form that is substan-\n",
      "tially free of bioavailability-enhancing agents.\n",
      "\n",
      "[0163] The C-terminal telopeptide (CTX) is one of the\n",
      "products from type I collagen degradation by osteoclasts\n",
      "during bone resorption. Thus, CTX serum levels may be\n",
      "used as a biomarker to indicate and monitor bone break-\n",
      "down, resorption, and loss. In some embodiments, zole-\n",
      "dronic acid and other bisphosphonates may be used to\n",
      "inhibit osteoclast activity and/or lower CTX serum levels,\n",
      "for example, by at least about 5%, at least about 10%, at least\n",
      "about 15%, at least about 20%, at least about 25%, at least\n",
      "about 30%, at least about 35%, at least about 40%, at leastconcentration curve of zoledronic acid of about 20 ng-h/mL\n",
      "to about 700 ng-h/mL to a human being to which the dosage\n",
      "form is administered.\n",
      "\n",
      "Embodiment 141\n",
      "\n",
      "[0453] The dosage form of embodiment 138, wherein the\n",
      "dosage form contains an amount of zoledronic acid in the\n",
      "disodium salt form that provides an area under the plasma\n",
      "concentration curve of zoledronic acid of about 4 ng-h/mL\n",
      "to about 100 ng-h/mL to a human being to which the dosage\n",
      "form is administered.\n",
      "\n",
      "Embodiment 142\n",
      "\n",
      "[0454] A dosage form comprising zoledronic acid in the\n",
      "disodium salt form,\n",
      "\n",
      "[0455] wherein the disodium salt form is present in a\n",
      "lower molar amount than would be present if the zoledronic\n",
      "acid were in the diacid form; and\n",
      "\n",
      "[0456] wherein the zoledronic acid in the disodium salt\n",
      "form has an improved bioavailability as compared to the\n",
      "zoledronic acid in the diacid form to the extent that the lower\n",
      "molar amount of the disodium salt in the dosage form does\n",
      "not reduce the amount of zoledronic acid delivered to the\n",
      "plasma of a mammal.\n",
      "\n",
      "Embodiment 143\n",
      "\n",
      "[0457] The dosage form of embodiment 137, 138, 139,\n",
      "140, 141, or 142, wherein the dosage form 1s a solid.\n",
      "\n",
      "Embodiment 144\n",
      "\n",
      "[0458] The dosage form of embodiment 142 or 143,\n",
      "wherein the bioavailability of zoledronic acid in the diso-\n",
      "dium salt form is improved by at least about 10% as\n",
      "compared to an otherwise identical dosage form containing\n",
      "zoledronic acid in the diacid form.\n",
      "\n",
      "Embodiment 145\n",
      "\n",
      "[0459] The dosage form of embodiment 142, 143, or 144,\n",
      "containing at least about 20 mole % less of the disodium salt\n",
      "form as compared to the amount of the zoledronic acid in the\n",
      "diacid form that would be present if the zoledronic acid were\n",
      "in the diacid form.\n",
      "\n",
      "Embodiment 146\n",
      "\n",
      "[0460] The dosage form of embodiment 142, wherein the\n",
      "disodium salt form is present in an amount, on a molar basis,\n",
      "that has a value of about 0.9nd to about 1.1 nd, wherein:\n",
      "\n",
      "ng-(b/ba)(Na)\n",
      "\n",
      "wherein b, is the bioavailability of the diacid form, b, is the\n",
      "bioavailability of the disodium salt form, and n, is the\n",
      "number of moles of the diacid form that would be present if\n",
      "the zoledronic acid were in the diacid form.\n",
      "\n",
      "Embodiment 147\n",
      "\n",
      "[0461] The dosage form of embodiment 146, wherein the\n",
      "disodium salt is administered in an amount that has a value\n",
      "of about n,,.\n",
      "\n",
      "Embodiment 148\n",
      "\n",
      "[0462] The method of any of embodiments 1-39, 62-77,\n",
      "and 120-136, wherein:\n",
      "\n",
      "[0463] only a single oral dosage form is administered; or\n",
      "[0464] a first oral dosage form is administered, and a\n",
      "second oral dosage form is administered after the first oral\n",
      "dosage form, wherein the second oral dosage form is admin-\n",
      "istered before the maximum pain relieving effect of the first\n",
      "oral dosage form is achieved, or the second oral dosage form\n",
      "is administered before an observable pain relieving effect is\n",
      "achieved.\n",
      "\n",
      "Embodiment 149\n",
      "\n",
      "[0465] The method of embodiment 148, wherein the sec-\n",
      "ond oral dosage form is administered before an observable\n",
      "pain relieving effect is achieved.\n",
      "\n",
      "Embodiment 150\n",
      "\n",
      "[0466] The method of any of embodiments 1-39, 62-77,\n",
      "and 120-132, wherein a first dosage form is administered,\n",
      "followed by administration of a second dosage form,\n",
      "wherein the second dosage form is administered after the\n",
      "maximum pain relieving effect of the first oral dosage form\n",
      "is achieved, and the second oral dosage form is administered\n",
      "while a pain relieving effect from the first oral dosage form\n",
      "is observable.\n",
      "\n",
      "Embodiment 151\n",
      "\n",
      "[0467] The method of embodiment 148, 149, or 150,\n",
      "wherein the second oral dosage form is administered about\n",
      "24 hours to about 28 days after the first oral dosage form is\n",
      "administered.\n",
      "\n",
      "Embodiment 152\n",
      "\n",
      "[0468] The method of any of embodiments 20-39, wherein\n",
      "the human being is about 30 years old to about 75 years old.\n",
      "\n",
      "Embodiment 153\n",
      "\n",
      "[0469] The method of any of embodiments 20-39, wherein\n",
      "the human being is about 1 year old to about 16 years old.\n",
      "\n",
      "Embodiment 154\n",
      "\n",
      "[0470] The method of any of embodiments 20-39, wherein\n",
      "the human being is about 80 years old to about 95 years old.\n",
      "\n",
      "Embodiment 155\n",
      "\n",
      "[0471] The method of any of embodiments 20-39, wherein\n",
      "the human being has suffered from the arthritis for at least\n",
      "2 months.\n",
      "\n",
      "Embodiment 156\n",
      "\n",
      "[0472] The method of any of embodiments 20-39, wherein\n",
      "the arthritis affects, a knee, an elbow, a wrist, a shoulder, or\n",
      "a hip.\n",
      "\n",
      "Embodiment 157\n",
      "\n",
      "[0473] The method of any of embodiments 1-44, 62-133,\n",
      "and 144-156, wherein the mammal or human being to whichTABLE 3\n",
      "\n",
      "Change in VAS Pain Scores at Three\n",
      "Months by OARSI Grade (mm)\n",
      "\n",
      "OARSI Grade 0 OARSI Grades 1-2\n",
      "\n",
      "Zoledronic Acid -24.6 -13.2\n",
      "\n",
      "Placebo -9.6 -12.9\n",
      "Difference from Placebo -15.0 -0.28\n",
      "[0281] With zoledronic acid treatment, pain was reduced\n",
      "\n",
      "significantly as compared to placebo in patients with base-\n",
      "line VAS pain intensity scores of 50 mm or greater, but not\n",
      "in patients with baseline VAS scores less than 50 mm. As\n",
      "shown in Table 4, average VAS scores were reduced by 9\n",
      "mm as compared to placebo in the patients with baseline\n",
      "VAS 250 mm, but only by 0.6 as compared to placebo in\n",
      "patients with baseline VAS <50 mm.\n",
      "\n",
      "TABLE 4\n",
      "\n",
      "Change in VAS Pain Scores at Three\n",
      "Months by Baseline VAS (mm)\n",
      "\n",
      "Baseline Baseline\n",
      "VAS = 50 mm VAS < 50 mm\n",
      "Zoledronic Acid 26.2 -7.3\n",
      "Placebo -17.2 -6.7\n",
      "Difference from Placebo -9.0 -0.6\n",
      "\n",
      "[0282] As summarized in Table 5 and illustrated in FIG.\n",
      "12, pain reduction was greater in patients with baseline VAS\n",
      ">50 mm, greater still in patients with OARSI Grade 0 joint\n",
      "space narrowing, and greatest in patients with both baseline\n",
      "VAS 250 mm and OARSI Grade 0 joint space narrowing.\n",
      "\n",
      "TABLE 5\n",
      "Pain Reduction Compared to Placebo at Three Months (mm)\n",
      "VAS Change\n",
      "All patients -4.8\n",
      "Baseline VAS = 50 mm -9.0\n",
      "OARSI Grade 0 -15.0\n",
      "Baseline VAS = 50 mm + OARSI Grade 0 -19.4\n",
      "\n",
      "[0283] BMLs were evaluated using proton density-\n",
      "weighted fat saturation MR images. BMLs were scored\n",
      "using Osiris software (University of Geneva, Geneva, Swit-\n",
      "zerland). The maximum size was measured in mm* using\n",
      "software cursors applied to the greatest area of each lesion.\n",
      "The lesion with the highest score was used if more than one\n",
      "was present at the same site. Each patient was given a BML\n",
      "score (mm7) at each of the four sites (medial tibial, medial\n",
      "femoral, lateral tibial, and lateral femoral sites) and these\n",
      "were summed to create a total BML score (mm7*). The\n",
      "change 1n the total area of BMLs from baseline to 6 months\n",
      "was calculated.\n",
      "\n",
      "[0284] The size of BMLs was reduced with zoledronic\n",
      "acid treatment. As shown in FIG. 13 and Table 6A, average\n",
      "BML area decreased by approximately 190 mm? as com-\n",
      "pared to placebo in the OARSI Grade 0 group, but only by\n",
      "approximately 33 mm? as compared to placebo in patients\n",
      "with OARSI Grades 1-2.\n",
      "\n",
      "TABLE 6A\n",
      "Change in BML Size (mm?)\n",
      "\n",
      "OARSI Grade 0 OARSI Grades 1-2\n",
      "\n",
      "Zoledronic Acid 244 -117\n",
      "\n",
      "Placebo 55 84\n",
      "\n",
      "Difference from Placebo -190 33\n",
      "Example 8\n",
      "\n",
      "Methods\n",
      "\n",
      "[0285] A study was performed to evaluate the efficacy of\n",
      "\n",
      "a single intravenous infusion of 5 mg ZA in comparison with\n",
      "intravenous placebo infusion among patients with chronic\n",
      "low back pain (LBP) and Modic changes on MRI. This study\n",
      "was a double-blinded, randomized, placebo-controlled clini-\n",
      "cal trial in patients with low back pain (LBP). Patients were\n",
      "included in the study if they had low back symptoms for at\n",
      "least three months, a LBP of at least six (6) on a 10-cm\n",
      "Visual Analog Scale (VAS) or an Oswestry Disability Index\n",
      "(ODI) of at least 30%, and an M1, mixed M1/2 or M2 type\n",
      "change on MRI performed within six months at most prior\n",
      "to enrolment.\n",
      "\n",
      "[0286] Patients were excluded from the study if they had\n",
      "renal impairment with reduced creatinine clearance defined\n",
      "as an estimated glomerular filtration rate (eGFR) below 40\n",
      "ml/min, hypocalcemia, known hypersensitivity to zole-\n",
      "dronic acid or other bisphosphonates or ingredients of the\n",
      "infusion product, the presence of red flags, nerve root\n",
      "entrapment or willingness for early retirement. Premeno-\n",
      "pausal women of childbearing potential were also excluded.\n",
      "Blood samples were taken prior to the infusion to assess the\n",
      "serum concentration of calcium and creatinine. The clinical\n",
      "examination included medical history and clinical assess-\n",
      "ment of lumbar flexibility, tendon signs, and motor and\n",
      "sensory testing.\n",
      "\n",
      "[0287] After confirmation of eligibility patients were ran-\n",
      "domized to receive a single intravenous infusion of 5 mg\n",
      "zoledronic acid (n=20) or 100 ml saline as placebo (n=20)\n",
      "over a 15-minute period. Information on use of the con-\n",
      "comitant medication and hospital admissions were recorded.\n",
      "Blood samples were taken for the assessment of safety,\n",
      "inflammatory mediators and markers of bone turnover at\n",
      "baseline, one month and one year.\n",
      "\n",
      "[0288] Clinical assessments were performed 14 days\n",
      "before enrolment (screening visit), and follow-up visits at\n",
      "one month and one year after the infusion. The primary\n",
      "outcome was the change in the intensity of LBP on VAS.\n",
      "Secondary outcomes included leg pain intensity, ODI,\n",
      "health-related quality of life assessed with RAND-36,\n",
      "patient-reported sick leaves and lumbar flexibility. These\n",
      "outcome measures were assessed at baseline and at each\n",
      "follow-up. Lumbar flexibility was evaluated using the fin-\n",
      "gers-to-floor and trunk side bending measures (in cm). The\n",
      "percentage of patients undergoing a 20% relative improve-\n",
      "ment, the proportion of patients reaching a VAS score of 40\n",
      "or less in the primary outcome, and patient acceptable\n",
      "symptom state (PASS) were also assessed. Pain medication\n",
      "use was inquired about during the follow-up visits.\n",
      "\n",
      "Results\n",
      "\n",
      "[0289] Zoledronic acid treatment resulted in a greater\n",
      "improvement in LBP intensity at one month as compared toTABLE 9\n",
      "Pain Reduction in Patients Treated Zoledronic Acid (cm)\n",
      "\n",
      "VAS Change from Baseline\n",
      "\n",
      "Baseline VAS < 6 -0.1\n",
      "Baseline VAS = 6 and < 7 -2.3\n",
      "Baseline VAS = 7 -3.4\n",
      "Example 9\n",
      "Methods:\n",
      "[0295] A study was performed to evaluate the efficacy of\n",
      "\n",
      "bisphosphonates such as oral zoledronic acid in inhibiting\n",
      "immune responses and pain behavior in a rat fracture model\n",
      "of CRPS.\n",
      "\n",
      "[0296] The effect of orally administered zoledronic acid\n",
      "was examined in the rat tibia fracture model of complex\n",
      "regional pain syndrome (CRPS). CRPS was induced in the\n",
      "rats by fracturing the right distal tibias of the animals and\n",
      "casting the fractured hindpaws for 4 weeks, as described in\n",
      "Guo T Z et al. (Pain. 2004; 108: 95-107). This animal model\n",
      "has been shown to replicate the inciting trauma (such as a\n",
      "fracture, a surgery, a crushing injury, a cutting injury, a\n",
      "scratch, or a puncture injury), natural history, signs, symp-\n",
      "toms, and pathologic changes observed in human CRPS\n",
      "patients (Kingery W S et al., Pain. 2003; 104:75-84).\n",
      "[0297] Starting four weeks after fracture and casting,\n",
      "animals were orally administered either vehicle (control) or\n",
      "zoledronic acid, a dose of 21 mg/kg on the first day and 3\n",
      "\n",
      "_\\ /=N\n",
      "\n",
      "SimN -\n",
      "J - 99.7%\n",
      "\n",
      "8\n",
      "\n",
      "PO3H>\n",
      "\n",
      "N POH\n",
      "(ow YY OH\n",
      "\n",
      "Compound 1\n",
      "\n",
      " /\n",
      "N O HCI, water\n",
      "GY ae\n",
      "\n",
      "mg/kg/day daily thereafter, or distilled water for 3 weeks\n",
      "(weeks 4-7 post-fracture). Drug was dissolved in distilled\n",
      "water and administered by gavage. Animals were fasted for\n",
      "4 hours before and 2 hours after dosing. At the end of the\n",
      "21-day period, casts were removed, and on the following\n",
      "day, the rats were tested for hindpaw pain, edema, and\n",
      "warmth.\n",
      "\n",
      "Results\n",
      "\n",
      "[0298] As illustrated in FIGS. 14-15, treatment with orally\n",
      "administered zoledronic acid reversed pain and restored\n",
      "weight bearing as compared to the vehicle treated animals.\n",
      "[0299] As illustrated in FIG. 14, von Frey pain thresholds\n",
      "for the right (fracture) hindpaw were reduced by over 100%\n",
      "as compared to baseline when oral zoledronic acid was\n",
      "administered.\n",
      "\n",
      "[0300] As illustrated in FIG. 15, reduction in weight\n",
      "bearing, a postural effect of pain, was significantly higher in\n",
      "the vehicle treated group as compared to the zoledronic acid\n",
      "treated group. Weight bearing on the fracture hindlimb was\n",
      "reduced to about 80% of normal in the vehicle treated group.\n",
      "Zoledronate treatment significantly restored hindlimb\n",
      "weight bearing as compared to vehicle treatment (over 90%\n",
      "of normal).\n",
      "\n",
      "[0301] As can be seen in FIG. 16, orally administering\n",
      "zoledronic acid four weeks after the fracture resulted in\n",
      "significantly greater improvement of pain relief as compared\n",
      "to administration at the time of injury.\n",
      "\n",
      "Example 10\n",
      "[0302]\n",
      "\n",
      "O\n",
      "\n",
      "87.7%\n",
      "\n",
      "H3PO3, PClz, HO\n",
      "\n",
      "  \n",
      " \n",
      "\n",
      "i. H3PO3, 10 egq.,\n",
      "toluene, 70 C., 20 min\n",
      "il. PClz, 95 C., 2h\n",
      "ili. HCl, HO, 100 C., 7 h,\n",
      "rt,2dHindpaw Pain Threshold (g)\n",
      "\n",
      " Zoledronic acidEmbodiment 33\n",
      "\n",
      "[0342] The method of embodiment 32, wherein the dosage\n",
      "form contains about 15 mg/m* to about 20 mg/m? of zole-\n",
      "dronic acid based upon the body surface area of the human\n",
      "being.\n",
      "\n",
      "Embodiment 34\n",
      "\n",
      "[0343] The method of any of embodiments 20-33, wherein\n",
      "about 50 mg/m* to about 200 mg/m? of zoledronic acid is\n",
      "orally administered per month, based upon the body surface\n",
      "area of the human being.\n",
      "\n",
      "Embodiment 35\n",
      "\n",
      "[0344] The method of any of embodiments 20-31, wherein\n",
      "the dosage form contains about 80 mg/m? to about 150\n",
      "mg/m? of zoledronic acid based upon the body surface area\n",
      "of the human being.\n",
      "\n",
      "Embodiment 36\n",
      "\n",
      "[0345] The method of embodiment 35, wherein about 300\n",
      "mg/m* to about 1000 mg/m? of zoledronic acid is orally\n",
      "administered per month, based upon the body surface area of\n",
      "the human being.\n",
      "\n",
      "Embodiment 37\n",
      "\n",
      "[0346] The method of any of embodiments 20-36, wherein\n",
      "the human being is not suffering from bone metastasis.\n",
      "\n",
      "Embodiment 38\n",
      "\n",
      "[0347] The method of any of embodiments 20-37, wherein\n",
      "the human being is not suffering from cancer.\n",
      "\n",
      "Embodiment 39\n",
      "\n",
      "[0348] The method of any preceding embodiment,\n",
      "wherein the zoledronic acid is in the disodium salt form.\n",
      "\n",
      "Embodiment 40\n",
      "\n",
      "[0349] An oral dosage form comprising zoledronic acid,\n",
      "wherein the oral bioavailability of zoledronic acid in the\n",
      "dosage form is about 0.01% to about 4%.\n",
      "\n",
      "Embodiment 41\n",
      "\n",
      "[0350] The oral dosage form of embodiment 40, wherein\n",
      "the oral dosage form contains about 10 mg to about 300 mg\n",
      "of zoledronic acid.\n",
      "\n",
      "Embodiment 42\n",
      "\n",
      "[0351] The oral dosage form of embodiment 40, wherein\n",
      "the oral dosage form contains about 10 mg to about 50 mg\n",
      "of zoledronic acid.\n",
      "\n",
      "Embodiment 43\n",
      "\n",
      "[0352] The oral dosage form of any of embodiments\n",
      "40-42, wherein the oral bioavailability of zoledronic acid in\n",
      "the dosage form is about 0.1% to about 2%.\n",
      "\n",
      "Embodiment 44\n",
      "\n",
      "[0353] A pharmaceutical product comprising more than\n",
      "one unit of an oral dosage form of embodiment 40.\n",
      "\n",
      "Embodiment 45\n",
      "\n",
      "[0354] The pharmaceutical product of embodiment 44,\n",
      "wherein each unit of the oral dosage form contains about 1\n",
      "mg to about 50 mg of zoledronic acid.\n",
      "\n",
      "Embodiment 46\n",
      "\n",
      "[0355] The pharmaceutical product of embodiment 45,\n",
      "comprising 28, 29, 30, or 31 units of the oral dosage form,\n",
      "for a total of about 28 mg to about 1600 mg of zoledronic\n",
      "acid to be administered in about 1 month.\n",
      "\n",
      "Embodiment 47\n",
      "\n",
      "[0356] The pharmaceutical product of embodiment 45,\n",
      "comprising 85 to 95 units of the oral dosage form, for a total\n",
      "of about 85 mg to about 4800 mg of zoledronic acid to be\n",
      "administered in about 3 months.\n",
      "\n",
      "Embodiment 48\n",
      "\n",
      "[0357] The pharmaceutical product of embodiment 45,\n",
      "comprising 170 to 200 units of the oral dosage form, for a\n",
      "total of about 170 mg to about 10,000 mg of zoledronic acid\n",
      "to be administered in about 6 months.\n",
      "\n",
      "Embodiment 49\n",
      "\n",
      "[0358] The pharmaceutical product of embodiment 45,\n",
      "comprising 350 to 380 units of the oral dosage form, for a\n",
      "total of about 350 mg to about 19,000 mg of zoledronic acid\n",
      "to be administered in about 1 year.\n",
      "\n",
      "Embodiment 50\n",
      "\n",
      "[0359] The pharmaceutical product of embodiment 44,\n",
      "wherein each unit of the oral dosage form contains about 10\n",
      "mg to about 300 mg.\n",
      "\n",
      "Embodiment 51\n",
      "\n",
      "[0360] The pharmaceutical product of embodiment 50,\n",
      "comprising 4 or 5 units of the oral dosage form, for a total\n",
      "of about 40 mg to about 1500 mg of zoledronic acid to be\n",
      "administered within a period of about 1 month.\n",
      "\n",
      "Embodiment 52\n",
      "\n",
      "[0361] The pharmaceutical product of embodiment 50,\n",
      "comprising 8 or 9 units of the oral dosage form, for a total\n",
      "of about 80 mg to about 2700 mg of zoledronic acid to be\n",
      "administered in about 2 months.\n",
      "\n",
      "Embodiment 53\n",
      "\n",
      "[0362] The pharmaceutical product of embodiment 50,\n",
      "comprising 12, 13 or 14 units of the oral dosage form, for a\n",
      "total of about 120 mg to about 4200 mg of zoledronic acid\n",
      "to be administered in about 3 months.\n",
      "\n",
      "Embodiment 54\n",
      "\n",
      "[0363] The pharmaceutical product of embodiment 50,\n",
      "comprising 22 to 30 units of the oral dosage form, for a total\n",
      "of about 220 mg to about 9000 mg of zoledronic acid to be\n",
      "administered in about 6 months.[0062] In some embodiments, an inhibitor of osteoclast\n",
      "activity can be used to treat bone marrow lesions.\n",
      "\n",
      "[0063] In some embodiments, an inhibitor of osteoclast\n",
      "activity can be used to treat bone marrow lesions of the knee,\n",
      "shoulder, ankle, wrist, hand, fingers, spine, or hip.\n",
      "\n",
      "[0064] Commonly used measures of pain intensity include\n",
      "the visual analog scale (VAS) and the numerical rating scale\n",
      "(NRS). With the VAS approach, patients rate the severity of\n",
      "their pain by marking a point on a 10-cm (or 100 mm) VAS\n",
      "(O=no pain and 10=worst possible pain). With the NRS\n",
      "approach, patients rate the severity of their pain by verbally\n",
      "responding to a 10-point NRS (O=no pain and 10=worst\n",
      "possible pain). VAS and NRS scores have been shown to be\n",
      "strongly correlated (slope of regression line, 1.01), indicat-\n",
      "ing that a score on the 10-cm VAS is equivalent to the same\n",
      "score on 10-point NRS (Bijur P E et al. Acad Emerg Med\n",
      "2003; 10:390-392). For example, a VAS score of 5 cm (or 50\n",
      "mm) is equivalent to an NRS score of 5. Knee pain in a\n",
      "person with a VAS score of 5 cm or 50 mm or higher, or an\n",
      "NRS score of 5 or higher, may be referred to herein as\n",
      "moderate to severe knee pain.\n",
      "\n",
      "[0065] In some embodiments, the patient suffering from\n",
      "pain, inflammation, a similar condition, or any of the con-\n",
      "ditions described herein, has an NRS of 5 or greater, or a\n",
      "VAS of 5 cm or greater. In some embodiments, the patient\n",
      "has an NRS of 4 or greater, or a VAS of 4 cm or greater. In\n",
      "some embodiments, the patient has an NRS of 6 or greater,\n",
      "or a VAS of 6 cm or greater. In some embodiments, the\n",
      "patient has an NRS of 7 or greater, or a VAS of 7 cm or\n",
      "greater. In some embodiments, the patient has an NRS of\n",
      "about 1, about 2, about 3, about 4, about 5, about 6, about\n",
      "7, about 8, about 9, or about 10. In some embodiments, the\n",
      "patient has a VAS of about 1 cm, about 2 cm, about 3 cm,\n",
      "about 4 cm, about 5 cm, about 6 cm, about 7 cm, about 8 cm,\n",
      "about 9 cm, or about 10 cm.\n",
      "\n",
      "[0066] For knee pain or pain associated with bone marrow\n",
      "lesions, in some embodiments, treatment with a nitrogen-\n",
      "containing bisphosphonate such as zoledronic acid may\n",
      "decrease the visual analog (VAS) pain score measured using\n",
      "a 100 mm scale, by at least about 5 mm, at least about 8 mm,\n",
      "at least about 10 mm, at least about 15 mm, up to about 50\n",
      "mm, or up to about 100 mm. In some embodiments, the VAS\n",
      "score, may be decreased by at least about 5 mm, at least\n",
      "about 8 mm, at least about 10 mm, at least about 15 mm, up\n",
      "to about 50 mm, or up to about 100 mm, as compared to a\n",
      "placebo.\n",
      "\n",
      "[0067] Treatment with a nitrogen-containing bisphospho-\n",
      "nate such as zoledronic acid may decrease the numerical\n",
      "rating scale (NRS) pain score measured using a 0-10 scale,\n",
      "by at least about 0.1, at least about 0.5, at least about 0.8, at\n",
      "least about 1, at least about 1.5, up to about 5, or up to about\n",
      "10. In some embodiments, the NRS score may be decreased\n",
      "by at least about 0.1, at least about 0.5, at least about 0.8, at\n",
      "least about 1, at least about 1.5, up to about 5, or up to about\n",
      "10, as compared to a placebo.\n",
      "\n",
      "[0068] In some embodiments, an inhibitor of osteoclast\n",
      "activity can be used to reduce the size of bone marrow\n",
      "lesions. The area of the lesions may be measured as the total\n",
      "area of all lesions or as the area of any one lesion. In some\n",
      "embodiments, the total area includes the medial tibial area,\n",
      "the medial femoral area, the lateral tibial area, and the lateral\n",
      "femoral area. In some embodiments the bone marrow lesion\n",
      "in located in the patella.\n",
      "\n",
      "[0069] In some embodiments, the use of an inhibitor of\n",
      "osteoclast activity achieves a reduction in the total area of\n",
      "the bone marrow lesions of at least about 240 mm7. In some\n",
      "embodiments, the reduction in total area is at least about 220\n",
      "mm, at least about 200 mm7, at least about 150 mm7, at\n",
      "least about 100 mm7, or at least about 50 mm. In some\n",
      "embodiments, the reduction in size of bone marrow lesions\n",
      "represents a reduction relative to baseline of at least about\n",
      "10%, at least about 20%, at least about 30%, at least about\n",
      "40%, at least about 50%, at least about 60%, at least about\n",
      "70% at least about 80%, at least about 90%, or about 100%.\n",
      "In some embodiments, the reduction in area of bone marrow\n",
      "lesions represents an improvement relative to placebo of at\n",
      "least about 10%, at least about 20%, at least about 30%, at\n",
      "least about 40%, at least about 50%, at least about 60%, at\n",
      "least about 70%, at least about 80%, at least about 90%, at\n",
      "least about 100%, at least about 120%, at least about 150%,\n",
      "at least about 170%, at least about 200%, at least about\n",
      "250%, at least about 300%, at least about 350%, at least\n",
      "about 400%, or at least about 450%. In some embodiments,\n",
      "the use of an inhibitor of osteoclast activity inhibits an\n",
      "increase in the size of the bone marrow lesions over time.\n",
      "\n",
      "[0070] Joint space narrowing (JSN) is typically graded\n",
      "using the Osteoarthritis Research Society International\n",
      "(OARSJ) atlas criteria, or the Kellgren and Lawrence (K/L)\n",
      "system. The OARS] atlas criteria grades JSN using a 0-3\n",
      "scale with Grade 0 indicating an absence of JSN, and Grades\n",
      "1, 2 and 3 indicating mild, moderate, and severe JSN,\n",
      "respectively (Altman and Gold, Osteoarthritis Cartilage\n",
      "2007; 15(Supp! A):A1-A56). The K/L system grades JSN\n",
      "using a 0-4 scale with Grade 0 indicating an absence of JSN,\n",
      "Grade 1 indicating doubtful JSN, and grades 2, 3 and 4\n",
      "indicating minimal, moderate, and severe JSN, respectively\n",
      "(Kellgren and Lawrence, Ann Rheum Dis 1957; 16:494-\n",
      "502). Based on these criteria, OARSI Grade 0 (absence of\n",
      "JSN), approximates K/L Grades 0-1 (absence of, or doubtful\n",
      "presence of JSN). Knee pain in a person having OARSI\n",
      "Grade 0 or K/L Grade or 1 JSN in the knee where the pain\n",
      "occurs may be referred to herein as a normal joint space\n",
      "knee pain.\n",
      "\n",
      "[0071] In some embodiments for patients having OARSI\n",
      "Grade 0 or K/L Grades 0-1 JSN, the use of an inhibitor of\n",
      "osteoclast activity achieves a reduction in the total area of\n",
      "the bone marrow lesions of at least about 240 mm7?. In some\n",
      "embodiments, the reduction in total area is at least about 220\n",
      "mm7, at least about 200 mm, at least about 150 mm7, at\n",
      "least about 100 mm, or at least about 50 mm. In some\n",
      "embodiments, the reduction in size of bone marrow lesions\n",
      "represents a reduction relative to baseline of at least about\n",
      "10%, at least about 15%, at least about 20%, at least about\n",
      "25%, at least about 30%, at least about 35%, at least about\n",
      "40%, at least about 45%, at least about 50%, at least about\n",
      "60%, at least about 70% at least about 80%, at least about\n",
      "90%, or about 100%. In some embodiments, the reduction in\n",
      "area of bone marrow lesions represents an improvement\n",
      "relative to placebo of at least about 10%, at least about 20%,\n",
      "at least about 30%, at least about 40%, at least about 50%,\n",
      "at least about 60%, at least about 70%, at least about 80%,\n",
      "at least about 90%, at least about 100%, at least about 120%,\n",
      "at least about 150%, at least about 170%, at least about\n",
      "200%, at least about 250%, at least about 300%, at least\n",
      "about 350%, at least about 400%, or at least about 450%. Into about 500 mg, about 50 mg to about 150 mg, about 50 mg,\n",
      "about 100 mg, about 50 mg to about 200 mg, about 50 mg\n",
      "to about 500 mg, about 150 mg to about 200 mg, about 100\n",
      "mg to about 2000 mg, about 300 mg to about 1500 mg, about\n",
      "200 mg to about 1000 mg, about 100 mg to about 500 mg,\n",
      "about 160 mg, or about 150 mg of osteoclast inhibitor, or any\n",
      "amount of osteoclast inhibitor in a range bounded by, or\n",
      "between, any of these values. In some embodiments, the oral\n",
      "osteoclast inhibitor is administered daily, weekly, bi-weekly,\n",
      "monthly, every two or three months, once a year, or twice a\n",
      "year.\n",
      "\n",
      "[0190] Any suitable amount of an osteoclast inhibitor,\n",
      "including a bisphosphonate, such as a nitrogen-containing\n",
      "bisphosphonate, e.g.  zoledronic acid, neridronate\n",
      "(neridronic acid), pamidronate, olpadronate, alendronate,\n",
      "risedronate, minodronic acid, or ibandronic acid, may be\n",
      "used. Some solid or liquid dosage forms, or units of dosage\n",
      "forms may contain about 0.005 mg to about 20 mg, about 0.1\n",
      "mg to about 10 mg, about 0.5 mg to about 10 mg, about 0.2\n",
      "mg to about 5 mg, about 1 mg to about 500 mg, about 1 mg\n",
      "to about 50 mg, about 10 mg to about 250 mg, about 100 mg\n",
      "to about 300 mg, about 20 mg to about 200 mg, about 20 mg\n",
      "to about 150 mg, about 30 mg to about 100 mg, about 50 mg\n",
      "to about 200 mg, about 1 mg to about 1,000 mg, about 10\n",
      "mg to about 50 mg, about 40 mg to about 60 mg, about 50\n",
      "mg to about 60 mg, about 55 mg, about 10 mg to about 300\n",
      "mg, about 10 mg to about 150 mg, about 10 mg to about 100\n",
      "mg, about 40 mg to about 150 mg, about 10 mg to about 600\n",
      "mg, about 40 mg to about 600 mg, about 40 mg to about\n",
      "2000 mg, about 40 mg to about 800 mg, about 25 mg to\n",
      "about 800 mg, about 30 mg to about 800 mg, about 10 mg\n",
      "to about 500 mg, about 50 mg to about 150 mg, about 50 mg,\n",
      "about 100 mg, about 50 mg to about 500 mg, about 150 mg\n",
      "to about 200 mg, about 100 mg to about 2000 mg, about 300\n",
      "mg to about 1500 mg, about 200 mg to about 1000 mg, about\n",
      "100 mg to about 500 mg, about 160 mg, or about 150 mg of\n",
      "a bisphosphonate in an acid form or in a salt form such as\n",
      "disodium salt form, or any amount of an osteoclast inhibitor,\n",
      "such as a bisphosphonate, in a range bounded by, or\n",
      "between, any of these values. In some embodiments, the oral\n",
      "or IV osteoclast inhibitor is administered daily, every other\n",
      "day, every third day, weekly, biweekly, monthly, every two\n",
      "or three months, every six months, once a year, or twice a\n",
      "year from day 1.\n",
      "\n",
      "[0191] Some dosage forms may contain about 0.005 mg to\n",
      "about 20 mg, about 0.1 mg to about 10 mg, about 0.5 mg to\n",
      "about 10 mg, about 0.2 mg to about 5 mg, about 1 mg to\n",
      "about 500 mg, about 1 mg to about 50 mg, about 10 mg to\n",
      "about 250 mg, about 100 mg to about 300 mg, about 20 mg\n",
      "to about 200 mg, about 20 mg to about 150 mg, about 30 mg\n",
      "to about 100 mg, about 1 mg to about 1,000 mg, about 10\n",
      "mg to about 50 mg, about 40 mg to about 60 mg, about 50\n",
      "mg to about 65 mg, about 65 mg to about 70 mg, about 50\n",
      "mg to about 60 mg, about 55 mg, about 10 mg to about 300\n",
      "mg, about 10 mg to about 150 mg, about 10 mg to about 100\n",
      "mg, about 40 mg to about 150 mg, about 10 mg to about 600\n",
      "mg, about 40 mg to about 600 mg, about 100 mg to about\n",
      "600 mg, about 40 mg to about 2000 mg, about 40 mg to\n",
      "about 800 mg, about 25 mg to about 800 mg, about 30 mg\n",
      "to about 800 mg, about 10 mg to about 500 mg, about 50 mg\n",
      "to about 150 mg, about 50 mg, about 100 mg, about 50 mg\n",
      "to about 200 mg, about 50 mg to about 500 mg, about 150\n",
      "mg to about 200 mg, about 100 mg to about 2000 mg, about\n",
      "300 mg to about 1500 mg, about 200 mg to about 1000 mg,\n",
      "\n",
      "about 100 mg to about 500 mg, about 160 mg, or about 150\n",
      "mg of osteoclast inhibitor, or any amount of osteoclast\n",
      "inhibitor in a range bounded by, or between, any of these\n",
      "values. In some embodiments, the oral or IV osteoclast\n",
      "inhibitor is administered daily, every other day, every third\n",
      "day, weekly, bi-weekly, monthly, every two or three months,\n",
      "every 6 months, once a year, or twice a year from day 1.\n",
      "[0192] In some embodiments, an oral dosage form may\n",
      "contain about 10 mg/m? to about 20 mg/m7, about 15 mg/m?\n",
      "to about 20 mg/m, about 18 mg/m*, about 80 mg/m? to\n",
      "about 150 mg/m, about 90 mg/m? to about 150 mg/m,\n",
      "about 100 mg/m? to about 150 mg/m? of zoledronic acid, or\n",
      "any amount of zoledronic in a range bounded by, or between,\n",
      "any of these values. All dosage ranges or amounts expressed\n",
      "in mg/m* are based upon the body surface area of the\n",
      "mammal.\n",
      "\n",
      "[0193] In some embodiments, the daily oral dose of an\n",
      "osteoclast inhibitor, including a bisphosphonate, such as a\n",
      "nitrogen-containing bisphosphonate, e.g. zoledronic acid,\n",
      "minodronic acid, or ibandronic acid, is about 0.005 mg to\n",
      "about 20 mg, about 0.1 mg to about 10 mg, about 0.5 mg to\n",
      "about 10 mg, about 0.2 mg to about 5 mg, or any amount in\n",
      "a range bounded by, or between, any of these values. In some\n",
      "embodiments, the daily oral dose of osteoclast inhibitor is\n",
      "less than about 35 mg/m, less than about 30 mg/m, less\n",
      "than about 25 mg/m, about 1 mg/m? to about 35 mg/m,\n",
      "about 1 mg/m? to about 30 mg/m, about 1.5 mg/m to about\n",
      "25 mg/m, about 1.8 mg/m? to about 20 mg/m, about 10\n",
      "mg/m* to about 20 mg/m*, about 10 mg/m* to about 30\n",
      "mg/m*, about 15 mg/m* to about 20 mg/m, about 18\n",
      "mg/m7, or any amount of zoledronic acid in a range bounded\n",
      "by, or between, any of these values.\n",
      "\n",
      "[0194] In some embodiments, the daily oral dose of an\n",
      "osteoclast inhibitor, including a bisphosphonate, such as a\n",
      "nitrogen-containing bisphosphonate, e.g. zoledronic acid,\n",
      "minodronic acid, or ibandronic acid, is about 0.005 mg to\n",
      "about 20 mg, about 0.1 mg to about 10 mg, about 0.5 mg to\n",
      "about 10 mg, about 0.2 mg to about 5 mg, or any amount of\n",
      "osteoclast inhibitor in a range bounded by, or between, any\n",
      "of these values. In some embodiments, the daily oral dose of\n",
      "osteoclast inhibitor is less than about 35 mg/m, less than\n",
      "about 30 mg/m, less than about 25 mg/m*, about 1 mg/m?\n",
      "to about 35 mg/m, about 1 mg/m? to about 30 mg/m, about\n",
      "1.5 mg/m? to about 25 mg/m, about 1.8 mg/m to about 20\n",
      "mg/m7, about 10 mg/m? to about 20 mg/m, about 10 mg/m?\n",
      "to about 30 mg/m, about 15 mg/m* to about 20 mg/m,\n",
      "about 18 mg/m*, or any amount of osteoclast inhibitor in a\n",
      "range bounded by, or between, any of these values.\n",
      "\n",
      "[0195] In some embodiments the daily oral dose of zole-\n",
      "dronic acid is about 0.005 mg to about 20 mg, about 0.1 mg\n",
      "to about 10 mg, about 0.5 mg to about 10 mg, about 0.2 mg\n",
      "to about 5 mg, or any amount of zoledronic acid in a range\n",
      "bounded by, or between, any of these values. In some\n",
      "embodiments, the daily oral dose of zoledronic acid is less\n",
      "than about 35 mg/m, less than about 30 mg/m, less than\n",
      "about 25 mg/m*, about 1 mg/m to about 35 mg/m, about\n",
      "1 mg/m? to about 30 mg/m7, about 1.5 mg/m? to about 25\n",
      "mg/m*, about 1.8 mg/m* to about 20 mg/m*, about 10\n",
      "mg/m* to about 20 mg/m*, about 10 mg/m* to about 30\n",
      "mg/m, about 15 mg/m? to about 20 mg/m, about 18\n",
      "mg/m, or any amount of zoledronic acid in a range bounded\n",
      "by, or between, any of these values.\n",
      "\n",
      "[0196] In some embodiments, the weekly oral dose of the\n",
      "osteoclast inhibitor, including a bisphosphonate, such as asome embodiments, the use of an inhibitor of osteoclast\n",
      "activity inhibits an increase in the size of bone marrow\n",
      "lesions over time.\n",
      "\n",
      "[0072] In some embodiments for patients having OARSI\n",
      "Grades 1-2 or K/L Grades 2-4 JSN, the use of an inhibitor\n",
      "of osteoclast activity achieves a reduction in the total area of\n",
      "the bone marrow lesions of at least about 100 mm. In some\n",
      "embodiments, the reduction in total area is at least about 50\n",
      "mm, at least about 60 mm, at least about 80 mm, at least\n",
      "about 85 mm, at least about 90 mm/7, at least about 100\n",
      "mm, at least about 105 mm, at least about 110 mm, or at\n",
      "least about 115 mm/?. In some embodiments, the reduction in\n",
      "size of bone marrow lesions represents a reduction relative\n",
      "to baseline of at least about 10%, at least about 20%, at least\n",
      "about 30%, at least about 40%, at least about 50%, at least\n",
      "about 60%, at least about 70% at least about 80%, at least\n",
      "about 90%, or about 100%. In some embodiments, the\n",
      "reduction in area of bone marrow lesions represents an\n",
      "improvement relative to placebo of at least about 10%, at\n",
      "least about 20%, at least about 30%, at least about 40%, at\n",
      "least about 50%, at least about 60%, at least about 70%, at\n",
      "least about 80%, at least about 90%, at least about 100%, at\n",
      "least about 115%, at least about 125%, at least about 135%,\n",
      "at least about 150%, at least about 170%, at least about\n",
      "200%, at least about 250%, at least about 300%, at least\n",
      "about 350%, at least about 400%, or at least about 450%. In\n",
      "some embodiments, the use of an inhibitor of osteoclast\n",
      "activity inhibits an increase in the size of bone marrow\n",
      "lesions over time.\n",
      "\n",
      "[0073] In some embodiments, an inhibitor of osteoclast\n",
      "activity, such as a nitrogen-containing bisphosphonate,\n",
      "including e.g. zoledronic acid, minodronic acid, etc., is used\n",
      "to treat fibromyalgia.\n",
      "\n",
      "[0074] According to some embodiments, administration\n",
      "of an inhibitor of osteoclast activity achieves a reduction in\n",
      "pain that lasts at least about one month, two months, three\n",
      "months, four months, six months, or even at least about\n",
      "twelve months. According some embodiments, administra-\n",
      "tion of an inhibitor of osteoclast activity achieves a reduc-\n",
      "tion in pain that is observed at greater than three hours, at\n",
      "about one day, at about two to about five days, at about one\n",
      "week, at about two weeks, at about three weeks, at about one\n",
      "month, at about five weeks, at about six weeks, at about\n",
      "seven weeks, at about two months, at about nine weeks, at\n",
      "about ten weeks, at about eleven weeks, at about three\n",
      "months, at about four months, at about six months, or at\n",
      "about twelve months after administration of the inhibitor of\n",
      "osteoclast activity.\n",
      "\n",
      "[0075] According some embodiments, administration of\n",
      "an inhibitor of osteoclast activity achieves a reduction in\n",
      "pain that is observed at greater than three hours, but at or\n",
      "before one week, two weeks, three weeks, four weeks, five\n",
      "weeks, six weeks, seven weeks, eight weeks, nine weeks, ten\n",
      "weeks, eleven weeks, twelve weeks, four months, five\n",
      "months, or six months.\n",
      "\n",
      "[0076] According some embodiments, administration of\n",
      "an inhibitor of osteoclast activity achieves a reduction in\n",
      "pain that is observed at greater than three hours with a\n",
      "duration of no more than about three months, no more than\n",
      "about four months, no more than about five months, or no\n",
      "more than about six months.\n",
      "\n",
      "[0077] According to some embodiments, after the admin-\n",
      "istration of an inhibitor of osteoclast activity, the area of\n",
      "bone marrow lesions relative to the size prior to adminis-\n",
      "\n",
      "tration remains reduced for up to three months, four months,\n",
      "five months, six months, or even up to twelve months or\n",
      "more. According to some embodiments, after the adminis-\n",
      "tration of an inhibitor of osteoclast activity, the area of bone\n",
      "marrow lesions relative to the size prior to administration 1s\n",
      "reduced at about three months, at about four months, at\n",
      "about five months, at about six months, or at about twelve\n",
      "months.\n",
      "\n",
      "[0078] According to some embodiments, after administra-\n",
      "tion of an inhibitor of osteoclast activity, the size of Modic\n",
      "changes or VESCs relative to the size prior to administration\n",
      "remains reduced for up to three months, four months, five\n",
      "months, six months, or even up to twelve months or more.\n",
      "According to some embodiments, after the administration of\n",
      "an inhibitor of osteoclast activity, the size of Modic changes\n",
      "or VESCs relative to the size prior to administration is\n",
      "reduced at about three months, at about four months, at\n",
      "about five months, at about six months, or at about twelve\n",
      "months.\n",
      "\n",
      "[0079] Insome embodiments, an osteoclast inhibitor, such\n",
      "as a nitrogen-containing bisphosphonate, e.g. zoledronic\n",
      "acid, ibandronic acid or minodronic acid, may be adminis-\n",
      "tered to relieve complex regional pain syndrome, such as\n",
      "complex regional pain syndrome type I (CRPS-I), complex\n",
      "regional pain syndrome type IT (CRPS-II), CRPS-NOS, or\n",
      "another type of CRPS.\n",
      "\n",
      "[0080] In some embodiments, zoledronic acid or another\n",
      "bisphosphonate may be administered orally to relieve com-\n",
      "plex regional pain syndrome, such as complex regional pain\n",
      "syndrome type I (CRPS-I), complex regional pain syndrome\n",
      "type II (CRPS-II), CRPS-NOS, or another type of CRPS.\n",
      "CRPS is a type of inflammatory pain. CRPS can also have\n",
      "a neuropathic component.\n",
      "\n",
      "[0081] Complex regional pain syndrome is a debilitating\n",
      "pain syndrome. It is characterized by severe pain in a limb\n",
      "that can be accompanied by edema, and autonomic, motor\n",
      "and sensory changes.\n",
      "\n",
      "[0082] Insome embodiments, an osteoclast inhibitor, such\n",
      "as a nitrogen-containing bisphosphonate, e.g. zoledronic\n",
      "acid or minodronic acid, may be used to reduce the use of\n",
      "non-steroidal anti-inflammatory drug (NSAIDs), opioids, or\n",
      "other pain medications, for a patient suffering from pain,\n",
      "inflammation, a similar condition, or any condition\n",
      "described herein. For example, use of NSAIDs, opioids, or\n",
      "other pain medications may be reduced by at least about 5%,\n",
      "at least about 10%, at least about 15%, at least about 20%,\n",
      "at least about 25%, at least about 30%, at least about 35%,\n",
      "at least about 40%, at least about 45%, at least about 50%,\n",
      "at least about 60%, at least about 70%, at least about 80%,\n",
      "or at least about 90%, up to about 100%, as compared to the\n",
      "use of NSAIDs, opioids or other pain medications without\n",
      "administration of the osteoclast inhibitor. Use of the opioids,\n",
      "NSAIDs, or other pain medications may be reduced by at\n",
      "least about 5%, at least about 10%, at least about 15%, at\n",
      "least about 20%, at least about 25%, at least about 30%, at\n",
      "least about 35%, at least about 40%, at least about 45%, at\n",
      "least about 50%, at least about 60%, at least about 70%, at\n",
      "least about 80%, or at least about 90%, up to about 100%,\n",
      "as compared to the use of NSAIDS, opioids, or other pain\n",
      "medications at baseline.\n",
      "\n",
      "[0083] The reduction in the use of NSAIDs, opioids, or\n",
      "other pain medications may be observed at about one week,\n",
      "about two weeks, about three weeks, about one month, about\n",
      "two months, about three months, about four months, aboutBer 150g  Oleodium roledronate.\n",
      "\n",
      "te 150 mg-Zoledronicadd =\n",
      "\n",
      "Time {hour}\n",
      "\n",
      " \n",
      "\n",
      "ee\n",
      "\n",
      "    \n",
      "\n",
      "a  s \n",
      "(qui fau) vorequssu\n",
      "\n",
      "FIG. 8safely repeated dose may be about 0.4 mg to about 10 mg,\n",
      "or any smaller range within this range, such as about 0.4\n",
      "mg/kg to about 0.6 mg/kg, about 0.6 mg/kg to about 0.8\n",
      "mg/kg, about 0.8 mg/kg to about 1 mg/kg, about 1 mg/kg to\n",
      "about 1.2 mg/kg, about 1.2 mg/kg to about 1.4 mg/kg, about\n",
      "1.4 mg/kg to about 1.6 mg/kg, about 1.6 mg/kg to about 1.8\n",
      "mg/kg, about 1.8 mg/kg to about 2 mg/kg, about 2 mg/kg to\n",
      "about 2.2 mg/kg, about 2.2 mg/kg to about 2.4 mg/kg, about\n",
      "2.4 mg/kg to about 2.6 mg/kg, about 2.6 mg/kg to about 2.8\n",
      "mg/kg, about 2.8 mg/kg to about 3 mg/kg, about 3 mg/kg to\n",
      "about 3.2 mg/kg, about 3.2 mg/kg to about 3.4 mg/kg, about\n",
      "3.4 mg/kg to about 3.6 mg/kg, about 3.6 mg/kg to about 3.8\n",
      "mg/kg, about 3.8 mg/kg to about 4 mg/kg, about 4 mg/kg to\n",
      "about 4.2 mg/kg, about 4.2 mg/kg to about 4.4 mg/kg, about\n",
      "4.4 mg/kg to about 4.6 mg/kg, about 4.6 mg/kg to about 4.8\n",
      "mg/kg, about 4.8 mg/kg to about 5 mg/kg, about 5 mg/kg to\n",
      "about 5.2 mg/kg, about 5.2 mg/kg to about 5.4 mg/kg, about\n",
      "5.4 mg/kg to about 5.6 mg/kg, about 5.6 mg/kg to about 5.8\n",
      "mg/kg, about 5.8 mg/kg to about 6 mg/kg, about 6 mg/kg to\n",
      "about 6.2 mg/kg, about 6.2 mg/kg to about 6.4 mg/kg, about\n",
      "6.4 mg/kg to about 6.6 mg/kg, about 6.6 mg/kg to about 6.8\n",
      "mg/kg, about 6.8 mg/kg to about 7 mg/kg, about 7 mg/kg to\n",
      "about 7.2 mg/kg, about 7.2 mg/kg to about 7.4 mg/kg, about\n",
      "7.4 mg/kg to about 7.6 mg/kg, about 7.6 mg/kg to about 7.8\n",
      "mg/kg, about 7.8 mg/kg to about 8 mg/kg, about 8 mg/kg to\n",
      "about 8.2 mg/kg, about 8.2 mg/kg to about 8.4 mg/kg, about\n",
      "8.4 mg/kg to about 8.6 mg/kg, about 8.6 mg/kg to about 8.8\n",
      "mg/kg, about 8.8 mg/kg to about 9 mg/kg, about 9 mg/kg to\n",
      "about 9.2 mg/kg, about 9.2 mg/kg to about 9.4 mg/kg, about\n",
      "9.4 mg/kg to about 9.6 mg/kg, about 9.6 mg/kg to about 9.8\n",
      "mg/kg, about 9.8 mg/kg to about 10 mg/kg, about 0.5 mg/kg\n",
      "to about 2 mg/kg, about 0.6 mg/kg to about 2 mg/kg, about\n",
      "0.7 mg/kg to about 2 mg/kg, about 0.8 mg/kg to about 2\n",
      "mg/kg, about 0.5 mg/kg to about 1.5 mg/kg, about 0.6 mg/kg\n",
      "to about 1.5 mg/kg, about 0.7 mg/kg to about 1.5 mg/kg,\n",
      "about 0.8 mg/kg to about 1.5 mg/kg, about 0.5 mg/kg to\n",
      "about 1 mg/kg, about 0.6 mg/kg to about 1 mg/kg, about 0.7\n",
      "mg/kg to about 1 mg/kg, about 0.8 mg/kg to about 1 mg/kg,\n",
      "or about 0.8 mg/kg to about 0.9 mg/kg,\n",
      "\n",
      "[0205] In some embodiments, the osteoclast inhibitor\n",
      "comprises zoledronic acid, and the oral zoledronic acid, or\n",
      "disodium salt thereof, may be administered in combination\n",
      "with about 0.1 mg to about 10 mg of zoledronic acid, or a\n",
      "salt thereof, administered parenterally, such as intrave-\n",
      "nously. In some embodiments, about 50 mg, about 100 mg,\n",
      "or about 150 mg of the disodium salt of zoledronic acid is\n",
      "administered orally in combination with 1 mg parenteral,\n",
      "such as intravenous, zoledronic acid. In some embodiments\n",
      "the parenteral dose of zoledronic acid is about 0.25 mg to\n",
      "about 25 mg, about 0.25 mg to about 10 mg, or about 0.5 mg\n",
      "to about 7.5 mg.\n",
      "\n",
      "[0206] With respect to oral administration of an osteoclast\n",
      "inhibitor, such as zoledronic acid, minodronic acid, iban-\n",
      "dronic acid, or another bisphosphonate, for the treatment of\n",
      "pain associated with inflammation, arthritis, CRPS, or any\n",
      "other condition recited herein, it may helpful if the mammal\n",
      "or human being to which the osteoclast inhibitor is admin-\n",
      "istered does not eat food or drink beverage, (other than any\n",
      "water required to swallow the oral dosage form) for at least\n",
      "about 1 hour, at least about 2 hours, at least about 4 hours,\n",
      "at least about 6 hours, at least about 8 hours, at least about\n",
      "10 hours, or at least about 12 hours before the osteoclast\n",
      "inhibitor is administered. It may also be helpful if the\n",
      "mammal or human being to which the osteoclast inhibitor is\n",
      "\n",
      "administered does not eat food or drink beverage for at least\n",
      "about 30 minutes, at least about 1 hour, at least about 2\n",
      "hours, at least about 3 hours, or at least about 4 hours after\n",
      "the osteoclast inhibitor is administered. In some embodi-\n",
      "ments, a human being to which the zoledronic acid is\n",
      "administered avoids lying down, or remains upright or sits\n",
      "upright, for at least about 30 minutes or about 1 hour after\n",
      "receiving a dosage form containing the osteoclast inhibitor.\n",
      "Avoiding food or beverage before or after oral administra-\n",
      "tion of the osteoclast inhibitor can improve the bioavailabil-\n",
      "ity of the osteoclast inhibitor.\n",
      "\n",
      "[0207] The oral bioavailability of osteoclast inhibitor in a\n",
      "dosage form can vary. Some dosage forms may have ingre-\n",
      "dients added to enhance the bioavailability. However, bio-\n",
      "availability enhancement is not necessary for an oral dosage\n",
      "form to be effective. In some embodiments, the dosage form\n",
      "is substantially free of bioavailability-enhancing agents,\n",
      "such as amino acids or large quantities (e.g. at least about\n",
      "5%, 10%, 20%, 50%, 70%, or more) of carboxylic acid salts.\n",
      "In some embodiments, an oral dosage form may have an oral\n",
      "bioavailability of the osteoclast inhibitorsuch as zole-\n",
      "dronic acid, minodronic acid, ibandronic acidof about\n",
      "0.01% to about 10%, about 0.1% to about 7%, about 0.1%\n",
      "to about 5%, etc. Without ingredients or other methods to\n",
      "enhance bioavailability, bisphosphonates such as zoledronic\n",
      "acid typically have a low bioavailability in an oral dosage\n",
      "form. In some embodiments, the oral bioavailability of\n",
      "zoledronic acid is unenhanced or substantially unenhanced.\n",
      "For example, the oral bioavailability of zoledronic acid can\n",
      "be about 0.01% to about 5%, about 0.01% to about 4%,\n",
      "about 0.1% to about 3%, about 0.1% to about 2%, about\n",
      "0.2% to about 2%, about 0.2% to about 1.5%, about 0.3% to\n",
      "about 1.5%, about 0.3% to about 1%, about 1% to about 3%,\n",
      "about 1.2% to about 3.5%, about 1.2% to about 3%, about\n",
      "1% to about 4%, about 1.5% to about 4.5%, about 0.1% to\n",
      "about 0.5%, about 0.3% to about 0.5%, about 0.5% to about\n",
      "1%, about 0.6% to about 0.7%, about 0.7% to about 0.8%,\n",
      "about 0.8% to about 0.9%, about 0.9%, about 1% to about\n",
      "1.1%, about 1.1% to about 1.2%, about 1.2% to about 1.3%,\n",
      "about 1.3% to about 1.4%, about 1.4% to about 1.5%, about\n",
      "1.5% to about 1.6%, about 1.6% to about 1.8%, about 1.8%\n",
      "to about 2%, about 2% to about 2.2%, about 2.2% to about\n",
      "2.4%, about 2.4% to about 2.6%, about 2.6% to about 2.8%,\n",
      "about 2.8% to about 3.0%, about 3% to about 3.2%, about\n",
      "3.2% to about 3.4%, about 3.4% to about 3.6%, about 3.6%\n",
      "to about 3.8%, about 3.8% to about 4%, about 2% to about\n",
      "2.5%, or any bioavailability of zoledronic acid in a range\n",
      "bounded by, or between, any of these values.\n",
      "\n",
      "[0208] One embodiment is a pharmaceutical composition\n",
      "comprising an osteoclast inhibitor such as zoledronic acid,\n",
      "minodronic acid, or ibandronic acid wherein the oral bio-\n",
      "availability of zoledronic acid in the dosage form is from\n",
      "about 0.01% to about 10%.\n",
      "\n",
      "[0209] In some embodiments, the oral bioavailability of\n",
      "the osteoclast inhibitor in the dosage form is about 0.01% to\n",
      "about 5%, about 0.1% to about 7%, about 0.1% to about 5%,\n",
      "about 0.1% to about 3%, about 0.1% to about 2%, about\n",
      "0.2% to about 2%, about 0.2% to about 1.5%, about 0.3% to\n",
      "about 1.5%, or about 0.3% to about 1.0%.\n",
      "\n",
      "[0210] In some embodiments, the oral bioavailability of\n",
      "zoledronic acid in the dosage form 1s about 0.01% to about\n",
      "5%.thereof 1s contemplated unless otherwise indicated herein or\n",
      "otherwise clearly contradicted by context.\n",
      "\n",
      "[0758] In closing, it is to be understood that the embodi-\n",
      "ments disclosed herein are illustrative of the principles of the\n",
      "claims. Other modifications that may be employed are\n",
      "within the scope of the claims. Thus, by way of example, but\n",
      "not of limitation, alternative embodiments may be utilized in\n",
      "accordance with the teachings herein. Accordingly, the\n",
      "claims are not limited to embodiments precisely as shown\n",
      "and described.\n",
      "\n",
      "What is claimed is:\n",
      "\n",
      "1. A method of treating arthritis comprising administering\n",
      "an oral dosage form containing zoledronic acid, in an acid\n",
      "form or a salt form, to a human being in need thereof,\n",
      "wherein the human being receives a total amount of about\n",
      "100 mg to about 500 mg of the zoledronic acid, wherein the\n",
      "oral dosage form does not contain a bioavailability enhancer,\n",
      "wherein the human being has been fasted for at least 1 hour\n",
      "before the administration of the dosage form and continues\n",
      "to fast for at least 1 hour after the administration of the\n",
      "dosage form, and wherein the human being experiences pain\n",
      "relief that lasts for a duration of at least 48 hours, and the\n",
      "human being receives the dosage form no more often than\n",
      "once daily.\n",
      "\n",
      "2. The method of claim 1, wherein the zoledronic acid is\n",
      "in the free acid form.\n",
      "\n",
      "3. The method of claim 1, wherein the zoledronic acid is\n",
      "in the salt form.\n",
      "\n",
      "4. The method of claim 3, wherein the zoledronic acid is\n",
      "in a disodium salt form.\n",
      "\n",
      "5. The method of claim 1, wherein the human being is\n",
      "fasted for at least 2 hours before the dosage form is admin-\n",
      "istered.\n",
      "\n",
      "6. The method of claim 1, wherein the human being is\n",
      "fasted for at least 4 hours before the dosage form is admin-\n",
      "istered.\n",
      "\n",
      "7. The method of claim 1, wherein the human being is\n",
      "fasted for at least 2 hours after the dosage form is admin-\n",
      "istered.\n",
      "\n",
      "8. The method of claim 1, wherein the dosage form is\n",
      "orally administered weekly.\n",
      "\n",
      "9. The method of claim 1, wherein the dosage form is\n",
      "orally administered monthly.\n",
      "\n",
      "10. The method of claim 8, wherein the dosage form is\n",
      "orally administered weekly for 1 to 2 months.\n",
      "\n",
      "11. The method of claim 1, wherein the dosage form\n",
      "contains about 40 mg to about 150 mg of the zoledronic acid.\n",
      "\n",
      "12. The method of claim 11, wherein the dosage form is\n",
      "orally administered approximately weekly for 4 to 8 con-\n",
      "secutive weeks.\n",
      "\n",
      "13. The method of claim 4, wherein the dosage form\n",
      "contains an amount of the disodium salt form of zoledronic\n",
      "acid that is equivalent to about 40 mg to about 60 mg of the\n",
      "free acid form of zoledronic acid.\n",
      "\n",
      "14. The method of claim 13, wherein the dosage form is\n",
      "orally administered approximately weekly for 6 consecutive\n",
      "weeks.\n",
      "\n",
      "15. The method of claim 11, wherein orally administering\n",
      "a single dose of the dosage form results in AUC,_4, of the\n",
      "zoledronic acid in the human being of about 100 ng-hr/mL\n",
      "to about 500 ng-hr/mL.\n",
      "\n",
      "16. The method of claim 4, wherein orally administering\n",
      "the dosage form containing the disodium salt form of\n",
      "zoledronic acid results in a 24-hour sustained plasma level\n",
      "factor in the human being that is at least about 2 times that\n",
      "of 4 mg of zoledronic acid administered intravenously.\n",
      "\n",
      "17. The method of claim 4, wherein the bioavailability of\n",
      "zoledronic acid in the dosage form is about 1.1% to about\n",
      "2% as determined when orally administered to the human\n",
      "being.\n",
      "\n",
      "18. The method of claim 1, wherein the arthritis affects a\n",
      "knee, an elbow, a wrist, a shoulder, or a hip.\n",
      "\n",
      "19. The method of claim 1, wherein the dosage form is\n",
      "orally administered to treat osteoarthritis.\n",
      "\n",
      "20. The method of claim 1, wherein the dosage form is\n",
      "orally administered to treat rheumatoid arthritis.\n",
      "\n",
      "21. The method of claim 1, wherein the dosage form is\n",
      "orally administered to treat juvenile rheumatoid arthritis.\n",
      "\n",
      "22. The method of claim 1, wherein the dosage form is\n",
      "orally administered to treat erosive osteoarthritis.\n",
      "\n",
      "23. The method of claim 1, wherein the dosage form is\n",
      "orally administered to treat transient osteoarthritis of the hip.\n",
      "\n",
      "24. The method of claim 1, wherein, at the beginning of\n",
      "treatment, the human being has an average weekly pain\n",
      "intensity of at least 5 on the 0-10 numeric rating scale, and\n",
      "wherein the pain is associated with arthritis.\n",
      "\n",
      "25. The method of claim 1, wherein the arthritis is\n",
      "associated with a bone marrow lesion.\n",
      "\n",
      "26. The method of claim 25, wherein the human being has\n",
      "OARSI Grade 0 joint space narrowing.\n",
      "\n",
      "* * * * *Embodiment 393\n",
      "\n",
      "[0722] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by about 90%-95%.\n",
      "\n",
      "Embodiment 394\n",
      "\n",
      "[0723] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 95%.\n",
      "\n",
      "Embodiment 395\n",
      "\n",
      "[0724] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 99%.\n",
      "\n",
      "Embodiment 396\n",
      "\n",
      "[0725] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 100%.\n",
      "\n",
      "Embodiment 397\n",
      "\n",
      "[0726] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 5%.\n",
      "\n",
      "Embodiment 398\n",
      "\n",
      "[0727] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 10%.\n",
      "\n",
      "Embodiment 399\n",
      "\n",
      "[0728] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 15%.\n",
      "\n",
      "Embodiment 400\n",
      "\n",
      "[0729] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 20%.\n",
      "\n",
      "Embodiment 401\n",
      "\n",
      "[0730] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 25%.\n",
      "\n",
      "Embodiment 402\n",
      "\n",
      "[0731] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 30%.\n",
      "\n",
      "Embodiment 403\n",
      "\n",
      "[0732] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 35%.\n",
      "\n",
      "Embodiment 404\n",
      "\n",
      "[0733] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 40%.\n",
      "\n",
      "Embodiment 405\n",
      "\n",
      "[0734] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 45%.\n",
      "\n",
      "Embodiment 406\n",
      "\n",
      "[0735] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 50%.\n",
      "\n",
      "Embodiment 407\n",
      "\n",
      "[0736] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 55%.\n",
      "\n",
      "Embodiment 408\n",
      "\n",
      "[0737] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 60%.\n",
      "\n",
      "Embodiment 409\n",
      "\n",
      "[0738] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by about 60%-70%.\n",
      "\n",
      "Embodiment 410\n",
      "\n",
      "[0739] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by about 70%-80%.\n",
      "\n",
      "Embodiment 411\n",
      "\n",
      "[0740] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by least about 70%.\n",
      "\n",
      "Embodiment 412\n",
      "\n",
      "[0741] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 75%.[0211] In some embodiments, the oral bioavailability of\n",
      "zoledronic acid in the dosage form is about 0.1% to about\n",
      "7%.\n",
      "\n",
      "[0212] In some embodiments, the oral bioavailability of\n",
      "zoledronic acid in the dosage form is about 0.1% to about\n",
      "5%.\n",
      "\n",
      "[0213] In some embodiments, the oral bioavailability of\n",
      "zoledronic acid in the dosage form is about 0.1% to about\n",
      "3%.\n",
      "\n",
      "[0214] In some embodiments, the oral bioavailability of\n",
      "zoledronic acid in the dosage form is about 0.1% to about\n",
      "2%.\n",
      "\n",
      "[0215] In some embodiments, the oral bioavailability of\n",
      "zoledronic acid in the dosage form is about 0.2% to about\n",
      "2%.\n",
      "\n",
      "[0216] In some embodiments, the oral bioavailability of\n",
      "zoledronic acid in the dosage form is about 0.2% to about\n",
      "1.5%.\n",
      "\n",
      "[0217] In some embodiments, the oral bioavailability of\n",
      "zoledronic acid in the dosage form is about 0.3% to about\n",
      "1.5%.\n",
      "\n",
      "[0218] In some embodiments, the oral bioavailability of\n",
      "zoledronic acid in the dosage form is about 0.3% to about\n",
      "1.0%.\n",
      "\n",
      "[0219] In some embodiments, an oral dosage form com-\n",
      "prises about 10 mg to about 300 mg of zoledronic acid,\n",
      "minodronic acid, or ibandronic acid and is administered\n",
      "daily for about 2 to about 15 consecutive days. This regimen\n",
      "may be repeated once monthly, once every two months, once\n",
      "every three months, once every four months, once every five\n",
      "months, once every six months, once yearly, or once every\n",
      "two years.\n",
      "\n",
      "[0220] In some embodiments, an oral dosage form com-\n",
      "prises about 10 mg to about 150 mg or about 10 mg to about\n",
      "100 mg of zoledronic acid, minodronic acid, or ibandronic\n",
      "acid and is administered daily for about 2 to about 15\n",
      "consecutive days. This regimen may be repeated once\n",
      "monthly, once every two months, once every three months,\n",
      "once every four months, once every five months, once every\n",
      "six months, once yearly, or once every two years.\n",
      "\n",
      "[0221] In some embodiments, an oral dosage form com-\n",
      "prises about 10 mg to about 150 mg or about 10 mg to about\n",
      "100 mg of zoledronic acid, minodronic acid, or ibandronic\n",
      "acid and is administered daily for about 5 to about 10\n",
      "consecutive days. This regimen may be repeated once\n",
      "monthly, once every two months, once every three months,\n",
      "once every four months, once every five months, once every\n",
      "six months, once yearly, or once every two years.\n",
      "\n",
      "[0222] In some embodiments, an oral dosage form com-\n",
      "prises about 40 mg to about 150 mg of zoledronic acid,\n",
      "minodronic acid, or ibandronic acid and is administered\n",
      "daily for about 5 to about 10 consecutive days. This regimen\n",
      "may be repeated once monthly, once every two months, once\n",
      "every three months, once every four months, once every five\n",
      "months, once every six months, once yearly, or once every\n",
      "two years.\n",
      "\n",
      "[0223] In some embodiments, the oral zoledronic acid,\n",
      "minodronic acid, or ibandronic acid may be administered as\n",
      "one dose of about 100 mg to about 2000 mg. In some\n",
      "embodiments, the oral zoledronic acid, minodronic acid, or\n",
      "ibandronic acid may be administered as one dose of about\n",
      "300 mg to about 1500 mg. In some embodiments, the oral\n",
      "zoledronic acid, minodronic acid, or ibandronic acid may be\n",
      "administered as one dose of about 200 mg to about 1000 mg.\n",
      "\n",
      "The dose of zoledronic acid, minodronic acid, or ibandronic\n",
      "acid may be administered in a single or divided dose.\n",
      "[0224] An osteoclast inhibitor, such as zoledronic acid,\n",
      "minodronic acid, or ibandronic acid, may be formulated for\n",
      "oral administration, for example, with an inert diluent or\n",
      "with an edible carrier, or it may be enclosed in hard or soft\n",
      "shell gelatin capsules, compressed into tablets, or incorpo-\n",
      "rated directly with the food of the diet. For oral therapeutic\n",
      "administration, the active compound may be incorporated\n",
      "with an excipient and used in the form of ingestible tablets,\n",
      "buccal tablets, coated tablets, troches, capsules, elixirs,\n",
      "dispersions, suspensions, solutions, syrups, wafers, patches,\n",
      "and the like.\n",
      "\n",
      "[0225] Tablets, troches, pills, capsules and the like may\n",
      "also contain one or more of the following: a binder such as\n",
      "gum tragacanth, acacia, corn starch or gelatin; an excipient,\n",
      "such as dicalcitum phosphate; a disintegrating agent such as\n",
      "corn starch, potato starch, alginic acid and the like; a\n",
      "lubricant such as magnesium stearate; a sweetening agent\n",
      "such as sucrose, lactose or saccharin; or a flavoring agent\n",
      "such as peppermint, oil of wintergreen or cherry flavoring.\n",
      "When the unit dosage form is a capsule, it may contain, in\n",
      "addition to materials of the above type, a liquid carrier.\n",
      "Various other materials may be present as coating, for\n",
      "instance, tablets, pills, or capsules may be coated with\n",
      "shellac, sugar or both. A syrup or elixir may contain the\n",
      "active compound, sucrose as a sweetening agent, methyl and\n",
      "propylparabens as preservatives, a dye and flavoring, such as\n",
      "cherry or orange flavor. It may be desirable for material in\n",
      "a dosage form or pharmaceutical composition to be phar-\n",
      "maceutically pure and substantially non toxic in the amounts\n",
      "employed.\n",
      "\n",
      "[0226] In some embodiments, an osteoclast inhibitor,\n",
      "including a bisphosphonate, such as zoledronic acid,\n",
      "neridronic acid, etc., is in a dosage form containing one of,\n",
      "or a combination of, the ingredients in the Table E below.\n",
      "\n",
      "TABLE E\n",
      "\n",
      "Iron\n",
      "\n",
      "Methyl Paraben\n",
      "Propyl Paraben\n",
      "Sorbitol\n",
      "\n",
      "Carob Bean Gum\n",
      "Mannitol\n",
      "\n",
      "Gum Tragacanth\n",
      "Guar Gum\n",
      "Benzoic Acid\n",
      "Sodium Benzoate\n",
      "Garlic and Oil of Garlic\n",
      "Oil of Rue\n",
      "\n",
      "Propyl Gallate\n",
      "Gum Ghatti\n",
      "\n",
      "Gum Arabic\n",
      "Sterculia Gum (karaya gum)\n",
      "Indian Dill Seed\n",
      "Pulps\n",
      "\n",
      "Clove Bud Extract\n",
      "Clove Bud Oil\n",
      "Clove Bud Oleoresin\n",
      "Clove Leaf Oil\n",
      "Clove Stem Oil\n",
      "Cholic acid\n",
      "Desoxycholic acid\n",
      "Glycocholic acid\n",
      "Ox bile extract\n",
      "Taurocholic acid\n",
      "Sorbose\n",
      "\n",
      "Sodium thiosulfate\n",
      "Gelatinmay receive, at least about 10 mole % less, at least about 20\n",
      "mole % less, at least about 40 mole % less, at least about 50\n",
      "mole % less, and/or up to about 90 mole % less or 95 mole\n",
      "% less, of the disodium salt form as compared the amount\n",
      "of the diacid form of zoledronic acid that would otherwise\n",
      "be administered, such as a molar amount that would be\n",
      "administered of zoledronic acid in the diacid form in order\n",
      "to achieve the same plasma levels of zoledronic acid.\n",
      "[0135] In some embodiments, a dosage form contains, or\n",
      "a mammal (such as a human being) is administered, an\n",
      "amount of the disodium salt form, on a molar basis, that has\n",
      "a value of about 0.8n,, to about 1.2n, or about 0.9n,, to about\n",
      "1.1 n,, wherein:\n",
      "\n",
      "ng-(b/ba)(Na)\n",
      "\n",
      "wherein b, is the bioavailability of the diacid form, b,, is the\n",
      "bioavailability of the disodium salt form, and n, is the\n",
      "number of moles of the diacid that would be administered in\n",
      "a dosage form containing the diacid form of zoledronic acid.\n",
      "For example, if the diacid form has a bioavailability (b,) of\n",
      "0.01 and the disodium salt form has a bioavailability (b,,) of\n",
      "0.015, and a dosage form would normally contain 0.001\n",
      "moles of the diacid, n,, would be (0.01/0.015)(0.001 moles),\n",
      "or about 0.00067 moles. In some embodiments, the diso-\n",
      "dium salt is administered in an amount that has a value of\n",
      "about ny.\n",
      "\n",
      "[0136] With respect to oral dosage forms comprising a\n",
      "reduced molar amount of the disodium salt of zoledronic\n",
      "acid as compared to the diacid form of zoledronic acid, in\n",
      "some embodiments, the bioavailability of the zoledronic\n",
      "acid in the disodium salt form is sufficiently high that, if the\n",
      "drug is administered to a mammal, at least as much zole-\n",
      "dronic acid is present in the blood of the mammal as would\n",
      "be present if zoledronic acid were administered 1n the diacid\n",
      "form.\n",
      "\n",
      "[0137] With respect to oral dosage forms comprising the\n",
      "disodium salt form of zoledronic acid, in some embodi-\n",
      "ments, the disodium salt form is present in a lower molar\n",
      "amount than would be present if the zoledronic acid were in\n",
      "the diacid form; and the zoledronic acid in the disodium salt\n",
      "form has an improved bioavailability as compared to the\n",
      "zoledronic acid in the diacid form to the extent that the lower\n",
      "molar amount of the disodium salt in the dosage form does\n",
      "not reduce the amount of zoledronic acid delivered to the\n",
      "plasma of a mammal.\n",
      "\n",
      "[0138] Some oral dosage forms comprising zoledronic\n",
      "acid have a dose of zoledronic acid and a configuration\n",
      "suitable for a particular species of mammal, e.g. dog, rat,\n",
      "human, etc. Such a dosage form may have zoledronic acid\n",
      "present in an amount that results in a desired range for an\n",
      "area under the plasma concentration curve (AUC) of zole-\n",
      "dronic acid in that particular species of mammal. For\n",
      "example the dose of zoledronic acid and a configuration of\n",
      "the oral dosage form may result in an AUC of zoledronic\n",
      "acid of about 1 ng-h/mL to about 700 ng-h/mL, about 3\n",
      "ng-h/mL to about 30 ng-h/mL, about 3 ng-h/mL to about 10\n",
      "ng-h/mL, about 50 ng-h/mL to about 700 ng-h/mL, about 130\n",
      "ng-h/mL to about 180 ng-h/mL, about 300 ng-h/mL to about\n",
      "450 ng-h/mL, about 300 ng-h/mL to about 350 ng-h/mL,\n",
      "about 300 ng:-h/mL to about 310 ng-h/mL, about 340 ng-h/\n",
      "mL to about 350 ng-h/mL, about 370 ng-h/mL to about 420\n",
      "ng-h/mL, about 380 ng-h/mL to about 390 ng-h/mL, about\n",
      "405 ng-h/mL to about 415 ng-h/mL, about 140 ng-h/mL to\n",
      "about 160 ng-h/mL, about 140 ng-h/mL to about 150 ng-h/\n",
      "\n",
      "mL, about 150 ng-h/mL to about 160 ng-h/mL, about 140\n",
      "ng-h/mL, 142 ng-h/mL, about 155 ng-h/mL, about 305\n",
      "ng-h/mL, 304 ng-h/mL, about 345 ng-h/mL, 343 ng-h/mL,\n",
      "about 385 ng-h/mL, 384 ng-h/mL, about 410 ng-h/mL, or\n",
      "any AUC in a range bounded by, or between, any of these\n",
      "values, upon administration of the oral dosage form to a\n",
      "mammal.\n",
      "\n",
      "[0139] Unless otherwise indicated, the AUC refers to the\n",
      "AUC calculated to the last measured concentration (AUC\n",
      "(o-4) and extrapolated to infinity (AUC @_;,,).\n",
      "\n",
      "[0140] An oral dosage form comprising zoledronic acid\n",
      "having a dose of zoledronic acid and a configuration suitable\n",
      "for a particular species of mammal may have zoledronic acid\n",
      "present in an amount that results ina C,,. of zoledronic acid\n",
      "of about 0.2 ng/mL to about 300 ng/mL, about 0.5 ng/mL to\n",
      "about 5 ng/mL, about 5 ng/mL to about 300 ng/mL, about 5\n",
      "ng/mL to about 50 ng/mL, about 20 ng/mL to about 50\n",
      "ng/mL, about 30 ng/mL to about 50 ng/mL, about 50 ng/mL\n",
      "to about 200 ng/mL, about 50 ng/mL to about 150 ng/mL,\n",
      "about 80 ng/mL to about 120 ng/mL, about 90 ng/mL to\n",
      "about 100 ng/mL, about 50 ng/mL to about 200 ng/mL,\n",
      "about 40 ng/mL, about 95 ng/mL, about 97 ng/mL, or any\n",
      "C,,ax 1 a range bounded by, or between, any of these values,\n",
      "upon administration of the oral dosage form to a mammal.\n",
      "[0141] An oral dosage form comprising zoledronic acid\n",
      "having a dose of zoledronic acid and a configuration suitable\n",
      "for a particular species of mammal may be configured so that\n",
      "administration of the oral dosage form to the particular\n",
      "species of mammal results in a T,,. of zoledronic acid of\n",
      "about 0.4 hr to about 1 hr, about 0.5 hr, or about 0.75 hr, or\n",
      "any Tin a range bounded by, or between, any of these\n",
      "values.\n",
      "\n",
      "[0142] In some embodiments, the zoledronic acid in the\n",
      "disodium salt form is present in an amount such that the oral\n",
      "dosage form provides an area under the plasma concentra-\n",
      "tion curve of zoledronic acid of about 4 ng-h/mL to about\n",
      "2000 ng-h/mL to the mammal each time the zoledronic acid\n",
      "in the disodium salt is administered.\n",
      "\n",
      "[0143] In some embodiments, the zoledronic acid, includ-\n",
      "ing zoledronic acid in an acid or a salt form, e.g the disodium\n",
      "salt form, is present in an amount such that the oral dosage\n",
      "form provides an area under the plasma concentration curve\n",
      "of zoledronic acid of about 100 ng-h/mL to about 2000\n",
      "ng-h/mL, about 100 ng-h/mL to about 1000 ng-h/mL, about\n",
      "500 ng-h/mL to about 1000 ng-h/mL, or about 500 ng-h/mL\n",
      "to about 700 ng-h/mL in the mammal to which the dosage\n",
      "form is administered. This amount may be suitable for\n",
      "administration of the oral dosage form about every 3 to 4\n",
      "weeks.\n",
      "\n",
      "[0144] In some embodiments, the zoledronic acid, such as\n",
      "zoledronic acid in an acid form or a salt form, such as the\n",
      "disodium salt form, is present in an amount such that the oral\n",
      "dosage form provides an area under the plasma concentra-\n",
      "tion curve (AUC) of zoledronic acid of about 20 ng-h/mL to\n",
      "about 700 ng-h/mL, about 50 ng-h/mL to about 500 ng-h/mL,\n",
      "about 50 ng-h/mL to about 400 ng-h/mL, about 50 ng-h/mL\n",
      "to about 300 ng-h/mL, about 50 ng-h/mL to about 200\n",
      "ng-h/mL, about 50 ng-h/mL to about 100 ng-h/mL, about 130\n",
      "ng-h/mL to about 150 ng-h/mL, about 130 ng-h/mL to about\n",
      "140 ng-h/mL, about 150 ng-h/mL to about 200 ng-h/mL,\n",
      "about 200 ng:-h/mL to about 300 ng-h/mL, about 250 ng-h/\n",
      "mL to about 300 ng-h/mL, about 300 ng-h/mL to about 400\n",
      "ng-h/mL, about 400 ng-h/mL to about 500 ng-h/mL, about\n",
      "350 ng-h/mL to about 400 ng-h/mL, about 450 ng-h/mL tonitrogen-containing bisphosphonate, e.g. zoledronic acid,\n",
      "minodronic acid, ibandronic acid, is about 1 mg to about\n",
      "1000 mg, about 1 mg to about 500 mg, about 10 mg to about\n",
      "250 mg, about 100 mg to about 300 mg, about 10 mg to\n",
      "about 100 mg, about 10 mg to about 150 mg, about 10 mg\n",
      "to about 100 mg, about 10 mg to about 300 mg, about 20 mg\n",
      "to about 150 mg, about 20 mg to about 60 mg, about 30 mg\n",
      "to about 70 mg, about 40 mg to about 60 mg, about 50 mg\n",
      "to about 70 mg, about 50 mg, about 55 mg, about 100 mg\n",
      "to about 150 mg, or about 30 mg to about 100 mg. In some\n",
      "embodiments, the weekly oral dose of the osteoclast inhibi-\n",
      "tor is less than about 250 mg/m, less than about 200 mg/m,\n",
      "less than about 175 mg/m, about 6 mg/m? to about 250\n",
      "mg/m*, about 10 mg/m* to about 210 mg/m, about 10\n",
      "mg/m* to about 170 mg/m, about 4 mg/m* to about 140\n",
      "mg/m, about 100 mg/m? to about 140 mg/m, about 126\n",
      "mg/m*, or any amount in a range bounded by, or between,\n",
      "any of these values. The weekly oral dose may be given as\n",
      "a single dose, given once during the week, or may be given\n",
      "in 2, 3, 4, 5, 6, or 7 individual doses during the week.\n",
      "\n",
      "[0197] In some embodiments the weekly oral dose of\n",
      "zoledronic acid is about 1 mg to about 1000 mg, about 1 mg\n",
      "to about 500 mg, about 10 mg to about 250 mg, about 100\n",
      "mg to about 300 mg, about 10 mg to about 100 mg, about\n",
      "10 mg to about 150 mg, about 10 mg to about 100 mg, about\n",
      "10 mg to about 300 mg, about 20 mg to about 150 mg, about\n",
      "20 mg to about 60 mg, about 30 mg to about 70 mg, about\n",
      "40 mg to about 60 mg, about 50 mg to about 70 mg, about\n",
      "50 mg, about 55 mg, about 100 mg to about 150 mg, or about\n",
      "30 mg to about 100 mg. In some embodiments, the weekly\n",
      "oral dose of zoledronic acid is less than about 250 mg/m,\n",
      "less than about 200 mg/m, less than about 175 mg/m,\n",
      "about 6 mg/m? to about 250 mg/m, about 10 mg/m? to about\n",
      "210 mg/m, about 10 mg/m* to about 170 mg/m, about 4\n",
      "mg/m* to about 140 mg/m7, about 100 mg/m* to about 140\n",
      "mg/m7, about 126 mg/m, or any amount of zoledronic acid\n",
      "in a range bounded by, or between, any of these values. The\n",
      "weekly oral dose may be given as a single dose, given once\n",
      "during the week, or may be given in 2, 3, 4, 5, 6, or 7\n",
      "individual doses during the week.\n",
      "\n",
      "[0198] In some embodiments, the monthly dose of the\n",
      "osteoclast inhibitor, including a bisphosphonate, such as a\n",
      "nitrogen-containing bisphosphonate, e.g. zoledronic acid,\n",
      "minodronic acid, or ibandronic acid, or the amount of the\n",
      "osteoclast inhibitor that is administered over a period of a\n",
      "month, is about 5000 mg or less, about 4000 mg or less,\n",
      "about 3000 mg or less, about 2000 mg or less, about 1000\n",
      "mg or less, about 700 mg or less, about 600 mg or less, about\n",
      "1 mg to about 4,000 mg, about 1 mg to about 1,000 mg,\n",
      "about 10 mg to about 1000 mg, about 50 mg to about 1000\n",
      "mg, about 10 mg to about 600 mg, about 40 mg to about 600\n",
      "mg, about 50 mg to about 600 mg, about 40 mg to about 400\n",
      "mg, about 50 mg to about 200 mg, about 200 mg to about\n",
      "300 mg, about 250 mg to about 350 mg, or about 100 mg to\n",
      "about 600 mg, about 40 mg to about 2000 mg, about 40 mg\n",
      "to about 800 mg, about 50 mg to about 800 mg, or about 100\n",
      "mg to about 800 mg, about 40 mg to about 1000 mg, about\n",
      "50 mg to about 1000 mg, or about 100 mg to about 1000 mg,\n",
      "or any monthly dose in a range bounded by, or between, any\n",
      "of these values. In some embodiments, the monthly oral\n",
      "dose of the osteoclast inhibitor is less than about 1000\n",
      "mg/m, less than about 800 mg/m, less than about 600\n",
      "mg/m, about 10 mg/m* to about 1000 mg/m, about 50\n",
      "mg/m* to about 800 mg/m, about 70 mg/m? to about 700\n",
      "\n",
      "mg/m*, about 100 mg/m* to about 700 mg/m*, about 100\n",
      "mg/m? to about 600 mg/m7, about 50 mg/m? to about 200\n",
      "mg/m*, about 300 mg/m* to about 600 mg/m*, about 450\n",
      "mg/m? to about 600 mg/m, about 300 mg/m? to about 1000\n",
      "mg/m*, about 400 mg/m? to about 1000 mg/m, about 500\n",
      "mg/m? to about 1000 mg/m7, about 400 mg/m? to about 700\n",
      "mg/m*, about 500 mg/m* to about 600 mg/m*, about 540\n",
      "mg/m*, or any amount in a range bounded by, or between,\n",
      "any of these values. Amonthly dose may be given as a single\n",
      "dose, or as two or more individual doses administered during\n",
      "the month. In some embodiments, the monthly dose is\n",
      "administered in 2 or 3 weekly doses. In some embodiments,\n",
      "the monthly dose is administered in 4 or 5 weekly doses. In\n",
      "some embodiments, the monthly dose is administered in 28\n",
      "to 31 daily doses. In some embodiments, the monthly dose\n",
      "is administered in 5 to 10 individual doses during the month.\n",
      "The monthly dose may be administered for only 1 month, or\n",
      "may be repeatedly administered for 2 or more months.\n",
      "\n",
      "[0199] In some embodiments, the monthly dose of zole-\n",
      "dronic acid, or the amount of zoledronic acid that is admin-\n",
      "istered over a period of a month, is about 5000 mg or less,\n",
      "about 4000 mg or less, about 3000 mg or less, about 2000\n",
      "mg or less, about 1000 mg or less, about 700 mg or less,\n",
      "about 600 mg or less, about 1 mg to about 4,000 mg, about\n",
      "1 mg to about 1,000 mg, about 10 mg to about 1000 mg,\n",
      "about 50 mg to about 1000 mg, about 10 mg to about 600\n",
      "mg, about 40 mg to about 600 mg, about 50 mg to about 600\n",
      "mg, about 40 mg to about 400 mg, about 50 mg to about 200\n",
      "mg, about 200 mg to about 300 mg, about 250 mg to about\n",
      "350 mg, or about 100 mg to about 600 mg, about 40 mg to\n",
      "about 2000 mg, about 40 mg to about 800 mg, about 50 mg\n",
      "to about 800 mg, or about 100 mg to about 800 mg, about\n",
      "40 mg to about 1000 mg, about 50 mg to about 1000 mg, or\n",
      "about 100 mg to about 1000 mg, or any monthly dose in a\n",
      "range bounded by, or between, any of these values. In some\n",
      "embodiments, the monthly oral dose of zoledronic acid is\n",
      "less than about 1000 mg/m, less than about 800 mg/m, less\n",
      "than about 600 mg/m, about 10 mg/m? to about 1000\n",
      "mg/m*, about 50 mg/m* to about 800 mg/m, about 70\n",
      "mg/m? to about 700 mg/m, about 100 mg/m? to about 700\n",
      "mg/m*, about 100 mg/m? to about 600 mg/m, about 50\n",
      "mg/m* to about 200 mg/m, about 300 mg/m* to about 600\n",
      "mg/m, about 450 mg/m? to about 600 mg/m, about 300\n",
      "mg/m* to about 1000 mg/m, about 400 mg/m* to about\n",
      "1000 mg/m?, about 500 mg/m? to about 1000 mg/m, about\n",
      "400 mg/m? to about 700 mg/m, about 500 mg/m? to about\n",
      "600 mg/m~, about 540 mg/m, or any amount of zoledronic\n",
      "acid in a range bounded by, or between, any of these values.\n",
      "A monthly dose may be given as a single dose, or as two or\n",
      "more individual doses administered during the month. In\n",
      "some embodiments, the monthly dose is administered in 2 or\n",
      "3 weekly doses. In some embodiments, the monthly dose is\n",
      "administered in 4 or 5 weekly doses. In some embodiments,\n",
      "the monthly dose is administered in 28 to 31 daily doses. In\n",
      "some embodiments, the monthly dose is administered in 5 to\n",
      "10 individual doses during the month. The monthly dose\n",
      "may be administered for only 1 month, or may be repeatedly\n",
      "administered for 2 or more months.\n",
      "\n",
      "[0200] In some embodiments, a six week dose of zole-\n",
      "dronic acid may be about 200 mg to about 500 mg, about\n",
      "300 mg to about 450 mg, or about 300 mg. In some\n",
      "embodiments, the six week dose of zoledronic acid may be\n",
      "administered only once. In some embodiments, the six week\n",
      "dose of zoledronic acid may be administered in six weekly-10.0\n",
      "\n",
      "~-15.0\n",
      "\n",
      "ween we Banetipe lin ni}\n",
      "\n",
      "-20.0\n",
      "\n",
      "  \n",
      "\n",
      "FIG. 11\n",
      "\n",
      "   \n",
      "\n",
      " \n",
      "\n",
      "     \n",
      "\n",
      "                    \n",
      "\n",
      "Change in VAS Pain Score Compared to Baseline\n",
      "\n",
      "with Zoledronic Acid Treatment\n",
      "\n",
      "OARSI Grade 0 OARS! Grade 1 OARS! Grade 2\n",
      "\n",
      "     \n",
      "\n",
      " \n",
      " \n",
      "     \n",
      "\n",
      "navacaeaeineneneatntteentens\n",
      "nn pee see\n",
      "Resanaceescectaneee\n",
      "\n",
      " \n",
      " \n",
      " \n",
      " \n",
      "\n",
      "   \n",
      "    \n",
      "   \n",
      " \n",
      "\n",
      "ne\n",
      "et eee\n",
      "\n",
      " ret atate\n",
      "retabater Benne iaigtgt see\n",
      "sees es re\n",
      "\n",
      "    \n",
      "   \n",
      "\n",
      "     \n",
      " \n",
      "\n",
      " \n",
      "  \n",
      "\n",
      "  \n",
      "   \n",
      "           \n",
      " \n",
      " \n",
      "\n",
      " \n",
      " \n",
      "     \n",
      " \n",
      "\n",
      "   \n",
      " \n",
      " \n",
      "  \n",
      "\n",
      " \n",
      "    \n",
      " \n",
      "      \n",
      "   \n",
      "   \n",
      " \n",
      "      \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      "\n",
      " \n",
      "      \n",
      "   \n",
      " \n",
      "         \n",
      "\n",
      ": seceemnens\n",
      "\n",
      "seas sagt! seeeas aia ee es a8, ie\n",
      "en cs ee meee Bare Bo oe a Sees\n",
      "ce sien a Bs -\n",
      "Se ee Sea Ketone\n",
      "seceesesene seca isha! sn\n",
      "7 anaes ss seaeee att\n",
      "Boe\n",
      "\n",
      "ron atatatatate aahgh hahahaha!\n",
      "wectst, 5.4.8 .8.8. 868,88 he\n",
      "eauchetcbemeehan cee\n",
      "\n",
      "satatetetatatatetetatatetetsplacebo treatment. Furthermore, the patients receiving zole-\n",
      "dronic acid reported NSAID use at one year significantly\n",
      "less often than those in the placebo group. Overall, the\n",
      "improvements in most of the evaluated parameters were\n",
      "greater in the zoledronic acid group throughout the follow-\n",
      "up period.\n",
      "\n",
      "[0290] The clinical characteristics of study participants at\n",
      "baseline are displayed in Table 6. The mean LBP duration\n",
      "was 293 days, initial LBP intensity on VAS 6.7, leg pain on\n",
      "VAS 2.9 and the ODI score was 32%. Altogether 19 patients\n",
      "in the ZA group and 18 in the placebo group had a M1/2\n",
      "lesion. Modic changes were most commonly (70%) situated\n",
      "at L4/5 or L5/S1. The zoledronic acid and placebo groups\n",
      "were similar as regards the demographic and background\n",
      "characteristics of all patients at baseline (Table 6B).\n",
      "\n",
      "[0291] The mean difference (MD) between the treatment\n",
      "groups in the primary outcome, intensity of LBP, signifi-\n",
      "cantly favored zoledronic acid at one month (MD 1.4; 95%\n",
      "Cl 0.01 to 2.9) while at one year no significant difference\n",
      "was observed (MD 0.7; 95% Cl -1.0 to 2.4; Table 7). The\n",
      "proportion of patients with at least 20% improvement in\n",
      "intensity of LBP and PASS both favored the zoledronic acid\n",
      "treatment at one month: zoledronic acid 55% vs. placebo\n",
      "25% (p=0.105) and zoledronic acid 50% vs. placebo 20%\n",
      "(p=0.096), respectively.\n",
      "\n",
      "[0292] For the patients who were treated with zoledronic\n",
      "acid, the reduction in pain intensity was greater in those with\n",
      "greater baseline pain intensity as shown in Table 9. The\n",
      "mean reduction in pain from baseline was 3.4 for patients\n",
      "with baseline pain intensity =7, as compared to a reduction\n",
      "of only 0.1 for patients with a baseline pain intensity <6.\n",
      "\n",
      "[0293] Of the secondary outcomes, the improvement in\n",
      "ODI, favored zoledronic acid at 1 month, the adjusted\n",
      "between-group difference being 6.0% (95% Cl -0.6 to 13),\n",
      "but not at one year (Table 7). Similarly, side bending (to right\n",
      "and left) favored the zoledronic acid treatment at one month\n",
      "but not at one year (Table 7). Changes in total RAND-36,\n",
      "and in the physical and mental components of RAND-36 are\n",
      "shown in Table 8.\n",
      "\n",
      "[0294] At baseline, there were no differences in self-\n",
      "reported use of non-steroidal anti-inflammatory drugs\n",
      "(NSAIDs) between the treatment groups, whereas at one\n",
      "year, only 20% of patients in the ZA group used NSAIDs\n",
      "versus 60% in the placebo group.\n",
      "\n",
      "TABLE 6B\n",
      "\n",
      "Baseline characteristics of study population\n",
      "\n",
      "according to treatment group\n",
      "\n",
      "Zoledronic Acid Pacebo\n",
      "Characteristics n= 20 n = 20\n",
      "Sex, n (%) men 15 (75) 11 (55)\n",
      "Age, mean (SD) years 49 (9.3) $1 (7.3)\n",
      "Smoking, n (%) regular smokers* 5 (25) 6 (30)\n",
      "BMI, mean (SD) kg/m 26 (3.3) 27 (31.2)\n",
      "\n",
      "TABLE 6B-continued\n",
      "\n",
      "Baseline characteristics of study population\n",
      "\n",
      "according to treatment group\n",
      "\n",
      "Characteristics\n",
      "\n",
      "Workload, n (%)\n",
      "\n",
      "Sedentary work with limited\n",
      "walking\n",
      "\n",
      "Fairly light work with considerable\n",
      "walking but no lifting or carrying\n",
      "heavy objects\n",
      "\n",
      "Fairly strenuous work with walking\n",
      "and lifting heaving objects or\n",
      "climbing stairs or uphill\n",
      "\n",
      "Very strenuous work with lifting or\n",
      "carrying heaving objects such as\n",
      "shoveling, digging, or hammering\n",
      "\n",
      "Type of worst MC-lesion**, n\n",
      "\n",
      "Type I\n",
      "\n",
      "Type I/II\n",
      "\n",
      "Type II\n",
      "\n",
      "MC at two or more levels, n (%)\n",
      "\n",
      "Levels of MC, n\n",
      "\n",
      "L2/3\n",
      "\n",
      "L3/4\n",
      "\n",
      "L4/5\n",
      "\n",
      "LS/S1\n",
      "\n",
      "Duration of LBP, median (IQ\n",
      "range) days\n",
      "\n",
      "Intensity of LBP, mean (SD)***\n",
      "Duration of leg pain, median (IQ\n",
      "range) days\n",
      "\n",
      "Intensity of leg pain, mean\n",
      "(SD)***\n",
      "\n",
      "Oswestry Disability Index, %,\n",
      "Mean (SD)\n",
      "\n",
      "Duration of sick leave during the\n",
      "past year, median (IQ range) days\n",
      "RAND-36, mean (SD)\n",
      "RAND-36 physical component,\n",
      "mean (SD)\n",
      "\n",
      "RAND-36 mental component,\n",
      "mean (SD)\n",
      "\n",
      "Zoledronic Acid\n",
      "\n",
      "n = 20\n",
      "\n",
      "4 (20)\n",
      "\n",
      "4 (20)\n",
      "\n",
      "8 (40)\n",
      "\n",
      "4 (20)\n",
      "\n",
      "19\n",
      "\n",
      "7 (3.5)\n",
      "\n",
      "AN Ww Bf\n",
      "\n",
      "7\n",
      "330 (200, 365)\n",
      "\n",
      "6.6 (1.4)\n",
      "50 (0, 100)\n",
      "\n",
      "3.0 (3.1)\n",
      "\n",
      "30 (11)\n",
      "\n",
      "14 (0, 48)\n",
      "\n",
      "50 (8)\n",
      "51 (8)\n",
      "\n",
      "51 (8)\n",
      "\n",
      "Pacebo\n",
      "\n",
      "n= 20\n",
      "\n",
      "4 (22)\n",
      "\n",
      "3 (17)\n",
      "\n",
      "6 (33)\n",
      "\n",
      "5 (28)\n",
      "\n",
      "18\n",
      "4 (20)\n",
      "\n",
      "0\n",
      "\n",
      "5\n",
      "\n",
      "5\n",
      "\n",
      "10\n",
      "\n",
      "315 (270, 365)\n",
      "\n",
      "6.8 (1.6)\n",
      "36 (0, 160)\n",
      "\n",
      "2.9 (2.3)\n",
      "\n",
      "35 (10)\n",
      "\n",
      "18 (1, 181)\n",
      "\n",
      "50 (7)\n",
      "49 (8)\n",
      "\n",
      "49 (9)\n",
      "\n",
      "BMI = Body Mass Index, MC = Modic Change, LBP = low back pain, SD = standard\n",
      "\n",
      "deviation, [Q = inter-quartile.\n",
      "\n",
      "*Smoking at least one cigarette per day.\n",
      "\n",
      "**Tf different types of MC at two or more levels, classification is based on the assumed\n",
      "severity of the type, 1.e., Type I > mixed Type I/II > Type IL.\n",
      "\n",
      "*** Assessed using a 10 cm Visual Analogue Scale (VAS).illustrated in FIG. 8. Detectable plasma levels of zoledronic\n",
      "acid were observed for the entire 48 hours that they were\n",
      "measured.\n",
      "\n",
      "TABLE 1\n",
      "\n",
      "Zoledronic Acid plasma concentrations in beagle dogs\n",
      "\n",
      "Plasma\n",
      "Time concentration\n",
      "\n",
      "(hour) (ng/mL)\n",
      "Group 1 (N = 3) Disodium Zoledronate 0 0.00\n",
      "Tablets 0.25 1193.97\n",
      "(150 mg acid equivalent) 0.5 1852.12\n",
      "0.75 1776.51\n",
      "1 1626.56\n",
      "2 640.57\n",
      "4 136.93\n",
      "6 53.11\n",
      "8 26.97\n",
      "12 13.74\n",
      "24 6.78\n",
      "48 5.39\n",
      "Group 2 (N = 3) Zoledronic Acid Tablets 0 0.00\n",
      "(150 mg acid equivalent) 0.25 390.92\n",
      "0.5 846.19\n",
      "0.75 819.15\n",
      "1 831.77\n",
      "2 477.76\n",
      "4 90.11\n",
      "6 28.22\n",
      "8 15.10\n",
      "12 6.13\n",
      "24 3.18\n",
      "48 1.84\n",
      "\n",
      "[0275] Disodium zoledronate produced significantly\n",
      "\n",
      "higher plasma levels of zoledronic acid than pure zoledronic\n",
      "acid, indicating improved oral absorption with the salt form.\n",
      "Measured using peak plasma concentrations (C,,,.), the\n",
      "disodium salt resulted in a 119% actual and 74% weight-\n",
      "adjusted increase in bioavailability as compared to pure\n",
      "zoledronic acid. Measured using area under the plasma\n",
      "concentration curve (AUC, ..), bioavailability was 84% and\n",
      "46% greater with the disodium salt than with pure zole-\n",
      "dronic acid, on an actual and weight-adjusted basis respec-\n",
      "tively. The average AUC,.., for the disodium salt was 4073\n",
      "ng-h/mL and the average AUC,.., for the diacid was 2217\n",
      "ng-+h/mL. The AUC,.., was found to be dose proportional.\n",
      "Thus, for beagle dogs similar to those tested, about 3 mg to\n",
      "about 4 mg of the disodium salt would be expected to result\n",
      "in an AUC,., of about 100 ng-h/mL, and about 7 mg to about\n",
      "8 mg of the disodium salt would be expected to result in an\n",
      "AUC,.., of about 200 ng-h/mL.\n",
      "\n",
      "Example 6. Hardness of Tablets Comprising\n",
      "Zoledronic Acid in the Free Acid and Disodium\n",
      "Salt Forms\n",
      "\n",
      "[0276] Tablets were prepared by blending zoledronic acid,\n",
      "either in the form of the free acid or the disodium salt, with\n",
      "identical excipients. For dosage forms with a greater amount\n",
      "of active, the amount of the excipients was reduced propor-\n",
      "tionally to keep the weight of the tablet at about 100 mg.\n",
      "After blending, the ingredients were compressed at varying\n",
      "pressures, followed by a film coating. The resulting tablets\n",
      "were then tested for hardness using a Dr. Schleuniger\n",
      "Pharmatron 8M Tablet Hardness Tester. The results are\n",
      "shown in Table 2 and FIG. 9.\n",
      "\n",
      "TABLE 2\n",
      "\n",
      "Compression Hardness (kPa)\n",
      "\n",
      "Force Diacid Disodium Salt Disodium Salt\n",
      "(psi) 50 mg 50 mg 71 mg\n",
      "800 4.0 8.7 4.8\n",
      "1100 6.1 11.2 6.8\n",
      "1500 7.7 13.7 7.4\n",
      "2000 8.7 16.3 10.7\n",
      "2400 8.7 11.3\n",
      "3000 11.4 14.1\n",
      "4400 12.5 14.9\n",
      "5500 12.8 18.2\n",
      "\n",
      "6100 13.0\n",
      "\n",
      "Example 7. Effects of Zoledronic Acid on Patients\n",
      "with Osteoarthritis and BML\n",
      "\n",
      "[0277] Some embodiments related to joint pain, bone\n",
      "marrow lesions, and osteoarthritis were conceived as a result\n",
      "of analyzing data from a clinical study. Some of the results\n",
      "of this study were reported by Laslett et al. in Ann Rheum\n",
      "Dis 2012; 71:1322-1328. Some of the description and data\n",
      "reported below was not published prior to filing the present\n",
      "application. Fifty-two (52) patients with clinical knee\n",
      "osteoarthritis and knee bone marrow lesions (BML) were\n",
      "randomized to receive either intravenous zoledronic acid (5\n",
      "mg) or placebo in a double blind fashion. All patients had to\n",
      "have at least one bone marrow lesion (BML) in the affected\n",
      "knee on magnetic resonance imaging (MRI). All patients\n",
      "had x-ray of the knee for determination of joint space\n",
      "narrowing (JSN), which was graded according to the\n",
      "Osteoarthritis Research Society International (OARSIJ) atlas.\n",
      "Patients had either no joint space narrowing (OARSI Grade\n",
      "0), or greater degrees of joint space narrowing (OARSI\n",
      "Grade 1 and Grade 2). Twenty six patients were treated with\n",
      "zoledronic acid (8, 6, and 12 with OARSI Grades 0, 1, and\n",
      "2, respectively). Twenty six patients received placebo (8, 8,\n",
      "and 10 with OARSI Grades 0, 1 and 2, respectively).\n",
      "\n",
      "[0278] Pain intensity was assessed, at baseline and at three\n",
      "months, using a 100 mm visual analog scale (VAS), with\n",
      "zero representing no pain and 100 representing extreme\n",
      "pain. The change in pain intensity from baseline to 3 months\n",
      "was calculated.\n",
      "\n",
      "[0279] With zoledronic acid treatment, pain was reduced\n",
      "significantly as compared to placebo in patients with no joint\n",
      "space narrowing (OARSI Grade 0), but not in patients with\n",
      "joint space narrowing (OARSI Grades 1-2). As shown in\n",
      "Table 3 and FIG. 10, average VAS scores were reduced by\n",
      "15 mm as compared to placebo in the OARSI Grade 0 group,\n",
      "but only by 0.28 as compared to placebo in patients with\n",
      "OARSI Grades 1-2.\n",
      "\n",
      "[0280] Inthe zoledronic acid group, average VAS scores at\n",
      "3 months decreased from baseline by approximately 25 mm\n",
      "and 21 mm in patients with OARSI Grades 0 and 1,\n",
      "respectively, but only by 9 mm in the OARSI Grade 2\n",
      "patients (FIG. 11).about 500 ng-h/mL, about 130 ng-h/mL to about 160 ng-h/\n",
      "mL, about 405 ng-h/mL to about 450 ng:h/mL, about 100\n",
      "ng-h/mL to about 500 ng-h/mL, about 100 ng-h/mL to about\n",
      "400 ng-h/mL, about 100 ng-h/mL to about 300 ng-h/mL,\n",
      "about 100 ng-h/mL to about 200 ng-h/mL, about 125 ng-h/\n",
      "mL to about 500 ng-h/mL, about 125 ng-h/mL to about 400\n",
      "ng-h/mL, about 125 ng-h/mL to about 300 ng-h/mL, about\n",
      "125 ng-h/mL to about 200 ng-h/mL, or about 200 ng-h/mL\n",
      "to about 300 ng-h/mL, in the mammal to which the dosage\n",
      "form is administered. This amount may be suitable for\n",
      "weekly administration of the oral dosage, or for administra-\n",
      "tion of 3 to 5 individual dosages during a month. The\n",
      "individual dosages could be given at regular intervals, given\n",
      "during the first week, or at any other schedule that provides\n",
      "3 to 5 dosages during the month.\n",
      "\n",
      "[0145] In some embodiments, the zoledronic acid is pres-\n",
      "ent in an amount such that the oral dosage form provides an\n",
      "area under the plasma concentration curve of zoledronic acid\n",
      "of about 4 ng-h/mL to about 100 ng-h/mL, about 10 ng-h/mL\n",
      "to about 50 ng-h/mL, about 10 ng-h/mL to about 30 ng-h/mL,\n",
      "20 ng-h/mL to about 700 ng:-h/mL, about 50 ng-h/mL to\n",
      "about 500 ng-h/mL, about 50 ng-h/mL to about 400 ng-h/mL,\n",
      "about 50 ng-h/mL to about 300 ng-h/mL, about 50 ng-h/mL\n",
      "to about 200 ng-h/mL, about 100 ng-h/mL to about 500\n",
      "ng-h/mL, about 100 ng-h/mL to about 400 ng-h/mL, about\n",
      "100 ng-h/mL to about 300 ng-h/mL, about 100 ng-h/mL to\n",
      "about 200 ng-h/mL, about 125 ng-h/mL to about 500 ng-h/\n",
      "mL, about 125 ng-h/mL to about 400 ng-h/mL, about 125\n",
      "ng-h/mL to about 300 ng-h/mL, about 125 ng-h/mL to about\n",
      "200 ng-h/mL, or about 200 ng-h/mL to about 300 ng-h/mL\n",
      "in the mammal to which the dosage form is administered.\n",
      "This amount may be suitable for daily administration of the\n",
      "oral dosage form. In some embodiments, the dosage form\n",
      "may be administered for 2, 3, 4, 5, 6, 7, 8, 9, or 10, 5 to 10,\n",
      "or 6 to 10 consecutive days.\n",
      "\n",
      "[0146] In some embodiments, the zoledronic acid, such as\n",
      "zoledronic acid in an acid form or a salt form, such as the\n",
      "disodium salt form, is present in an amount such that the oral\n",
      "administration of the dosage form in a fasted state results in\n",
      "an area under the plasma concentration curve (AUC) of\n",
      "zoledronic acid of about 50 ng-h/mL to about 500 ng-h/mL,\n",
      "about 50 ng-h/mL to about 100 ng-h/mL, about 100 ng-h/mL\n",
      "to about 200 ng-h/mL, about 130 ng-h/mL to about 180\n",
      "ng-h/mL, about 130 ng-h/mL to about 150 ng-h/mL, about\n",
      "130 ng-h/mL to about 140 ng-h/mL, about 140 ng-h/mL to\n",
      "about 150 ng-h/mL, about 150 ng-h/mL to about 200 ng-h/\n",
      "mL, about 200 ng-h/mL to about 300 ng:h/mL, about 250\n",
      "ng-h/mL to about 300 ng-h/mL, about 300 ng-h/mL to about\n",
      "400 ng-h/mL, about 300 ng-h/mL to about 350 ng-h/mL,\n",
      "about 400 ng-h/mL to about 500 ng-h/mL, about 350 ng-h/\n",
      "mL to about 400 ng-h/mL, about 450 ng-h/mL to about 500\n",
      "ng-h/mL, about 130 ng-h/mL to about 160 ng-h/mL, about\n",
      "405 ng-h/mL to about 450 ng-h/mL, measured over a 24 hour\n",
      "period.\n",
      "\n",
      "[0147] In some embodiments, molecular complex com-\n",
      "prising neridronic acid is administered in an amount that\n",
      "results in an AUC of neridronic acid, measured over the\n",
      "entire course of treatment, of about 10,000-30,000 ng-h/mL\n",
      "about 30,000-100,000 ng-h/mL about 30,000-50,000 ng-h/\n",
      "mL, about 30,000-40,000 ng-h/mL, about 40,000-50,000\n",
      "ng-h/mL, about 50,000-60,000 ng-h/mL, about 60,000-70,\n",
      "000 ng-h/mL, about 50,000-70,000 ng-h/mL, about 70,000-\n",
      "80,000 ng-h/mL, about 80,000-90,000 ng-h/mL, about\n",
      "90,000-100,000 ng-h/mL, about 70,000-100,000 ng-h/mL,\n",
      "\n",
      "about 100,000-200,0000 ng-h/mL, about 200,000-300,0000\n",
      "ng-h/mL, about 300,000-400,0000 ng-h/mL, about 400,000-\n",
      "500,0000 ng-h/mL, or any AUC in a range bounded by any\n",
      "of these values.\n",
      "\n",
      "[0148] In some embodiments, an osteoclast inhibitor, a\n",
      "bisphosphonate, or a RANK/RANKL antagonist, such as\n",
      "zoledronic acid, etc., is administered at an interval of about\n",
      "once, twice, or thrice daily, or every 1, 2, 3, 4, 5, 6, 7, 8, 9,\n",
      "10, 11, 12, 13, or 14 days; or 15, 16, 17, 18, 19, 20, or 21\n",
      "days; or 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 days; or 32,\n",
      "33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, or 45; or 46,\n",
      "47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 days;\n",
      "or 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75,\n",
      "76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90\n",
      "days; or 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103,\n",
      "104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115,\n",
      "116, 117, 118, 119, or 120 days.\n",
      "\n",
      "[0149] Oral administration of zoledronic acid, particularly\n",
      "oral administration of the disodium salt form of zoledronic\n",
      "acid, can result in more sustained plasma levels of the drug\n",
      "as compared to parenteral modes of administration, such\n",
      "intravenous or subcutaneous. For example, the amount of\n",
      "zoledronic acid in the plasma can be significantly higher for\n",
      "oral administration of the disodium salt about 24 hours or 48\n",
      "hours, or longer, after administration. In some embodiments,\n",
      "oral zoledronic acid has a 24 hour sustained plasma level\n",
      "factor of about 1 or higher, such as about 1 to about 10, about\n",
      "1 to about 5, about 3 to about 5, or about 3 to about 4. In\n",
      "some embodiments, an orally administered dosage form of\n",
      "zoledronic acid has a 24 hour sustained plasma level factor\n",
      "ora 48 hour sustained plasma level factor that is higher, such\n",
      "as at least 1.2 times, at least about 2 times, at least about 5\n",
      "times, about 1.2 times to about 20 times, about 2 times to\n",
      "about 15 times, about 5 times to about 10 times, or about 8\n",
      "to about 15 times that of intravenously administered zole-\n",
      "dronic acid. A sustained plasma level factor, p, is deter-\n",
      "mined by the equation:\n",
      "\n",
      "p-=-1000(C/C\n",
      "\n",
      "IRAX. )\n",
      "\n",
      "wherein C,,, 1s the maximum plasma concentration of\n",
      "zoledronic acid after it is administered and C, is the plasma\n",
      "concentration of zoledronic acid at the time of interest, such\n",
      "as 24 hours. For parenteral administration, the C,,, can be\n",
      "about the C,, or the concentration right after injection of the\n",
      "entire amount of the drug into the body. Sustained plasma\n",
      "level factors can also be obtained for other times, such as 48\n",
      "hours, by using the plasma concentration of zoledronic acid\n",
      "for C, in the equation above. For example, if the maximum\n",
      "plasma level of zoledronic acid after administration is 1000\n",
      "ng/mL and the plasma level of zoledronic acid at 24 hours\n",
      "is 1 ng/mL, the 24 hour sustained plasma level factor is 1.\n",
      "[0150] An oral dosage form comprising zoledronic acid\n",
      "having a dose of zoledronic acid and a configuration suitable\n",
      "for a particular species of mammal may be configured so that\n",
      "the zoledronic acid has a 12 hour sustained plasma level\n",
      "factor of about 12 to about 50, about 20 to about 40, about\n",
      "25 to about 30, about 30 to about 35, about 35 to about 40,\n",
      "about 33, about 30, about 35, or any 12 hour sustained\n",
      "plasma level factor in a range bounded by, or between, any\n",
      "of these values, for the particular species of mammal.\n",
      "\n",
      "[0151] An oral dosage form comprising zoledronic acid\n",
      "having a dose of zoledronic acid and a configuration suitable\n",
      "for a particular species of mammal may be configured so that\n",
      "the zoledronic acid has a 24 hour sustained plasma levelditions by administering a dosage form comprising zole-\n",
      "dronic acid in the form of a disodium salt. This may allow\n",
      "a reduced molar amount of the disodium salt to be used as\n",
      "compared to what would be used with the diacid form.\n",
      "\n",
      "[0047] Insome embodiments, the mammal being treated is\n",
      "not suffering from bone metastasis. In some embodiments,\n",
      "the mammal being treated is not suffering from cancer. In\n",
      "some embodiments, the mammal being treated is not suf-\n",
      "fering from osteoporosis.\n",
      "\n",
      "[0048] For example, zoledronic acid or another bisphos-\n",
      "phonate may be administered orally to relieve musculoskel-\n",
      "etal pain including low back pain, and pain associated with\n",
      "rheumatoid arthritis, juvenile rheumatoid arthritis, osteoar-\n",
      "thritis, erosive osteoarthritis, sero-negative (non-rheuma-\n",
      "toid) arthropathies, non-articular rheumatism, peri-articular\n",
      "disorders, axial spondyloarthritis including ankylosing\n",
      "spondylitis, Pagets disease, fibrous dysplasia, SAPHO syn-\n",
      "drome, transient osteoarthritis of the hip, vertebral crush\n",
      "fractures, osteoporosis, etc. In some embodiments, enhanced\n",
      "bioavailability of the zoledronic acid may be achieved in\n",
      "treating one of these conditions by administering a dosage\n",
      "form comprising zoledronic acid in the form of a disodium\n",
      "salt. This may allow a reduced molar amount of the diso-\n",
      "dium salt to be used as compared to what would be used with\n",
      "the diacid form.\n",
      "\n",
      "[0049] An osteoclast inhibitor, such as a bisphosphonate,\n",
      "e.g. zoledronic acid, may also be used to treat bone fractures\n",
      "or to enhance the healing of bone fractures. In some embodi-\n",
      "ments, a human being that is treated for CRPS, suffered from\n",
      "a precipitating injury such as a bone fracture associated with\n",
      "the CRPS at least 4 weeks, at least 8 weeks, at least 12\n",
      "weeks, at least six months, or at least 1 year before first\n",
      "administering an osteclast inhibitor, such as a bisphospho-\n",
      "nate, including zoledronic acid, neridronic acid, etc.\n",
      "Examples of a precipitating event include a fracture, a\n",
      "cutting injury, a scratch, a puncture injury, etc.\n",
      "\n",
      "[0050] In some embodiments, zoledronic acid or another\n",
      "bisphosphonate may also be administered orally to relieve\n",
      "neuropathic pain, including diabetic peripheral neuropathy,\n",
      "post-herpetic neuralgia, trigeminal neuralgia, monoradicu-\n",
      "lopathies, phantom limb pain, and central pain. Other causes\n",
      "of neuropathic pain include cancer-related pain, lumbar\n",
      "nerve root compression, spinal cord injury, post-stroke pain,\n",
      "central multiple sclerosis pain, HIV-associated neuropathy,\n",
      "and radio-therapy or chemo-therapy associated neuropathy.\n",
      "In some embodiments, enhanced bioavailability of the zole-\n",
      "dronic acid may be achieved in treating one of these con-\n",
      "ditions by administering a dosage form comprising zole-\n",
      "dronic acid in the form of a disodium salt. This may allow\n",
      "a reduced molar amount of the disodium salt to be used as\n",
      "compared to what would be used with the diacid form.\n",
      "\n",
      "[0051] In some embodiments, zoledronic acid or another\n",
      "bisphosphonate may be administered orally to relieve\n",
      "inflammatory pain including musculoskeletal pain, arthritis\n",
      "pain, and complex regional pain syndrome. In some embodi-\n",
      "ments, enhanced bioavailability of the zoledronic acid may\n",
      "be achieved in treating one of these conditions by adminis-\n",
      "tering a dosage form comprising zoledronic acid in the form\n",
      "of a disodium salt. This may allow a reduced molar amount\n",
      "of the disodium salt to be used as compared to what would\n",
      "be used with the diacid form.\n",
      "\n",
      "[0052] Examples of musculoskeletal pain include low\n",
      "back pain; and pain associated with vertebral crush fractures,\n",
      "\n",
      "fibrous dysplasia, osteogenesis imperfecta, Pagets disease\n",
      "of bone, transient osteoporosis, and transient osteoporosis of\n",
      "the hip.\n",
      "\n",
      "[0053] Arthritis refers to inflammatory joint diseases that\n",
      "can be associated with pain. Examples of arthritis pain\n",
      "include pain associated with osteoarthritis, erosive osteoar-\n",
      "thritis, rheumatoid arthritis, juvenile rheumatoid arthritis,\n",
      "sero-negative (non-rheumatoid) arthropathies, non-articular\n",
      "rheumatism, peri-articular disorders, neuropathic arthropa-\n",
      "thies including Charcots foot, axial spondyloarthritis\n",
      "including ankylosing spondylitis, and SAPHO syndrome.\n",
      "[0054] In some embodiments, a human being that is\n",
      "treated for a disease or condition, such as an inflammatory\n",
      "condition, e.g. arthritis or CRPS, by an osteoclast inhibitor,\n",
      "such as a bisphosphonate, e.g. an oral dosage form of\n",
      "zoledronic acid, has an age of at least 18 years, at least 50\n",
      "years (including a male of at least 50 years), a postmeno-\n",
      "pausal female, about 10 years to about 90 years, about 20\n",
      "years to about 80 years, about 30 years to about 75 years,\n",
      "about 40 years to about 70 years, about 1 year to about 16\n",
      "years, or about 80 years to about 95 years. In some embodi-\n",
      "ments, the human being is a male at least 50 years of age or\n",
      "a postmenopausal female, with knee osteoarthritis (OA) and\n",
      "bone marrow lessions (BMLs), having moderate or worse\n",
      "knee pain.\n",
      "\n",
      "[0055] In some embodiments, a human being that is\n",
      "treated for a disease or condition, such as an inflammatory\n",
      "condition, e.g. arthritis, low back pain, or CRPS, by an\n",
      "osteoclast inhibitor, such as a bisphosphonate, e.g. an oral\n",
      "dosage form of zoledronic acid, has suffered from the\n",
      "inflammatory condition for at least 1 month, at least 2\n",
      "months, at least 3 months, at least 6 months, or at least 1\n",
      "year.\n",
      "\n",
      "[0056] In some embodiments, the arthritis affects a knee,\n",
      "an elbow, a finger, a wrist, a shoulder, an ankle, the spine, or\n",
      "a hip.\n",
      "\n",
      "[0057] For treatment of arthritis or joint pain, such as knee\n",
      "pain, in some embodiments the person being treated has\n",
      "OARSI Grade 0, or Kellgren and Lawrence Grades 0 or 1,\n",
      "joint space narrowing.\n",
      "\n",
      "[0058] In some embodiments, the person has lesions, such\n",
      "as bone marrow lesions. In some embodiments the person\n",
      "being treated for bone marrow lesions has normal joint space\n",
      "knee pain, OARSI Grade 0, or Kellgren and Lawrence\n",
      "Grades 0 or 1, joint space narrowing.\n",
      "\n",
      "[0059] Insome embodiments, the person has baseline pain\n",
      "intensity of 5 or greater measured using the 0-10 numerical\n",
      "rating scale (NRS), or 50 mm or greater using the 100 mm\n",
      "visual analog scale (VAS). In some embodiments the person\n",
      "being treated for pain has normal joint space knee pain,\n",
      "OARSI Grade 0, or Kellgren and Lawrence Grades 0 or 1,\n",
      "joint space narrowing.\n",
      "\n",
      "[0060] Bone marrow lesions (BMLs) include regional\n",
      "bone marrow signal intensity alterations on magnetic reso-\n",
      "nance imaging (MRI). BMLs can be present in the knee and\n",
      "can be an important feature of osteoarthritis of the knee.\n",
      "BMLs have also been described in other rheumatic condi-\n",
      "tions such as rheumatoid arthritis, osteonecrosis, ankylosing\n",
      "spondylitis, and transient osteoporosis of the hip and are\n",
      "often referred to as bone marrow edema (BME).\n",
      "\n",
      "[0061] In some embodiments, a person being treated for\n",
      "arthritis, such as with zoledronic acid, has osteoarthritis of\n",
      "the knee associated with bone marrow lesions.TABLE 7\n",
      "\n",
      "Low back symptoms and lumbar flexibility at baseline, one month and 12 months according to treatment\n",
      "group and between group comparisons of difference from baseline to one month and 12 months\n",
      "\n",
      "Mean (SD) original values Unadjusted analyses Adjusted analyses\n",
      "\n",
      " \n",
      "\n",
      "ZA Placebo Mean (SD) change Difference Difference\n",
      "n = 20 n = 20 ZA Placebo (95% CI) P (95% CI) p*\n",
      "Intensity of LBP\n",
      "Baseline 6.6 (1.4) 6.8 (1.6)\n",
      "\n",
      "1 mo. 4.3 (2.3) 5.8 (2.2)  -2.2 (2.7) -0.9 (2.1) 1.3 (-0.2 to 2.8) 0.097 1.4 (0.01 to 2.9) 0.049\n",
      "12 mos. 3.8 (2.5) 4.6 (2.9)  -2.8 (2.9) -2.2 (2.5) 0.6 (-1.1 to 2.4) 0.474 0.7 (-1.0 to 2.4) 0.387\n",
      "Intensity of leg pain\n",
      "\n",
      "Baseline 3.0 (3.1) 2.9 (2.3)\n",
      "\n",
      "1 mo. 2.0 (2.3) 3.0 (2.4) -0.6 (2.4) 0.1 (2.6) 0.8 (-0.9 to 2.4) 0.367 0.8 (-0.6 to 2.2) 0.237\n",
      "12 mos. 2.1 (2.8) 2.7 (2.6) -0.9 (3.4) -0.3 (3.0) 0.6 (-1.5 to 2.7) 0.573 0.5 (-1.3 to 2.2) 0.573\n",
      "Oswestry disability index, %\n",
      "\n",
      "Baseline 30 (11) 35 (10)\n",
      "\n",
      "1 mo. 24 (10) 33 (13) -5.9 (11) -1.7(9.7) 43 (-2.5to11l) 0.212 6.0 (-0.6to 13) 0.071\n",
      "12 mos. 25 (13) 33 (15) -5.0 (15) -1.9 (12) 3.1 (-5.6to 12) 0475 5.1 (-34to 14) 0.231\n",
      "Fingers-to-floor, cm\n",
      "\n",
      "Baseline 23 (19) 19 (18)\n",
      "\n",
      "1 mo. 17 (17) 19 (17) -5.1 (20) -0.1 (8.3) 5.0 (-4.8to 15) 0.306 3.6 (-5.0to 12) 0.403\n",
      "12 mos. 16 (16) 20 (19) -6.3 (23) 0.9 (11) 7.1 (-4.3 to18) 0.215 5.3 (-45to 15) 0.277\n",
      "Sidebending to right, cm\n",
      "\n",
      "Baseline 14.1 (4.9) 13.8 (7.2)\n",
      "\n",
      "1 mo. 15.7 (5.9) 13.3 (6.9) 1.5 (4.7) -O.5 (2.2) -2.0 (-4.3 to 0.4) 0.101 -2.0 (-4.4 to 0.3) 0.087\n",
      "12 mos. 15.7 (5.6) 13.8 (6.5) 1.6 (4.8) -0.1 (3.5) -1.6 (-4.3 to 1.1) 0.227 -1.7 (-4.2 to 0.8) 0.180\n",
      "Sidebending to left, cm\n",
      "\n",
      "Baseline 15.0 (5.4) 13.3 (5.5)\n",
      "1 mo. 16.1 (5.3) 12.8 (5.9) 1.1 (3.0) -0.5 (2.2) -1.5 (-3.2 to0.1) 0.072 -1.7 (-3.4to 0.0) 0.051\n",
      "12 mos. 16.2 (6.7) 13.7 (5.7) 1.2 (5.3) 0.5 (3.2) -0.7 (-3.5 to 2.1) 0.601 -1.0 (-3.8 to 1.8) 0.458\n",
      "\n",
      "SD = standard deviation, CI = confidence interval, ZA = zoledronic acid, LBP = low back pain.\n",
      "*ANCOVA: Difference between follow-up and baseline, treatment effect adjusted for baseline value.\n",
      "\n",
      "?One subject missing at baseline in placebo group and in ZA group, and one subject at 1 month in ZA group.\n",
      "\n",
      "Baseline\n",
      "1 mo.\n",
      "12 mos.\n",
      "\n",
      "Baseline\n",
      "1 mo.\n",
      "12 mos.\n",
      "\n",
      "Baseline\n",
      "1 mo.\n",
      "12 mos.\n",
      "\n",
      "TABLE 8\n",
      "\n",
      "Health-related quality of life assessed using RAND-36 at baseline, one\n",
      "month, and 12 months according to treatment group and between group\n",
      "\n",
      "comparisons of difference from baseline to one month and 12 months\n",
      "\n",
      "ZA\n",
      "\n",
      "n = 20\n",
      "\n",
      "50 (8)\n",
      "51 (8)\n",
      "51 (8)\n",
      "\n",
      "52 (8)\n",
      "52 (9)\n",
      "52 (8)\n",
      "\n",
      "49 (9)\n",
      "50 (9)\n",
      "51 (9)\n",
      "\n",
      "Mean (SD) original values\n",
      "\n",
      "Placebo\n",
      "\n",
      "n= 20\n",
      "\n",
      "50 (7)\n",
      "49 (8)\n",
      "49 (9)\n",
      "\n",
      "48 (8)\n",
      "48 (8)\n",
      "48 (2)\n",
      "\n",
      "51 (8)\n",
      "50 (9)\n",
      "49 (9)\n",
      "\n",
      "ZA\n",
      "\n",
      "Placebo\n",
      "\n",
      "Total RAND-36\n",
      "\n",
      "0.6 (6.4)\n",
      "1.0 (8.7)\n",
      "\n",
      "Physical component\n",
      "\n",
      "0.1 (8.6)\n",
      "0.3 (10)\n",
      "\n",
      "-0.6 (5.0) 1.2 (-3 to 5)\n",
      "2.1 (-3 to 7)\n",
      "\n",
      "-1.0 (5.9)\n",
      "\n",
      "-0.1 (5.5)\n",
      "-0.3 (6.5)\n",
      "\n",
      "Mental component\n",
      "\n",
      "1.0 (6.1)\n",
      "1.8 (9.0)\n",
      "\n",
      "-1.0 (5.6)\n",
      "-1.8 (6.7)\n",
      "\n",
      "SD = standard deviation, CI = confidence interval, ZA = zoledronic acid.\n",
      "*ANCOVA: Difference between follow-up and baseline, treatment effect adjusted for baseline value.\n",
      "\n",
      "Mean (SD) change Difference\n",
      "\n",
      "(95% CI)\n",
      "\n",
      "0.3 (-4 to 5)\n",
      "0.7 (-5 to 6)\n",
      "\n",
      "P\n",
      "\n",
      "0.530\n",
      "0.378\n",
      "\n",
      "0.897\n",
      "0.808\n",
      "\n",
      "2.0 (-2 to 6) 0.286\n",
      "3.5 (-2 to 9) 0.167\n",
      "\n",
      "Unadjusted analyses __ Adjusted analyses\n",
      "\n",
      "Difference\n",
      "\n",
      "(95% CI) P*\n",
      "\n",
      "1.3 (-3 to 5)\n",
      "2.2 (-2 to 7)\n",
      "\n",
      "1.3 (-3 to 6)\n",
      "2.1 (-3 to 7)\n",
      "\n",
      "1.6 (-2 to 5)\n",
      "2.7 (-2 to 7)\n",
      "\n",
      "0.477\n",
      "0.314\n",
      "\n",
      "0.554\n",
      "0.405\n",
      "\n",
      "0.396\n",
      "0.261Embodiment 77\n",
      "\n",
      "[0386] The method of embodiment 76, wherein the dosage\n",
      "form contains about 15 mg/m* to about 20 mg/m? of zole-\n",
      "dronic acid based upon the body surface area of the mam-\n",
      "mal.\n",
      "\n",
      "Embodiment 78\n",
      "\n",
      "[0387] A method of treating complex regional pain syn-\n",
      "drome, comprising administering pamidronic acid to a\n",
      "human being in need thereof.\n",
      "\n",
      "Embodiment 79\n",
      "\n",
      "[0388] A method of treating complex regional pain syn-\n",
      "drome, comprising administering neridronic acid to a human\n",
      "being in need thereof.\n",
      "\n",
      "Embodiment 80\n",
      "\n",
      "[0389] A method of treating complex regional pain syn-\n",
      "drome, comprising administering olpadronic acid to a\n",
      "human being in need thereof.\n",
      "\n",
      "Embodiment 81\n",
      "\n",
      "[0390] A method of treating complex regional pain syn-\n",
      "drome, comprising administering alendronic acid to a\n",
      "human being in need thereof.\n",
      "\n",
      "Embodiment 82\n",
      "\n",
      "[0391] A method of treating complex regional pain syn-\n",
      "drome, comprising administering incadronic acid to a\n",
      "human being in need thereof.\n",
      "\n",
      "Embodiment 83\n",
      "\n",
      "[0392] A method of treating complex regional pain syn-\n",
      "drome, comprising administering ibandronic acid to a\n",
      "human being in need thereof.\n",
      "\n",
      "Embodiment 84\n",
      "\n",
      "[0393] A method of treating complex regional pain syn-\n",
      "drome, comprising administering risedronic acid to a human\n",
      "being in need thereof.\n",
      "\n",
      "Embodiment 85\n",
      "\n",
      "[0394] A method of treating pain, comprising administer-\n",
      "ing pamidronic acid to a human being in need thereof.\n",
      "\n",
      "Embodiment 86\n",
      "\n",
      "[0395] A method of treating pain, comprising administer-\n",
      "ing neridronic acid to a human being in need thereof.\n",
      "\n",
      "Embodiment 87\n",
      "\n",
      "[0396] A method of treating pain, comprising administer-\n",
      "ing olpadronic acid to a human being in need thereof.\n",
      "\n",
      "Embodiment 88\n",
      "\n",
      "[0397] A method of treating pain, comprising administer-\n",
      "ing alendronic acid to a human being in need thereof.\n",
      "\n",
      "Embodiment 89\n",
      "\n",
      "[0398] A method of treating pain, comprising administer-\n",
      "ing incadronic acid to a human being in need thereof.\n",
      "\n",
      "Embodiment 90\n",
      "\n",
      "[0399] A method of treating pain, comprising administer-\n",
      "ing ibandronic acid to a human being in need thereof.\n",
      "\n",
      "Embodiment 91\n",
      "\n",
      "[0400] A method of treating pain, comprising administer-\n",
      "ing risedronic acid to a human being in need thereof.\n",
      "\n",
      "Embodiment 92\n",
      "\n",
      "[0401] A method of treating arthritis pain, comprising\n",
      "administering pamidronic acid to a human being in need\n",
      "thereof.\n",
      "\n",
      "Embodiment 93\n",
      "\n",
      "[0402] A method of treating arthritis pain, comprising\n",
      "administering neridronic acid to a human being in need\n",
      "thereof.\n",
      "\n",
      "Embodiment 94\n",
      "\n",
      "[0403] A method of treating arthritis pain, comprising\n",
      "administering olpadronic acid to a human being in need\n",
      "thereof.\n",
      "\n",
      "Embodiment 95\n",
      "\n",
      "[0404] A method of treating arthritis pain, comprising\n",
      "administering alendronic acid to a human being in need\n",
      "thereof.\n",
      "\n",
      "Embodiment 96\n",
      "\n",
      "[0405] <A method of treating arthritis pain, comprising\n",
      "administering incadronic acid to a human being in need\n",
      "thereof.\n",
      "\n",
      "Embodiment 97\n",
      "\n",
      "[0406] A method of treating arthritis pain, comprising\n",
      "administering ibandronic acid to a human being in need\n",
      "thereof.\n",
      "\n",
      "Embodiment 98\n",
      "\n",
      "[0407] A method of treating arthritis pain, comprising\n",
      "administering risedronic acid to a human being in need\n",
      "thereof.\n",
      "\n",
      "Embodiment 99\n",
      "\n",
      "[0408] A method of treating inflammatory pain, compris-\n",
      "ing administering pamidronic acid to a human being in need\n",
      "thereof.\n",
      "\n",
      "Embodiment 100\n",
      "\n",
      "[0409] A method of treating inflammatory pain, compris-\n",
      "ing administering neridronic acid to a human being in need\n",
      "thereof.tf eho ~& Vehicle\n",
      "pos Poledrantc Acid\n",
      "\n",
      "       \n",
      "\n",
      "sy.\n",
      ".\n",
      "-\n",
      "a.\n",
      "S.\n",
      "an\n",
      "\n",
      "Hindpaw Nociceptive Threshald (4 g}\n",
      "aH &\n",
      "\n",
      " \n",
      "\n",
      "Sasoline Week 4 Week Week 6. Week 7\n",
      "\n",
      "Time after Fracture\n",
      "\n",
      "FIG. 14; | <> Vehicle\n",
      "~~---~~- Zoledronic acid 18 ma/m sa.\n",
      "t- - Zoledronic acid 120 mg/m sq.\n",
      "\n",
      "%* Zoledronic acid 900 mg/m sq.\n",
      "\n",
      "    \n",
      "\n",
      "1604\n",
      "\n",
      " \n",
      "\n",
      "ean Paw Compression Thresholds (g)\n",
      "\n",
      "M\n",
      "\n",
      "- Day 1 Day 1 Day 1 Day 1 . Day? . Day? Day 3 . Day3\n",
      "BL = (O.5hr) (ihr) (3hr) BL (thr) BL = (1hr)\n",
      "\n",
      "FIG. 1yb\n",
      "\n",
      "Cs AWKES\n",
      "aaversnenene ssaen un\n",
      "aaoe\n",
      "\n",
      "ND\n",
      "\n",
      " \n",
      "\n",
      "poet ween 50 rg Disodiurn Salt\n",
      "\n",
      "ye\n",
      "\n",
      "o'Se oo 0 0000.0.c80.0.0,0,0,0,0.9,\n",
      "\n",
      "Tablet Hardness (kPa)\n",
      "= :.Mehidelesion of the knee and OARSI Grade 0 or Kellgren and\n",
      "Lawrence Grade 0 or Grade 1 of joint space narrowing, and\n",
      "administering an inhibitor of osteoclast activity to the patient\n",
      "for the treatment of the bone marrow lesion.\n",
      "\n",
      "Embodiment 201\n",
      "\n",
      "[0517] The method of embodiment 200, wherein the\n",
      "inhibitor of osteoclast activity is administered at least twice.\n",
      "\n",
      "Embodiment 202\n",
      "\n",
      "[0518] The method of embodiment 201, wherein the\n",
      "inhibitor of osteoclast activity is administered about every\n",
      "three months, or more frequently.\n",
      "\n",
      "Embodiment 203\n",
      "[0519] The method of embodiment 200, wherein the\n",
      "\n",
      "inhibitor of osteoclast activity comprises a nitrogen-contain-\n",
      "ing bisphosphonate.\n",
      "Embodiment 204\n",
      "\n",
      "[0520] The method of embodiment 203, wherein the\n",
      "inhibitor of osteoclast activity is zoledronic acid.\n",
      "\n",
      "Embodiment 205\n",
      "\n",
      "[0521] The method of embodiment 203, wherein the\n",
      "inhibitor of osteoclast activity is pamidronic acid.\n",
      "\n",
      "Embodiment 206\n",
      "\n",
      "[0522] The method of embodiment 203, wherein the\n",
      "inhibitor of osteoclast activity is neridronic acid.\n",
      "\n",
      "Embodiment 207\n",
      "\n",
      "[0523] The method of embodiment 203, wherein the\n",
      "inhibitor of osteoclast activity is olpadronic acid.\n",
      "\n",
      "Embodiment 208\n",
      "\n",
      "[0524] The method of embodiment 203, wherein the\n",
      "inhibitor of osteoclast activity is minodronic acid.\n",
      "\n",
      "Embodiment 209\n",
      "\n",
      "[0525] The method of embodiment 203, wherein the\n",
      "inhibitor of osteoclast activity is incadronic acid.\n",
      "\n",
      "Embodiment 210\n",
      "\n",
      "[0526] The method of embodiment 203, wherein the\n",
      "inhibitor of osteoclast activity is ibandronic acid.\n",
      "\n",
      "Embodiment 211\n",
      "\n",
      "[0527] The method of embodiment 203, wherein the\n",
      "inhibitor of osteoclast activity is risedronic acid.\n",
      "\n",
      "Embodiment 212\n",
      "\n",
      "[0528] The method of embodiment 203, wherein the\n",
      "inhibitor of osteoclast activity is alendronic acid.\n",
      "\n",
      "Embodiment 213\n",
      "\n",
      "[0529] The method of embodiment 200, wherein the\n",
      "inhibitor of osteoclast activity is administered orally.\n",
      "\n",
      "Embodiment 214\n",
      "\n",
      "[0530] The method of embodiment 200, wherein the\n",
      "inhibitor of osteoclast activity is administered intravenously.\n",
      "\n",
      "Embodiment 215\n",
      "\n",
      "[0531] The method of embodiment 200, wherein the\n",
      "patient experiences a reduction in bone marrow lesion size\n",
      "that is at least about 15% within about 6 months after the\n",
      "inhibitor of osteoclast activity is administered to the patient.\n",
      "\n",
      "Embodiment 216\n",
      "\n",
      "[0532] The method of embodiment 200, wherein the\n",
      "patient experiences a reduction in bone marrow lesion size\n",
      "that is at least about 25% within about 6 months after the\n",
      "inhibitor of osteoclast activity is administered to the patient.\n",
      "\n",
      "Embodiment 217\n",
      "\n",
      "[0533] The method of embodiment 201, wherein the\n",
      "inhibitor of osteoclast activity is administered at least twice\n",
      "over a period of at least four weeks.\n",
      "\n",
      "Embodiment 218\n",
      "\n",
      "[0534] The method of embodiment 201, wherein the\n",
      "inhibitor of osteoclast activity is administered once weekly\n",
      "for a period of six weeks.\n",
      "\n",
      "Embodiment 219\n",
      "\n",
      "[0535] The method of embodiment 218, wherein the\n",
      "inhibitor of osteoclast activity comprises zoledronic acid,\n",
      "and the weekly dose is between about 25 mg and about 75\n",
      "mg.\n",
      "\n",
      "Embodiment 220\n",
      "\n",
      "[0536] A method of treating knee pain comprising:\n",
      "[0537] a. selecting a patient having knee pain, and:\n",
      "[0538] 1. OARSI Grade 0 or Kellgren and Lawrence\n",
      "\n",
      "Grade 0 or Grade 1 of joint space narrowing, or\n",
      "\n",
      "[0539] 11. pain intensity of 5 or greater measured using\n",
      "the 0-10 NRS or 5 cm or greater using the 10 cm VAS;\n",
      "and\n",
      "\n",
      "[0540] b. administering an inhibitor of osteoclast activity\n",
      "to the patient.\n",
      "\n",
      "Embodiment 221\n",
      "\n",
      "[0541] The method of embodiment 220, comprising\n",
      "selecting a patient having OARSI Grade 0 or Kellgren and\n",
      "Lawrence Grade 0 or Grade 1 of joint space narrowing.\n",
      "\n",
      "Embodiment 222\n",
      "\n",
      "[0542] The method of embodiment 220 or 221, compris-\n",
      "ing selecting a patient having pain intensity of 5 or greater\n",
      "measured using the 0-10 NRS or 5 cm or greater using the\n",
      "10 cm VAS.\n",
      "\n",
      "Embodiment 223\n",
      "\n",
      "[0543] The method of embodiment 220, wherein the\n",
      "inhibitor of osteoclast activity is administered at least twice.doses, e.g about 35 mg to about 80 mg or about 50 mg to\n",
      "about 75 mg in each weekly dose.\n",
      "\n",
      "[0201] With respect to orally administering zoledronic\n",
      "acid to a mammal, such as a dog, a rat, a rabbit, a monkey,\n",
      "an ape, or a human being, doses of about 0.03 mg/kg to\n",
      "about 10 mg/kg, or any smaller range within this range, such\n",
      "as about 0.4 mg/kg to about 3 mg/kg, about 0.4 mg/kg to\n",
      "about 1.5 mg/kg, mg/kg, about 0.4 mg/kg to about 0.5\n",
      "mg/kg, about 0.5 mg/kg to about 0.6 mg/kg, about 0.6 mg/kg\n",
      "to about 0.7 mg/kg, about 0.7 mg/kg to about 0.8 mg/kg,\n",
      "about 0.8 mg/kg to about 0.9 mg/kg, about 0.9 mg/kg to\n",
      "about 1 mg/kg, about 1 mg/kg to about 1.1 mg/kg, about 1.1\n",
      "mg/kg to about 1.2 mg/kg, about 1.2 mg/kg to about 1.3\n",
      "mg/kg, about 1.3 mg/kg to about 1.4 mg/kg, about 1.4 mg/kg\n",
      "to about 1.5 mg/kg, about 1.5 mg/kg to about 1.6 mg/kg,\n",
      "about 1.6 mg/kg to about 1.7 mg/kg, about 1.7 mg/kg to\n",
      "about 1.8 mg/kg, about 1.8 mg/kg to about 1.9 mg/kg, about\n",
      "1.9 mg/kg to about 2 mg/kg, about 2 mg/kg to about 2.1\n",
      "mg/kg, about 2.1 mg/kg to about 2.2 mg/kg, about 2.2 mg/kg\n",
      "to about 2.3 mg/kg, about 2.3 mg/kg to about 2.4 mg/kg,\n",
      "about 2.4 mg/kg to about 2.5 mg/kg, about 2.5 mg/kg to\n",
      "about 2.6 mg/kg, about 2.6 mg/kg to about 2.7 mg/kg, about\n",
      "2.7 mg/kg to about 2.8 mg/kg, about 2.8 mg/kg to about 2.9\n",
      "mg/kg, about 2.9 mg/kg to about 3 mg/kg, about 3 mg/kg to\n",
      "about 3.1 mg/kg, about 3.1 mg/kg to about 3.2 mg/kg, about\n",
      "3.2 mg/kg to about 3.3 mg/kg, about 3.3 mg/kg to about 3.4\n",
      "mg/kg, about 3.4 mg/kg to about 3.5 mg/kg, about 3.5 mg/kg\n",
      "to about 3.6 mg/kg, about 3.6 mg/kg to about 3.7 mg/kg,\n",
      "about 3.7 mg/kg to about 3.8 mg/kg, about 3.8 mg/kg to\n",
      "about 3.9 mg/kg, about 3.9 mg/kg to about 4 mg/kg, about\n",
      "0.4 mg/kg to about 0.6 mg/kg, about 0.6 mg/kg to about 0.8\n",
      "mg/kg, about 0.8 mg/kg to about 1 mg/kg, about 1 mg/kg to\n",
      "about 1.2 mg/kg, about 1.2 mg/kg to about 1.4 mg/kg, about\n",
      "1.4 mg/kg to about 1.6 mg/kg, about 1.6 mg/kg to about 1.8\n",
      "mg/kg, about 1.8 mg/kg to about 2 mg/kg, about 2 mg/kg to\n",
      "about 2.2 mg/kg, about 2.2 mg/kg to about 2.4 mg/kg, about\n",
      "2.4 mg/kg to about 2.6 mg/kg, about 2.6 mg/kg to about 2.8\n",
      "mg/kg, about 2.8 mg/kg to about 3 mg/kg, about 3 mg/kg to\n",
      "about 3.2 mg/kg, about 3.2 mg/kg to about 3.4 mg/kg, about\n",
      "3.4 mg/kg to about 3.6 mg/kg, about 3.6 mg/kg to about 3.8\n",
      "mg/kg, about 3.8 mg/kg to about 4 mg/kg, about 0.4 mg/kg\n",
      "to about 0.7 mg/kg, about 0.7 mg/kg to about 1 mg/kg, about\n",
      "1 mg/kg to about 1.3 mg/kg, about 1.3 mg/kg to about 1.6\n",
      "mg/kg, about 1.6 mg/kg to about 1.9 mg/kg, about 1.9 mg/kg\n",
      "to about 2.2 mg/kg, about 2.2 mg/kg to about 2.5 mg/kg,\n",
      "about 2.5 mg/kg to about 2.8 mg/kg, about 2.8 mg/kg to\n",
      "about 3 mg/kg, about 3.3 mg/kg to about 3.6 mg/kg, about\n",
      "3.6 mg/kg to about 4 mg/kg, about 0.4 mg/kg to about 1\n",
      "mg/kg, or about 0.5 mg/kg to about 1 mg/kg, may be a safe\n",
      "dose for repeated oral administration, such as once daily\n",
      "dosing to once yearly dosing, once daily dosing to twice\n",
      "yearly dosing, once daily dosing to thrice yearly dosing,\n",
      "once daily dosing to dosing every three months, once daily\n",
      "dosing to dosing every two months, once daily dosing to\n",
      "dosing every two months, once daily dosing to dosing every\n",
      "month, once daily dosing to dosing every 2-4 weeks, once\n",
      "daily dosing to once weekly dosing, etc.\n",
      "\n",
      "[0202] The doses referred to in the paragraph above for\n",
      "administration of zoledronic acid to a mammal may be\n",
      "safely administered 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,\n",
      "or 15 times, or about 3 to about 10 times, once a day, or less\n",
      "frequently, such as once week, once every two weeks, once\n",
      "a month, etc.\n",
      "\n",
      "[0203] For once daily to once weekly oral administration\n",
      "of zoledronic acid to a mammal such as a mouse, rat, dog,\n",
      "primate, or a human being, in some embodiments, a safely\n",
      "repeated dose may be about 0.03 mg/kg to about 4 mg/kg,\n",
      "or any smaller range within this range, such as about 0.01\n",
      "mg/kg to about 0.02 mg/kg, about 0.02 mg/kg to about 0.03\n",
      "mg/kg, about 0.03 mg/kg to about 0.04 mg/kg, about 0.04\n",
      "mg/kg to about 0.05 mg/kg, about 0.05 mg/kg to about 0.06\n",
      "mg/kg, about 0.06 mg/kg to about 0.07 mg/kg, about 0.07\n",
      "mg/kg to about 0.08 mg/kg, about 0.08 mg/kg to about 0.09\n",
      "mg/kg, about 0.09 mg/kg to about 0.1 mg/kg, about 0.1\n",
      "mg/kg to about 0.11 mg/kg, about 0.11 mg/kg to about 0.12\n",
      "mg/kg, about 0.12 mg/kg to about 0.13 mg/kg, about 0.13\n",
      "mg/kg to about 0.14 mg/kg, about 0.14 mg/kg to about 0.15\n",
      "mg/kg, about 0.15 mg/kg to about 0.16 mg/kg, about 0.16\n",
      "mg/kg to about 0.17 mg/kg, about 0.17 mg/kg to about 0.18\n",
      "mg/kg, about 0.18 mg/kg to about 0.19 mg/kg, about 0.19\n",
      "mg/kg to about 0.2 mg/kg, about 0.2 mg/kg to about 0.21\n",
      "mg/kg, about 0.21 mg/kg to about 0.22 mg/kg, about 0.22\n",
      "mg/kg to about 0.23 mg/kg, about 0.23 mg/kg to about 0.24\n",
      "mg/kg, about 0.24 mg/kg to about 0.25 mg/kg, about 0.25\n",
      "mg/kg to about 0.26 mg/kg, about 0.26 mg/kg to about 0.27\n",
      "mg/kg, about 0.27 mg/kg to about 0.28 mg/kg, about 0.28\n",
      "mg/kg to about 0.29 mg/kg, about 0.29 mg/kg to about 0.3\n",
      "mg/kg, about 0.3 mg/kg to about 0.31 mg/kg, about 0.31\n",
      "mg/kg to about 0.32 mg/kg, about 0.32 mg/kg to about 0.33\n",
      "mg/kg, about 0.33 mg/kg to about 0.34 mg/kg, about 0.34\n",
      "mg/kg to about 0.35 mg/kg, about 0.35 mg/kg to about 0.36\n",
      "mg/kg, about 0.36 mg/kg to about 0.37 mg/kg, about 0.37\n",
      "mg/kg to about 0.38 mg/kg, about 0.38 mg/kg to about 0.39\n",
      "mg/kg, about 0.39 mg/kg to about 0.4 mg/kg, about 0.05\n",
      "mg/kg to about 0.2 mg/kg, about 0.05 mg/kg to about 0.15\n",
      "mg/kg, about 0.06 mg/kg to about 0.15 mg/kg, about 0.07\n",
      "mg/kg to about 0.15 mg/kg, about 0.08 mg/kg to about 0.15\n",
      "mg/kg, about 0.09 mg/kg to about 0.15 mg/kg, about 0.1\n",
      "mg/kg to about 0.15 mg/kg, about 0.03 mg/kg to about 0.5\n",
      "mg/kg, about 0.06 mg/kg to about 0.2 mg/kg, about 0.07\n",
      "mg/kg to about 0.2 mg/kg, about 0.08 mg/kg to about 0.2\n",
      "mg/kg, about 0.09 mg/kg to about 0.2 mg/kg, about 0.1\n",
      "mg/kg to about 0.2 mg/kg, about 0.4 mg to about 4 mg,\n",
      "about 0.4 mg/kg to about 0.6 mg/kg, about 0.6 mg/kg to\n",
      "about 0.8 mg/kg, about 0.8 mg/kg to about 1 mg/kg, about\n",
      "1 mg/kg to about 1.2 mg/kg, about 1.2 mg/kg to about 1.4\n",
      "mg/kg, about 1.4 mg/kg to about 1.6 mg/kg, about 1.6 mg/kg\n",
      "to about 1.8 mg/kg, about 1.8 mg/kg to about 2 mg/kg, about\n",
      "2 mg/kg to about 2.2 mg/kg, about 2.2 mg/kg to about 2.4\n",
      "mg/kg, about 2.4 mg/kg to about 2.6 mg/kg, about 2.6 mg/kg\n",
      "to about 2.8 mg/kg, about 2.8 mg/kg to about 3 mg/kg, about\n",
      "3 mg/kg to about 3.2 mg/kg, about 3.2 mg/kg to about 3.4\n",
      "mg/kg, about 3.4 mg/kg to about 3.6 mg/kg, about 3.6 mg/kg\n",
      "to about 3.8 mg/kg, about 3.8 mg/kg to about 4 mg/kg, about\n",
      "0.5 mg/kg to about 2 mg/kg, about 0.6 mg/kg to about 2\n",
      "mg/kg, about 0.7 mg/kg to about 2 mg/kg, about 0.8 mg/kg\n",
      "to about 2 mg/kg, about 0.5 mg/kg to about 1.5 mg/kg, about\n",
      "0.6 mg/kg to about 1.5 mg/kg, about 0.7 mg/kg to about 1.5\n",
      "mg/kg, about 0.8 mg/kg to about 1.5 mg/kg, about 0.5 mg/kg\n",
      "to about 0.9 mg/kg, about 0.6 mg/kg to about 0.9 mg/kg,\n",
      "about 0.7 mg/kg to about 0.9 mg/kg, about 0.5 mg/kg to\n",
      "about 1 mg/kg, about 0.6 mg/kg to about 1 mg/kg, about 0.7\n",
      "mg/kg to about 1 mg/kg, about 0.8 mg/kg to about 1 mg/kg,\n",
      "or about 0.8 mg/kg to about 0.9 mg/kg.\n",
      "\n",
      "[0204] For once weekly or less frequent oral administra-\n",
      "tion of zoledronic acid to a mammal such as a mouse, rat,\n",
      "dog, primate, or a human being, in some embodiments, avehicle. Pain threshold measurements taken at various times\n",
      "are shown in FIG. 1. Paw compression thresholds in the 18\n",
      "mg/m* group were higher than for vehicle during the entire\n",
      "measurement period after 30 minutes from the start of\n",
      "treatment. On day three, paw compression thresholds for\n",
      "both the 18 mg/m and 900 mg/m groups were greater than\n",
      "for vehicle. An improvement in pain threshold of 49% and\n",
      "83% from baseline was observed for the 18 mg/m? and the\n",
      "900 mg/m? groups respectively.\n",
      "\n",
      "[0249] Orally administered zoledronic acid produced a\n",
      "29% reversal of inflammatory pain at the 18 mg/m, and a\n",
      "48% reversal at the 900 mg/m* dose. This magnitude of\n",
      "effect is comparable to that obtained with clinical doses of\n",
      "commercially available NSAIDs when tested in a similar\n",
      "model of inflammatory pain. Under current FDA guidelines,\n",
      "the reference body surface area of a human adult is 1.62 m7.\n",
      "Thus, a daily dose of 18 mg/m* corresponds to a monthly\n",
      "dose of about 500-560 mg/m? or a human dose of about\n",
      "800-900 mg.\n",
      "\n",
      "[0250] Surprisingly, the two higher doses resulted in\n",
      "thresholds that were lower than vehicle on the first two days\n",
      "of dosing. The 120 mg/m* group was approximately equal or\n",
      "inferior to vehicle at all time points during the assessment\n",
      "period. While the 900 mg/m group showed effectiveness on\n",
      "day 3, this result was accompanied by significant toxicity\n",
      "necessitating euthanization of all the animals in this group\n",
      "two days after cessation of dosing.\n",
      "\n",
      "Example 2\n",
      "\n",
      "Effect of Orally Administered Zoledronic Acid in Rat Model\n",
      "of Arthritis Pain\n",
      "\n",
      "Method:\n",
      "\n",
      "[0251] The effect of orally administered zoledronic acid\n",
      "on arthritis pain was examined in the rat complete Freunds\n",
      "adjuvant (CFA) model of arthritis pain. In this model,\n",
      "injection of 100% complete Freunds adjuvant (CFA) in a 75\n",
      "uL, volume into the left hind paws is followed by a 10-14 day\n",
      "period to allow for the development of arthritis pain. Ani-\n",
      "mals were orally administered vehicle (control), zoledronic\n",
      "acid 54 mg/m? (or 9 mg/kg), or zoledronic acid 360 mg/m*\n",
      "(or 60 mg/kg), divided in three equal daily doses on the first\n",
      "three days post CFA injection. Drug was dissolved in\n",
      "distilled water and prepared fresh daily. Animals were fasted\n",
      "prior to dosing.\n",
      "\n",
      "[0252] Arthritis pain (mechanical hyperalgesia) in the\n",
      "vehicle and drug-treated animals was evaluated on day 14\n",
      "post CFA injection using a digital Randall-Selitto device\n",
      "(dRS; IITC Life Sciences, Woodland Hills, Calif.). Animals\n",
      "were placed in a restraint sling that suspended the animal,\n",
      "leaving the hind limbs available for testing. Paw compres-\n",
      "sion threshold was measured by applying increasing pres-\n",
      "sure to the plantar surface of the hind paw with a dome-\n",
      "shaped tip placed between the 3rd and 4th metatarsus.\n",
      "Pressure was applied gradually over approximately 10 sec-\n",
      "onds. Measurements were taken from the first observed\n",
      "nocifensive behavior of vocalization, struggle or with-\n",
      "drawal. A cut-off value of 300 g was used to prevent injury\n",
      "to the animal.\n",
      "\n",
      "[0253] Reversal of arthritis pain in the ipsilateral (CFA-\n",
      "injected) paw was calculated according to the formula:\n",
      "\n",
      "% reversal=(ipsilateral drug threshold-ipsilateral\n",
      "vehicle threshold)/(contralateral vehicle thresh-\n",
      "old-ipsilateral vehicle threshold)x100.\n",
      "\n",
      "[0254] The experiment was carried out using 7-10 animals\n",
      "per group.\n",
      "\n",
      "Results:\n",
      "\n",
      "[0255] Oral administration of zoledronic acid significantly\n",
      "improved arthritis pain thresholds compared to vehicle. As\n",
      "shown in FIGS. 2A and 2B, orally administered zoledronic\n",
      "acid produced a dose-dependent reversal of arthritis pain. A\n",
      "reversal of 33% was observed in the 54 mg/m? group, and\n",
      "reversal of 54% was observed in the 360 mg/m* group.\n",
      "Under current FDA guidelines, the reference body surface\n",
      "area of a human adult is 1.62 m*. Thus, 54 mg/m in a rat is\n",
      "equivalent to an implied human dose of about 87 mg, and\n",
      "360 mg/m? in a rat is equivalent to an implied human dose\n",
      "of about 583 mg.\n",
      "\n",
      "Example 3. Treatment of Complex Regional Pain\n",
      "Syndrome with Orally Administered Zoledronic\n",
      "Acid\n",
      "\n",
      "[0256] The effect of orally administered zoledronic acid\n",
      "was examined in the rat tibia fracture model of complex\n",
      "regional pain syndrome (CRPS). CRPS was induced in the\n",
      "rats by fracturing the right distal tibias of the animals and\n",
      "casting the fractured hindpaws for 4 weeks, as described in\n",
      "Guo T Z et al. (Pain. 2004; 108: 95-107). This animal model\n",
      "has been shown to replicate the inciting trauma (such as a\n",
      "fracture, a surgery, a crushing injury, a cutting injury, a\n",
      "scratch, or a puncture injury), natural history, signs, symp-\n",
      "toms, and pathologic changes observed in human CRPS\n",
      "patients (Kingery W S et al., Pain. 2003; 104:75-84).\n",
      "[0257] Animals were orally administered either vehicle\n",
      "(control) or zoledronic acid, in a dosage of 18 mg/m7/day (3\n",
      "mg/kg/day) for 28 days, starting on the day of fracture and\n",
      "casting. Drug was dissolved in distilled water and adminis-\n",
      "tered by gavage. Animals were fasted for 4 hours before and\n",
      "2 hours after dosing. At the end of the 28-day period, casts\n",
      "were removed, and on the following day, the rats were tested\n",
      "for hindpaw pain, edema, and warmth.\n",
      "\n",
      "Pain Assessments\n",
      "\n",
      "[0258] Pain was assessed by measuring hyperalgesia, and\n",
      "weight bearing.\n",
      "[0259] To measure hyperalgesia, an up-down von Frey\n",
      "\n",
      "testing paradigm was used. Rats were placed in a clear\n",
      "plastic cylinder (20 cm in diameter) with a wire mesh bottom\n",
      "and allowed to acclimate for 15 minutes. The paw was tested\n",
      "with one of a series of eight von Frey hairs ranging in\n",
      "stiffness from 0.41 g to 15.14 g. The von Frey hair was\n",
      "applied against the hindpaw plantar skin at approximately\n",
      "midsole, taking care to avoid the tori pads. The fiber was\n",
      "pushed until it slightly bowed and then it was jiggled in that\n",
      "position for 6 seconds. Stimuli were presented at an interval\n",
      "of several seconds. Hindpaw withdrawal from the fiber was\n",
      "considered a positive response. The initial fiber presentation\n",
      "was 2.1 g and the fibers were presented according to the\n",
      "up-down method of Dixon to generate six responses in the\n",
      "immediate vicinity of the 50% threshold. Stimuli were\n",
      "presented at an interval of several seconds.100%\n",
      "\n",
      "75%\n",
      "\n",
      "20%\n",
      "\n",
      "29%\n",
      "\n",
      "% Reversal of von Frey pain Threshold\n",
      "\n",
      "0%\n",
      "\n",
      "MP MTR HAO OPE AYR NET Re a\n",
      "\n",
      " \n",
      "\n",
      "   \n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "       \n",
      "\n",
      "   \n",
      "\n",
      "ORAL IL CNY epee DIR MRE Ep RIOR REN ke He Na we Bed bear ee ee ea eee ere oa Maver\n",
      "\n",
      " \n",
      "\n",
      "O weeks 4 weeks\n",
      "\n",
      "Time Between Fracture and Oral Administration\n",
      "Zoledronic Acid\n",
      "\n",
      "IAM ARN RIN ANDI UEUE MeN Ath SORE HET NA HAAN AEA ARIAT AGRE RL GE RETR ER RS NG MOAN MMH em ER HE ER EERE BORN POM OR Mate\n",
      "\n",
      " \n",
      "\n",
      "   \n",
      " \n",
      "\n",
      "SEEN EAEM NNER EE AORN ETI HO EPR one IN Me\n",
      "\n",
      "Sentra eenetwcne\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "ern ane me ea me a ern ee mh nn grantee mn an RAN nSuen tact nate\n",
      "\n",
      "of\n",
      "\n",
      "EASELS mR MeN ee Re HoarEmbodiment 55\n",
      "\n",
      "[0364] The pharmaceutical product of embodiment 50,\n",
      "comprising 45 to 60 units of the oral dosage form, for a total\n",
      "of about 450 mg to about 18000 mg of zoledronic acid to be\n",
      "administered in about 1 year.\n",
      "\n",
      "Embodiment 56\n",
      "\n",
      "[0365] The pharmaceutical product of embodiment 44,\n",
      "comprising | to 10 units of the oral dosage form, wherein the\n",
      "product contains about 200 mg to about 2000 mg of zole-\n",
      "dronic acid.\n",
      "\n",
      "Embodiment 57\n",
      "\n",
      "[0366] The oral dosage form of any preceding embodi-\n",
      "ment, wherein the zoledronic acid is in the form of a sodium\n",
      "salt.\n",
      "\n",
      "Embodiment 58\n",
      "\n",
      "[0367] The oral dosage form of any preceding embodi-\n",
      "ment, wherein the zoledronic acid is in a form that has an\n",
      "aqueous solubility greater than 1% (w/v).\n",
      "\n",
      "Embodiment 59\n",
      "\n",
      "[0368] The oral dosage form of any preceding embodi-\n",
      "ment, wherein the zoledronic acid is in a form that has an\n",
      "aqueous solubility of about 5% (w/v) to about 50% (w/v).\n",
      "\n",
      "Embodiment 60\n",
      "\n",
      "[0369] An oral dosage form comprising zoledronic acid\n",
      "and an excipient, wherein the zoledronic acid is in a form\n",
      "that has an aqueous solubility greater than 1% (w/v).\n",
      "\n",
      "Embodiment 61\n",
      "\n",
      "[0370] The oral dosage form of embodiment 60, wherein\n",
      "the zoledronic acid 1s in a form that has an aqueous solubility\n",
      "of about 5% (w/v) to about 50% (w/v).\n",
      "\n",
      "Embodiment 62\n",
      "\n",
      "[0371] A method of treating complex regional pain syn-\n",
      "drome comprising administering an oral dosage form con-\n",
      "taining zoledronic acid to a mammal in need thereof.\n",
      "\n",
      "Embodiment 63\n",
      "\n",
      "[0372] The method of embodiment 62, wherein the mam-\n",
      "mal is a human being that receives an amount of zoledronic\n",
      "acid that is about 30 mg/m? to about 700 mg/m? in a period\n",
      "of one month or less.\n",
      "\n",
      "Embodiment 64\n",
      "\n",
      "[0373] The method of embodiment 63, wherein 4 or 5\n",
      "weekly doses are administered in a period of one month or\n",
      "less.\n",
      "\n",
      "Embodiment 65\n",
      "\n",
      "[0374] The method of embodiment 63, wherein 28 to 31\n",
      "daily doses are administered in a period of one month or less.\n",
      "\n",
      "Embodiment 66\n",
      "\n",
      "[0375] The method of embodiment 63, wherein 5 to 10\n",
      "individual doses are administered during a period of one\n",
      "month or less.\n",
      "\n",
      "Embodiment 67\n",
      "\n",
      "[0376] The method of embodiment 63, wherein about 30\n",
      "mg/m? to about 700 mg/m? of zoledronic acid is adminis-\n",
      "tered during only one month.\n",
      "\n",
      "Embodiment 68\n",
      "\n",
      "[0377] The method of embodiment 63, wherein about 30\n",
      "mg/m* to about 700 mg/m? of zoledronic acid is adminis-\n",
      "tered in a period of one month or less for 2 or more\n",
      "consecutive months.\n",
      "\n",
      "Embodiment 69\n",
      "\n",
      "[0378] The method of embodiment 62, wherein the mam-\n",
      "mal receives about 10 mg/m* to about 30 mg/m? of zole-\n",
      "dronic acid daily.\n",
      "\n",
      "Embodiment 70\n",
      "\n",
      "[0379] The method of embodiment 62, wherein the mam-\n",
      "mal is a human being that receives a total weekly dose of\n",
      "zoledronic acid that is about 10 mg to about 300 mg.\n",
      "\n",
      "Embodiment 71\n",
      "\n",
      "[0380] The method of embodiment 70, wherein the total\n",
      "weekly dose is a single dose, administered once a week.\n",
      "\n",
      "Embodiment 72\n",
      "\n",
      "[0381] The method of embodiment 70, wherein the total\n",
      "weekly dose is administered in 2 to 7 individual doses during\n",
      "the week.\n",
      "\n",
      "Embodiment 73\n",
      "\n",
      "[0382] The method of any of embodiments 62-72, wherein\n",
      "the complex regional pain syndrome is complex regional\n",
      "pain syndrome type I.\n",
      "\n",
      "Embodiment 74\n",
      "\n",
      "[0383] The method of any of embodiments 62-72, wherein\n",
      "the complex regional pain syndrome is complex regional\n",
      "pain syndrome type II.\n",
      "\n",
      "Embodiment 75\n",
      "\n",
      "[0384] The method of any preceding embodiment,\n",
      "wherein the zoledronic acid is in a salt form.\n",
      "\n",
      "Embodiment 76\n",
      "\n",
      "[0385] The method of any of embodiments 62-75, wherein\n",
      "the dosage form contains about 10 mg/m to about 20 mg/m\n",
      "of zoledronic acid based upon the body surface area of the\n",
      "mammal.Embodiment 289\n",
      "\n",
      "[0614] The molecular complex of\n",
      "wherein the amino acid is DL-lysine.\n",
      "\n",
      "Embodiment 290\n",
      "\n",
      "[0615] The molecular complex of\n",
      "wherein the amino acid is a glycine.\n",
      "\n",
      "Embodiment 291\n",
      "\n",
      "[0616] The molecular complex of\n",
      "wherein the amino acid is L-glycine.\n",
      "\n",
      "Embodiment 292\n",
      "\n",
      "[0617] The molecular complex of\n",
      "wherein the amino acid is D-glycine.\n",
      "\n",
      "Embodiment 293\n",
      "\n",
      "[0618] The molecular complex of\n",
      "wherein the amino acid is DL-glycine.\n",
      "\n",
      "Embodiment 294\n",
      "\n",
      "[0619] The molecular complex of\n",
      "wherein the amide is nicotinamide.\n",
      "\n",
      "Embodiment 295\n",
      "\n",
      "[0620] The molecular complex of\n",
      "wherein the amine is adenine.\n",
      "\n",
      "Embodiment 296\n",
      "\n",
      "Embodiment\n",
      "\n",
      "Embodiment\n",
      "\n",
      "Embodiment\n",
      "\n",
      "Embodiment\n",
      "\n",
      "Embodiment\n",
      "\n",
      "Embodiment\n",
      "\n",
      "Embodiment\n",
      "\n",
      "285,\n",
      "\n",
      "285,\n",
      "\n",
      "285,\n",
      "\n",
      "285,\n",
      "\n",
      "285,\n",
      "\n",
      "283,\n",
      "\n",
      "283,\n",
      "\n",
      "[0621] The molecular complex of Embodiment 285,\n",
      "\n",
      "wherein the amino acid (including the DL-mixture, a\n",
      "\n",
      "D-enantiomer, or an L-enantiomer) is alanine.\n",
      "\n",
      "Embodiment 297\n",
      "\n",
      "[0622] The molecular complex of Embodiment 285,\n",
      "\n",
      "wherein the amino acid (including the DL-mixture, a\n",
      "\n",
      "D-enantiomer, or an L-enantiomer) is arginine.\n",
      "\n",
      "Embodiment 298\n",
      "\n",
      "[0623] The molecular complex of Embodiment 285,\n",
      "\n",
      "wherein the amino acid (including the DL-mixture, a\n",
      "\n",
      "D-enantiomer, or an L-enantiomer) is asparagine.\n",
      "\n",
      "Embodiment 299\n",
      "\n",
      "[0624] The molecular complex of Embodiment 285,\n",
      "\n",
      "wherein the amino acid (including the DL-mixture, a\n",
      "\n",
      "D-enantiomer, or an L-enantiomer) is aspartic acid.\n",
      "\n",
      "Embodiment 300\n",
      "\n",
      "[0625] The molecular complex of Embodiment 285,\n",
      "\n",
      "wherein the amino acid (including the DL-mixture, a\n",
      "\n",
      "D-enantiomer, or an L-enantiomer) is cysteine.\n",
      "\n",
      "Embodiment 301\n",
      "\n",
      "[0626] The molecular complex of Embodiment 285,\n",
      "\n",
      "wherein the amino acid (including the DL-mixture, a\n",
      "\n",
      "D-enantiomer, or an L-enantiomer) is glutamic acid.\n",
      "\n",
      "Embodiment 302\n",
      "\n",
      "[0627] The molecular complex of Embodiment 285,\n",
      "wherein the amino acid (including the DL-mixture, a\n",
      "D-enantiomer, or an L-enantiomer) is glutamine.\n",
      "\n",
      "Embodiment 303\n",
      "\n",
      "[0628] The molecular complex of Embodiment 285,\n",
      "wherein the amino acid (including the DL-mixture, a\n",
      "D-enantiomer, or an L-enantiomer) is histidine.\n",
      "\n",
      "Embodiment 304\n",
      "\n",
      "[0629] The molecular complex of Embodiment 285,\n",
      "wherein the amino acid (including the DL-mixture, a\n",
      "D-enantiomer, or an L-enantiomer) is isoleucine.\n",
      "\n",
      "Embodiment 305\n",
      "\n",
      "[0630] The molecular complex of Embodiment 285,\n",
      "wherein the amino acid (including the DL-mixture, a\n",
      "D-enantiomer, or an L-enantiomer) is leucine.\n",
      "\n",
      "Embodiment 306\n",
      "\n",
      "[0631] The molecular complex of Embodiment 285,\n",
      "wherein the amino acid (including the DL-mixture, a\n",
      "D-enantiomer, or an L-enantiomer) is methionine.\n",
      "\n",
      "Embodiment 307\n",
      "\n",
      "[0632] The molecular complex of Embodiment 285,\n",
      "wherein the amino acid (including the DL-mixture, a\n",
      "D-enantiomer, or an L-enantiomer) is phenylalanine.\n",
      "\n",
      "Embodiment 308\n",
      "\n",
      "[0633] The molecular complex of Embodiment 285,\n",
      "wherein the amino acid (including the DL-mixture, a\n",
      "D-enantiomer, or an L-enantiomer) is proline.\n",
      "\n",
      "Embodiment 309\n",
      "\n",
      "[0634] The molecular complex of Embodiment 285,\n",
      "wherein the amino acid (including the DL-mixture, a\n",
      "D-enantiomer, or an L-enantiomer) is serine.\n",
      "\n",
      "Embodiment 310\n",
      "\n",
      "[0635] The molecular complex of Embodiment 285,\n",
      "wherein the amino acid (including the DL-mixture, a\n",
      "D-enantiomer, or an L-enantiomer) is threonine.\n",
      "\n",
      "Embodiment 311\n",
      "\n",
      "[0636] The molecular complex of Embodiment 285,\n",
      "wherein the amino acid (including the DL-mixture, a\n",
      "D-enantiomer, or an L-enantiomer) is tryptophan.\n",
      "\n",
      "Embodiment 312\n",
      "\n",
      "[0637] The molecular complex of Embodiment 285,\n",
      "wherein the amino acid (including the DL-mixture, a\n",
      "D-enantiomer, or an L-enantiomer) is tyrosine.\n",
      "\n",
      "Embodiment 313\n",
      "\n",
      "[0638] The molecular complex of Embodiment 285,\n",
      "wherein the amino acid (including the DL-mixture, a\n",
      "D-enantiomer, or an L-enantiomer) is valine.Embodiment 224\n",
      "\n",
      "[0544] The method of embodiment 223, wherein the\n",
      "inhibitor of osteoclast activity is administered about every\n",
      "three months, or more frequently.\n",
      "\n",
      "Embodiment 225\n",
      "[0545] The method of embodiment 220, wherein the\n",
      "\n",
      "inhibitor of osteoclast activity comprises a nitrogen-contain-\n",
      "ing bisphosphonate.\n",
      "Embodiment 226\n",
      "\n",
      "[0546] The method of embodiment 220, wherein the\n",
      "patient experiences pain relief within about three months\n",
      "after the inhibitor of osteoclast activity is administered to the\n",
      "patient.\n",
      "\n",
      "Embodiment 227\n",
      "\n",
      "[0547] The method of embodiment 226, wherein the\n",
      "patient experiences pain relief at least 24 hours after the\n",
      "inhibitor of osteoclast activity is administered to the patient.\n",
      "\n",
      "Embodiment 228\n",
      "\n",
      "[0548] The method of embodiment 220, wherein the\n",
      "inhibitor of osteoclast activity is zoledronic acid.\n",
      "\n",
      "Embodiment 229\n",
      "\n",
      "[0549] The method of embodiment 220, wherein the\n",
      "inhibitor of osteoclast activity is minodronic acid.\n",
      "\n",
      "Embodiment 230\n",
      "\n",
      "[0550] The method of embodiment 220, wherein the\n",
      "inhibitor of osteoclast activity is neridronic acid.\n",
      "\n",
      "Embodiment 231\n",
      "\n",
      "[0551] The method of embodiment 220, wherein the\n",
      "inhibitor of osteoclast activity is olpadronic acid.\n",
      "\n",
      "Embodiment 232\n",
      "\n",
      "[0552] The method of embodiment 220, wherein the\n",
      "inhibitor of osteoclast activity is alendronic acid.\n",
      "\n",
      "Embodiment 233\n",
      "\n",
      "[0553] The method of embodiment 220, wherein the\n",
      "inhibitor of osteoclast activity is incadronic acid.\n",
      "\n",
      "Embodiment 234\n",
      "\n",
      "[0554] The method of embodiment 220, wherein the\n",
      "inhibitor of osteoclast activity is ibandronic acid.\n",
      "\n",
      "Embodiment 235\n",
      "\n",
      "[0555] The method of embodiment 220, wherein the\n",
      "inhibitor of osteoclast activity is risedronic acid.\n",
      "\n",
      "Embodiment 236\n",
      "\n",
      "[0556] The method of embodiment 220, wherein the\n",
      "patient experiences a reduction in pain intensitywhen\n",
      "using a 100 mm visual analog scaleof at least about 5.\n",
      "\n",
      "Embodiment 237\n",
      "\n",
      "[0557] The method of embodiment 220, wherein the\n",
      "inhibitor of osteoclast activity is administered at least twice\n",
      "over a period of at least four weeks.\n",
      "\n",
      "Embodiment 238\n",
      "\n",
      "[0558] The method of embodiment 220, wherein the\n",
      "inhibitor of osteoclast activity is administered once weekly\n",
      "for a period of six weeks.\n",
      "\n",
      "Embodiment 239\n",
      "\n",
      "[0559] The method of embodiment 238, wherein the\n",
      "inhibitor of osteoclast activity comprises zoledronic acid,\n",
      "and the weekly dose is between about 25 mg and about 75\n",
      "mg.\n",
      "\n",
      "Embodiment 240\n",
      "\n",
      "[0560] A method of treating moderate to severe knee pain\n",
      "comprising administering an inhibitor of osteoclast activity\n",
      "to a person suffering from moderate to severe knee pain.\n",
      "\n",
      "Embodiment 241\n",
      "\n",
      "[0561] The method of embodiment 240, wherein the per-\n",
      "son suffering from moderate to severe knee pain has a\n",
      "normal joint space in the knee.\n",
      "\n",
      "Embodiment 242\n",
      "\n",
      "[0562] The method of embodiment 240, wherein the\n",
      "inhibitor of osteoclast activity is administered at least twice.\n",
      "\n",
      "Embodiment 243\n",
      "\n",
      "[0563] The method of embodiment 240, wherein the\n",
      "inhibitor of osteoclast activity is administered about every\n",
      "three months, or more frequently.\n",
      "\n",
      "Embodiment 244\n",
      "\n",
      "[0564] The method of embodiment 240, wherein the\n",
      "inhibitor of osteoclast activity comprises a nitrogen-contain-\n",
      "ing bisphosphonate.\n",
      "\n",
      "Embodiment 245\n",
      "\n",
      "[0565] The method of embodiment 240, wherein the\n",
      "patient experiences pain relief within about three months\n",
      "after the inhibitor of osteoclast activity is administered to the\n",
      "patient.\n",
      "\n",
      "Embodiment 246\n",
      "\n",
      "[0566] The method of embodiment 245, wherein the\n",
      "patient experiences pain relief at least 24 hours after the\n",
      "inhibitor of osteoclast activity is administered to the patient.\n",
      "\n",
      "Embodiment 247\n",
      "\n",
      "[0567] The method of embodiment 240, wherein the\n",
      "inhibitor of osteoclast activity is zoledronic acid.\n",
      "\n",
      "Embodiment 248\n",
      "\n",
      "[0568] The method of embodiment 240, wherein the\n",
      "inhibitor of osteoclast activity is minodronic acid.Solubility (g/100 mL)[0099] Unless otherwise indicated, any reference to a\n",
      "compound herein, such as zoledronic acid, by structure,\n",
      "name, or any other means, includes pharmaceutically\n",
      "acceptable salts, such as the disodium salt; alternate solid\n",
      "forms, such as polymorphs, solvates, hydrates, etc.; tautom-\n",
      "ers; or any other chemical species that may rapidly convert\n",
      "to a compound described herein under conditions in which\n",
      "the compounds are used as described herein. Unless other-\n",
      "wise indicated, a phrase such as administering a bisphos-\n",
      "phonate, administering an osteoclast inhibitor, admin-\n",
      "istering zoledronic acid, includes administering any form\n",
      "of the bisphosphonate, osteoclast inhibitor, zoledronic acid,\n",
      "etc., such as those recited above.\n",
      "\n",
      "[0100] In some embodiments, zoledronic acid is adminis-\n",
      "tered in a dosage form comprising a salt form, such as a salt\n",
      "of a dianion of zoledronic acid. In some embodiments,\n",
      "zoledronic acid is administered in a dosage form comprising\n",
      "a disodium salt form of zoledronic acid. In some embodi-\n",
      "ments, zoledronic acid is administered in a sodium salt form,\n",
      "such as a monosodium salt, a disodium salt, a trisodium salt,\n",
      "etc. In some circumstances, use of the disodium salt may be\n",
      "desirable. For example, the disodium salt is much more\n",
      "soluble in water than the diacid form. As a result, in some\n",
      "processes, the disodium salt can be easier to work with than\n",
      "the diacid form. Additionally, the sodium salt may be more\n",
      "bioavailable and/or more rapidly absorbed when taken orally\n",
      "as compared to the diacid form.\n",
      "\n",
      "[0101] In some embodiments, a RANK/RANKL antago-\n",
      "nists or an osteoclast inhibitor, such as zoledronic acid or\n",
      "neridronic acid may be in the form of a molecular complex.\n",
      "For example, molecular complexes of zoledronic acid\n",
      "include cocrystals, salts, solvates such as hydrates and\n",
      "mixed solvates of an acid or a salt form, and mixtures\n",
      "containing such materials. Molecular complexes of zole-\n",
      "dronic acid may be in amorphous forms or polymorphs.\n",
      "[0102] Of particular interest are compositions, or com-\n",
      "plexes comprising zoledronic acid or neridronic acid and the\n",
      "standard amino acids or natural existing amino acids, such\n",
      "as alanine, arginine, asparagine, aspartic acid, cysteine,\n",
      "glutamic acid, glutamine, glycine, histidine, isoleucine, leu-\n",
      "cine, lysine, methionine, phenylalanine, proline, serine,\n",
      "threonine, tryptophan, tyrosine, valine, etc. Some examples\n",
      "of useful molecular complexes include, but are not limited\n",
      "to, complexes of zoledronic acid or neridronic acid with\n",
      "sodium cation, ammonium, ammonia, L-lysine, DL-lysine,\n",
      "nicotinamide, adenine, glycine, and Selenocysteine.\n",
      "\n",
      "[0103] Zoledronic acid may also be in a form represented\n",
      "by one of the structural depictions below.\n",
      "\n",
      "29 66\n",
      "\n",
      " \n",
      "\n",
      "NH;*\n",
      "\n",
      " \n",
      "\n",
      "HO P anOH\n",
      "fe No:\n",
      "\n",
      "[0104]\n",
      "\n",
      "Zoledronic acid in a salt or an acid form may be\n",
      "present in a molecular complex having strong X-ray powder\n",
      "\n",
      "diffraction peaks in one of the following positions:\n",
      "\n",
      "Form\n",
      "\n",
      "zoledronic acid, sodium\n",
      "zoledronate and water complex\n",
      "ammonium zoledronate salt and\n",
      "water complex\n",
      "\n",
      "zoledronic acid, L-lysine, and\n",
      "water complex\n",
      "\n",
      "zoledronic acid, DL-lysine, and\n",
      "water complex\n",
      "\n",
      "zoledronic acid, DL-lysine,\n",
      "ethanol, and water complex\n",
      "zoledronic acid, nicotinamide,\n",
      "and water complex\n",
      "\n",
      "strong X-ray powder diffraction\n",
      "peaks (20 + 0.2)\n",
      "\n",
      "about 8.1, about 13.3, about 21.5,\n",
      "about 24.6, and about 25.6\n",
      "\n",
      "about 11.0, about 14.6, about 15.4,\n",
      "about 19.9, and about 29.4\n",
      "\n",
      "about 9.0, about 14.4, about 18.1,\n",
      "about 26.0, and about 29.6\n",
      "\n",
      "about 9.1, about 14.7, about 18.0,\n",
      "about 21.2, and about 26.0\n",
      "\n",
      "about 8.8, about 9.7, about 17.6,\n",
      "about 23.1, and about 26.5\n",
      "\n",
      "13.1, about 15.2, about 21.0, about\n",
      "23.9, and about 26.5\n",
      "\n",
      "about 13.6, about 15.9, about 19.7,\n",
      "about 27.9, and about 29.5\n",
      "\n",
      "about 10.2, about 17.8, about 19.9,\n",
      "about 22.9, and about 28.1\n",
      "\n",
      "about 12.2, about 13.0, about 14.1,\n",
      "about 17.1, and about 19.3\n",
      "\n",
      "about 8.3, about 11.8, about 12.3,\n",
      "about 15.8, and about 20.8\n",
      "\n",
      "about 9.6, about 10.7, about 14.3,\n",
      "about 21.4, and about 23.5\n",
      "\n",
      "about 9.7, about 10.8, about 14.4,\n",
      "about 18.9, and about 21.4\n",
      "\n",
      "7.2, about 14.0, about 18.3, about\n",
      "19.1, about 20.7, about 24.6, and\n",
      "about 34.4\n",
      "\n",
      "6.6, about 11.0, about 14.2, about\n",
      "\n",
      "zoledronic acid, adenine, and\n",
      "water complex\n",
      "\n",
      "zoledronic acid and glycine\n",
      "complex\n",
      "\n",
      "zoledronic acid diammonia, and\n",
      "water complex\n",
      "\n",
      "zoledronic acid, DL-lysine, and\n",
      "water complex\n",
      "\n",
      "zoledronic acid, L-lysine, and\n",
      "water complex\n",
      "\n",
      "zoledronic acid, DL-lysine, and\n",
      "water complex\n",
      "\n",
      "zoledronic acid, DL-lysine\n",
      "complex\n",
      "\n",
      "zoledronic acid, DL-lysine\n",
      "\n",
      "complex 18.3, about 19.7, about 22.7, and\n",
      "about 27.6\n",
      "[0105] Solid forms of zoledronic acid such as complexes\n",
      "\n",
      "of zoledronic acid with sodium, ammonium, ammonia,\n",
      "L-lysine, DL-lysine, nicotinamide, adenine and glycine may\n",
      "be prepared by methods such as dry or solvent-drop grinding\n",
      "(liquid assisted grinding), heating or solvent evaporation of\n",
      "their solution in single or mixed solvent systems, slurry\n",
      "suspension, supercritical fluids or other techniques known to\n",
      "a person skilled in the art.\n",
      "\n",
      "[0106] For example, zoledronic acid and nicotinamide\n",
      "may be complexed by dissolving both compounds in water:\n",
      "ethyl acetate (1:1 v/v) and allowing the solvents in the\n",
      "mixture to evaporate to form crystalline material.\n",
      "\n",
      "[0107] In some embodiments, a zoledronic acid complex\n",
      "may have an excess at least one coformer (e.g. the compo-\n",
      "nent other than zoledronic acid) to the zoledronic acid\n",
      "complexes, which may be the same as the coformer in the\n",
      "complex, a different coformer, or a mixture thereof. In some\n",
      "embodiments, the excess coformer may be a standard or\n",
      "natural amino acid. Examples of compounds in salt forms\n",
      "containing Jon 1 are shown below:\n",
      "\n",
      "O PO3H> x\n",
      "\n",
      "A Sb (Lion\n",
      "OH\n",
      "\n",
      "PO3H-\n",
      "O\n",
      "\n",
      "1 = /\\\n",
      "J S04 a voit\n",
      "HO Y\n",
      "\n",
      "HEmbodiment 314\n",
      "\n",
      "[0639] A dosage form comprising the molecular complex\n",
      "of Embodiment 282, 283, 284, 285, 286, 287, 288, 289, 290,\n",
      "291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302,\n",
      "303, 304, 305, 306, 307, 308, 309, 310, 311, 312, or 313.\n",
      "\n",
      "Embodiment 315\n",
      "\n",
      "[0640] The dosage form of Embodiment 314, which is an\n",
      "oral dosage form.\n",
      "\n",
      "Embodiment 316\n",
      "\n",
      "[0641] A method of treating pain, a musculoskeletal con-\n",
      "dition, or a condition related to bone or joint comprising\n",
      "administering a dosage form of Embodiment 314 or 315 to\n",
      "a mammal in need thereof.\n",
      "\n",
      "Embodiment 317\n",
      "\n",
      "[0642] The method of Embodiment 316, wherein the\n",
      "mammal is a human being.\n",
      "\n",
      "Embodiment 318\n",
      "\n",
      "[0643] The method of Embodiment 316 or 317, compris-\n",
      "ing treating acute pain, central pain, radio-therapy or chemo-\n",
      "therapy associated neuropathy, ankylosing spondylitis,\n",
      "arthritis, axial spondyloarthritis, blood cancers, bone frac-\n",
      "ture, bone metastases from solid tumors, bone metastasis,\n",
      "breast cancer, cancer, central multiple sclerosis pain, Char-\n",
      "cots foot, chronic pain, complex regional pain syndrome,\n",
      "diabetic peripheral neuropathy, erosive osteoarthritis, exces-\n",
      "sive bone resorption, fibrous dysplasia, giant cell tumor of\n",
      "bone, HIV-associated neuropathy, hypercalcemia of malig-\n",
      "nancy, inflammatory pain, juvenile rheumatoid arthritis,\n",
      "leukemias, low back pain, lumbar nerve root compression,\n",
      "lumbosacral pain, lung cancer, metastatic bone cancer,\n",
      "monoradiculopathies, multiple myeloma, musculoskeletal\n",
      "pain, neuropathic arthropaties, neuropathic pain, non-articu-\n",
      "lar rheumatism, osteoarthritis, osteogenesis imperfecta,\n",
      "osteoporosis, Pagets disease, Pagets disease of bone, peri-\n",
      "articular disorders, phantom limb pain, post-herpetic neu-\n",
      "ralgia, postoperative pain, post-stroke pain, prostate cancer,\n",
      "rheumatoid arthritis, SAPHO syndrome, sero-negative (non-\n",
      "rheumatoid) arthropathies, solid tumors or cancers, spinal\n",
      "cord injury, systemic lupus erythematosus, transient osteoar-\n",
      "thritis of the hip, transient osteoporosis, transient osteopo-\n",
      "rosis of the hip, trigeminal neuralgia, tumor induced\n",
      "hypocalcemia, or vertebral crush fracture.\n",
      "\n",
      "Embodiment 319\n",
      "\n",
      "[0644] The method of Embodiment 316 or 317, compris-\n",
      "ing treating arthritis.\n",
      "\n",
      "Embodiment 320\n",
      "\n",
      "[0645] The method of Embodiment 319, comprising\n",
      "relieving pain associated with arthritis.\n",
      "\n",
      "Embodiment 321\n",
      "\n",
      "[0646] The method of Embodiment 320, wherein the\n",
      "arthritis affects a knee, an elbow, a wrist, a shoulder, or a hip.\n",
      "\n",
      "Embodiment 322\n",
      "\n",
      "[0647] The method of Embodiment 321, wherein the\n",
      "arthritis affects a knee.\n",
      "\n",
      "Embodiment 323\n",
      "\n",
      "[0648] The method of Embodiment 316 or 317, compris-\n",
      "ing treating musculoskeletal pain.\n",
      "\n",
      "Embodiment 324\n",
      "\n",
      "[0649] The method of Embodiment 316 or 317, compris-\n",
      "ing treating a bone marrow lesion.\n",
      "\n",
      "Embodiment 325\n",
      "\n",
      "[0650] The method of Embodiment 324, wherein the\n",
      "mammal is a human being that experiences a reduction in\n",
      "bone marrow lesion size that is at least about 15% within\n",
      "about 6 months after the inhibitor of osteoclast activity is\n",
      "administered to the human being.\n",
      "\n",
      "Embodiment 326\n",
      "\n",
      "[0651] The method of Embodiment 324, wherein the\n",
      "mammal is a human being that experiences a reduction in\n",
      "bone marrow lesion size that is at least about 25% within\n",
      "about 6 months after the inhibitor of osteoclast activity is\n",
      "administered to the human being.\n",
      "\n",
      "Embodiment 327\n",
      "\n",
      "[0652] The method of Embodiment 324, 325, or 326,\n",
      "wherein the bone marrow lesion affects a knee.\n",
      "\n",
      "Embodiment 328\n",
      "\n",
      "[0653] The method of Embodiment 324, 325, 326, or 327,\n",
      "comprising treating a bone marrow lesion of the knee by\n",
      "selecting a patient having a bone marrow lesion of the knee\n",
      "and OARSI Grade 0 or Kellgren and Lawrence Grade 0 or\n",
      "Grade 1 of joint space narrowing, and administering the\n",
      "dosage form to the patient for the treatment of the bone\n",
      "marrow lesion.\n",
      "\n",
      "Embodiment 329\n",
      "\n",
      "[0654] The method of Embodiment 316 or 317, compris-\n",
      "ing treating osteoarthritis.\n",
      "\n",
      "Embodiment 330\n",
      "\n",
      "[0655] The method of Embodiment 329, wherein the\n",
      "osteoarthritis affects a knee.\n",
      "\n",
      "Embodiment 331\n",
      "\n",
      "[0656] The method of Embodiment 329 or 330, compris-\n",
      "ing treating an osteolytic lesion associated with osteoarthri-\n",
      "tis.\n",
      "\n",
      "Embodiment 332\n",
      "\n",
      "[0657] The method of Embodiment 316, 317, 318, 319,\n",
      "320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, or\n",
      "331, comprising treating knee pain.TABLE E-continued\n",
      "\n",
      "Pectinic acid\n",
      "\n",
      "Carboxymethyl cellulose\n",
      "Cellulose acetate\n",
      "\n",
      "Ethyl cellulose\n",
      "Hydroxypropylmethy! cellulose\n",
      "Methylcellulose\n",
      "\n",
      "Sodium Carboxymethy1 cellulose\n",
      "Rennet\n",
      "\n",
      "Tannic acid (hydrolyzable gallotannins)\n",
      "Acetic acid\n",
      "\n",
      "Sodium acetate\n",
      "\n",
      "Sodium diacetate\n",
      "\n",
      "Pyridoxine\n",
      "\n",
      "Pyridoxine hydrochloride\n",
      "Sodium oleate\n",
      "\n",
      "Sodium palmitate\n",
      "\n",
      "Ethyl acrylate, monomeric\n",
      "Methyl acrylate, monomeric\n",
      "Ethyl acrylate, polymeric\n",
      "Methyl acrylate, polymeric\n",
      "Bentonite\n",
      "\n",
      "Clay (kaolin)\n",
      "\n",
      "Corn silk\n",
      "\n",
      "Ammonium citrate\n",
      "\n",
      "Calcium citrate\n",
      "\n",
      "Citric acid\n",
      "\n",
      "Isopropyl citrate\n",
      "\n",
      "Potassium citrate\n",
      "\n",
      "Sodium citrate\n",
      "\n",
      "Stearyl citrate\n",
      "\n",
      "Triethyl citrate\n",
      "\n",
      "Biotin\n",
      "\n",
      "Enzymatically hydrolyzed casein\n",
      "Acid hydrolyzed proteins\n",
      "Enzymatically hydrolyzed protein\n",
      "Soy sauces\n",
      "\n",
      "Yeast autolyzates\n",
      "\n",
      "Caffeine\n",
      "\n",
      "L-Glutamic acid\n",
      "\n",
      "L-Glutamic acid hydrochloride\n",
      "Monoammonium L-glutamate\n",
      "Monopotassium L-glutamate\n",
      "Monosodium L-glutamate\n",
      "Calcium Lactate\n",
      "\n",
      "L(+)-calcium lactate\n",
      "D(-)-Lactic acid\n",
      "\n",
      "Lactic acid\n",
      "\n",
      "L(+)-lactic acid\n",
      "\n",
      "Butylated Hydroxyanisole (BHA)\n",
      "D- or DL- Calcium pantothenate\n",
      "D-Pantotheny! alcohol\n",
      "\n",
      "D- or DL- Sodium pantothenate\n",
      "Urea\n",
      "\n",
      "Thiamine hydrochloride\n",
      "Thiamine mononitrate\n",
      "Magnesium gluconate\n",
      "Potassium gluconate\n",
      "\n",
      "Sodium gluconate\n",
      "\n",
      "Zinc gluconate\n",
      "\n",
      "Vitamin B12 (cyanocobalamin)\n",
      "Vitamin D2 (ergocalciferol)\n",
      "Vitamin D3 (cholecalciferol)\n",
      "Potassium chloride\n",
      "\n",
      "Sodium chloride\n",
      "\n",
      "Soy protein isolate\n",
      "Hydrochloric acid\n",
      "\n",
      "Copper (cupric) gluconate\n",
      "Copper (cupric) sulfate\n",
      "Cuprous iodide\n",
      "\n",
      "Calcium caseinate\n",
      "\n",
      "Casein\n",
      "\n",
      "Sodium caseinate\n",
      "\n",
      "Aluminum calcium silicate\n",
      "Calcium silicate\n",
      "\n",
      "Diatomaceous earth (filter aid)\n",
      "Magnesium silicate\n",
      "\n",
      "Perlite (filter aid)\n",
      "\n",
      "TABLE E-continued\n",
      "\n",
      "Potassium silicate\n",
      "\n",
      "Silica aerogel\n",
      "\n",
      "Silicon dioxides\n",
      "\n",
      "Sodium aluminosilicate\n",
      "\n",
      "Sodium calcium aluminosilicate\n",
      "Sodium silicate\n",
      "\n",
      "Talc (basic magnesium silicate)\n",
      "Tricalcium silicate\n",
      "\n",
      "L(+)-potassium acid tartrate\n",
      "L(+)-sodium tartrate\n",
      "\n",
      "L(+)-tartaric acid\n",
      "\n",
      "Manganous chloride\n",
      "\n",
      "Manganous citrate\n",
      "\n",
      "Manganous gluconate\n",
      "\n",
      "Manganous oxide\n",
      "\n",
      "Manganous sulfate\n",
      "\n",
      "Lecithin\n",
      "\n",
      "Lecithin, hydrogen peroxide bleached\n",
      "Riboflavin\n",
      "\n",
      "Riboflavin-5'-phosphate\n",
      "\n",
      "Calcium propionate\n",
      "\n",
      "Dilauryl thiodipropionate\n",
      "Propionic acid\n",
      "\n",
      "Sodium propionate\n",
      "Thiodipropionic acid\n",
      "\n",
      "Hydrogen peroxide\n",
      "\n",
      "Carbon dioxide\n",
      "\n",
      "Nickel (elemental)\n",
      "\n",
      "Niacin (nicotinic acid)\n",
      "Niacinamide (nicotinamide)\n",
      "Carotene (beta-carotene)\n",
      "L-Ascorbic acid\n",
      "\n",
      "Ascorbyl palmitate (palmitoyl L-ascorbic)\n",
      "Calcium L-ascorbate\n",
      "\n",
      "Erythorbic acid (D-isoascorbic acid)\n",
      "Sodium erythorbate (sodium D-isoascorbate)\n",
      "Sodium L-ascorbate\n",
      "\n",
      "Acetylated Distarch Adipate\n",
      "Acetylated Distarch Glycerol\n",
      "Acetylated Distarch Phosphate\n",
      "Acetylated Distarch Oxypropanol\n",
      "Acid Modified Starch\n",
      "\n",
      "Arrowroot Starch\n",
      "\n",
      "Bleached Starch\n",
      "\n",
      "Cornstarch\n",
      "\n",
      "Distarch Glycerol\n",
      "\n",
      "Distarch Oxypropanol\n",
      "\n",
      "Distarch Phosphate\n",
      "\n",
      "High Amylose Cornstarch\n",
      "Hydroxypropy! Distarch Glycerol\n",
      "Hydroxypropy! Distarch Phosphate\n",
      "Hydroxypropyl Starch\n",
      "Hydroxypropyl Starch, oxidized\n",
      "Milo Starch\n",
      "\n",
      "Monostarch Phosphate\n",
      "\n",
      "Potato starch\n",
      "\n",
      "Pregelatinized starch\n",
      "\n",
      "Rice Starch\n",
      "\n",
      "Sodium Hydroxide Gelatinized Starch\n",
      "Starch Acetate\n",
      "\n",
      "Starch Aluminum Octenyl Succinate\n",
      "Starch Sodium Succinate\n",
      "\n",
      "Starch Sodium Octenyl Succinate\n",
      "Succinyl Distarch Glycerol\n",
      "Tapioca Starch\n",
      "\n",
      "Waxy Maize Starch\n",
      "\n",
      "Wheat Starch\n",
      "\n",
      "Phosphated Distarch Phosphate\n",
      "Starch, Sodium Hypochlorite oxidized\n",
      "Vitamin A\n",
      "\n",
      "Vitamin A acetate\n",
      "\n",
      "Vitamin A palmitate\n",
      "\n",
      "Diacetyl\n",
      "\n",
      "Starter distillate\n",
      "\n",
      "Carbonyl Iron\n",
      "\n",
      "Carbonyl Iron\n",
      "\n",
      "Electrolytic IronEmbodiment 333\n",
      "\n",
      "[0658] The method of Embodiment 332, comprising treat-\n",
      "ing moderate to severe knee pain.\n",
      "\n",
      "Embodiment 334\n",
      "\n",
      "[0659] The method of Embodiment 332 or 333, wherein\n",
      "the mammal is a human being that has a normal joint space\n",
      "in the knee.\n",
      "\n",
      "Embodiment 335\n",
      "\n",
      "[0660] The method of Embodiment 332, comprising treat-\n",
      "ing knee pain by:\n",
      "[0661] 1) selecting a patient having knee pain, and:\n",
      "[0662] a. OARSI Grade 0 or Kellgren and Lawrence\n",
      "Grade 0 or Grade 1 of joint space narrowing, or\n",
      "[0663] b. pain intensity of 5 or greater measured\n",
      "\n",
      "using the 0-10 NRS, or 5 cm or greater using the 10\n",
      "cm VAS; and\n",
      "\n",
      "[0664] 2) administering the dosage form to the patient.\n",
      "Embodiment 336\n",
      "[0665] The method of Embodiment 335, comprising\n",
      "\n",
      "selecting a patient having OARSI Grade 0 or Kellgren and\n",
      "Lawrence Grade 0 or Grade 1 of joint space narrowing.\n",
      "\n",
      "Embodiment 337\n",
      "\n",
      "[0666] The method of Embodiment 335, comprising\n",
      "selecting a patient having pain intensity of 5 or greater\n",
      "measured using the 0-10 NRS, or 5 cm or greater using the\n",
      "10 cm VAS.\n",
      "\n",
      "Embodiment 338\n",
      "\n",
      "[0667] The method of Embodiment 335, 336, or 337,\n",
      "wherein the patient experiences a reduction in pain inten-\n",
      "sitywhen using a 100 mm visual analog scaleof at least\n",
      "about 5 mm.\n",
      "\n",
      "Embodiment 339\n",
      "\n",
      "[0668] The method of Embodiment 316 or 317, compris-\n",
      "ing treating musculoskeletal pain.\n",
      "\n",
      "Embodiment 340\n",
      "\n",
      "[0669] The method of Embodiment 316 or 317, compris-\n",
      "ing treating inflammatory pain.\n",
      "\n",
      "Embodiment 341\n",
      "\n",
      "[0670] The method of Embodiment 316 or 317, compris-\n",
      "ing treating back pain.\n",
      "\n",
      "Embodiment 342\n",
      "\n",
      "[0671] The method of Embodiment 341, wherein the back\n",
      "pain comprises low back pain.\n",
      "\n",
      "Embodiment 343\n",
      "\n",
      "[0672] The method of Embodiment 342, wherein the low\n",
      "back pain is related to a vertebral change.\n",
      "\n",
      "Embodiment 344\n",
      "\n",
      "[0673] The method of Embodiment 316 or 317, compris-\n",
      "ing treating type 1 Modic changes, or type 1 and type 2\n",
      "Modic changes.\n",
      "\n",
      "Embodiment 345\n",
      "\n",
      "[0674] The method of Embodiment 344, wherein the\n",
      "Modic change is located at C1/2, C2/3, C3/4, C4/5, C5/6, or\n",
      "C6/7.\n",
      "\n",
      "Embodiment 346\n",
      "\n",
      "[0675] The method of Embodiment 344, wherein the\n",
      "Modic change is located at C7/T1, T1/2, T2/3, T3/4, T4/5,\n",
      "15/6, T6/7, 17/8, T8/9, T9/10, T10/11, or T11/12.\n",
      "\n",
      "Embodiment 347\n",
      "\n",
      "[0676] The method of Embodiment 344, wherein the\n",
      "Modic change is located at T12/L1, L1/2, L2/3, L3/4, L4/5,\n",
      "or L5/S1.\n",
      "\n",
      "Embodiment 348\n",
      "\n",
      "[0677] The method of Embodiment 316 or 317, compris-\n",
      "ing treating pain in an extremity.\n",
      "\n",
      "Embodiment 349\n",
      "[0678] The method of Embodiment 316 or 317, compris-\n",
      "ing treating joint pain.\n",
      "\n",
      "Embodiment 350\n",
      "\n",
      "[0679] The method of Embodiment 316 or 317, compris-\n",
      "ing treating muscle pain.\n",
      "\n",
      "Embodiment 351\n",
      "[0680] The method of Embodiment 316 or 317, compris-\n",
      "ing treating neuropathic pain.\n",
      "\n",
      "Embodiment 352\n",
      "\n",
      "[0681] The method of Embodiment 316 or 317, compris-\n",
      "ing treating complex regional pain syndrome.\n",
      "\n",
      "Embodiment 353\n",
      "\n",
      "[0682] The method of Embodiment 352, wherein the\n",
      "complex regional pain syndrome is complex regional pain\n",
      "syndrome type I.\n",
      "\n",
      "Embodiment 354\n",
      "\n",
      "[0683] The method of Embodiment 352, wherein the\n",
      "complex regional pain syndrome is complex regional pain\n",
      "syndrome type II.\n",
      "\n",
      "Embodiment 355\n",
      "\n",
      "[0684] The method of Embodiment 316 or 317, compris-\n",
      "ing treating Pagets disease of bone.\n",
      "\n",
      "Embodiment 356\n",
      "\n",
      "[0685] The method of Embodiment 316 or 317, compris-\n",
      "ing treating multiple myeloma.muscular, subcutaneous, intraocular, intrasynovial, transepi-\n",
      "thelial including transdermal, sublingual and buccal; topi-\n",
      "cally; nasal inhalation via insufflation; and rectal systemic.\n",
      "[0177] The effective amount of zoledronic acid or another\n",
      "bisphosphonate will vary depending on various factors\n",
      "known to the treating physicians, such as the severity of the\n",
      "condition to be treated, route of administration, formulation\n",
      "and dosage forms, physical characteristics of the bisphos-\n",
      "phonate compound used, and age, weight and response of\n",
      "the individual patients.\n",
      "\n",
      "[0178] In some embodiments, the daily oral dose of\n",
      "pamidronate is about 10 mg to about 1,000 mg, about 50 mg\n",
      "to about 500 mg, about 100 mg to about 500 mg, or about\n",
      "150 mg to about 300 mg. In some embodiments, the par-\n",
      "enteral dose of pamidronate is about 5 mg to about 500 mg,\n",
      "about 5 mg to about 200 mg, or about 10 mg to about 150\n",
      "mg.\n",
      "\n",
      "[0179] In some embodiments, the daily oral dose of\n",
      "neridronate is about 10 mg to about 1,000 mg, about 50 mg\n",
      "to about 500 mg, about 100 mg to about 500 mg, or about\n",
      "150 mg to about 300 mg. In some embodiments, the par-\n",
      "enteral dose of neridronate is about 5 mg to about 500 mg,\n",
      "about 5 mg to about 200 mg, or about 10 mg to about 150\n",
      "mg.\n",
      "\n",
      "[0180] In some embodiments, the daily oral dose of alen-\n",
      "dronate is about 0.5 mg to about 200 mg, about 1 mg to\n",
      "about 100 mg, about 5 mg to about 100 mg, or about 2 mg\n",
      "to about 50 mg. In some embodiments, the parenteral dose\n",
      "of alendronate is about 1 mg to about 100 mg, about 1 mg\n",
      "to about 40 mg, or about 2 mg to about 30 mg.\n",
      "\n",
      "[0181] In some embodiments, the daily oral dose of olpad-\n",
      "ronate is about 0.5 mg to about 200 mg, about 1 mg to about\n",
      "100 mg, about 5 mg to about 100 mg, or about 2 mg to about\n",
      "50 mg. In some embodiments, the parenteral dose of olpad-\n",
      "ronate is about 1 mg to about 100 mg, about 1 mg to about\n",
      "40 mg, or about 2 mg to about 30 mg.\n",
      "\n",
      "[0182] In some embodiments, the daily oral dose of iban-\n",
      "dronate is about 0.25 mg to about 100 mg, about 0.5 mg to\n",
      "about 50 mg, about 2.5 mg to about 50 mg, or about 1 mg\n",
      "to about 25 mg. In some embodiments, the parenteral dose\n",
      "of ibandronate is about 0.5 mg to about 50 mg, about 0.5 mg\n",
      "to about 20 mg, or about 1 mg to about 15 mg.\n",
      "\n",
      "[0183] In some embodiments, the daily oral dose of rise-\n",
      "dronate is about 0.25 mg to about 100 mg, about 0.5 mg to\n",
      "about 50 mg, about 2.5 mg to about 50 mg, or about 1 mg\n",
      "to about 25 mg. In some embodiments, the parenteral dose\n",
      "of risedronate is about 0.25 mg to about 25 mg, about 0.25\n",
      "mg to about 10 mg, or about 0.5 mg to about 7.5 mg.\n",
      "[0184] In some embodiments, the daily oral dose of zole-\n",
      "dronate is about 0.005 mg to about 20 mg, about 0.1 mg to\n",
      "about 10 mg, about 0.5 mg to about 10 mg, or about 0.2 mg\n",
      "to about 5 mg. In some embodiments, the parenteral dose of\n",
      "zoledronate is about 0.25 mg to about 25 mg, about 0.25 mg\n",
      "to about 10 mg, or about 0.5 mg to about 7.5 mg.\n",
      "\n",
      "[0185] The dose of pamidronate, neridronate, olpadronate,\n",
      "alendronate, ibandronate, risedronate, zoledronate or\n",
      "another bisphosphonate compound may be administered in\n",
      "a single or divided dose.\n",
      "\n",
      "[0186] The amount of zoledronic acid or another bispho-\n",
      "sphonate in a therapeutic composition may vary. For\n",
      "example, some liquid compositions may comprise about\n",
      "0.0001% (w/v) to about 50% (w/v), about 0.01% (w/v) to\n",
      "about 20% (w/v), about 0.01% to about 10% (w/v), about\n",
      "0.001% (w/v) to about 1% (w/v), about 0.1% (w/v) to about\n",
      "\n",
      "0.5% (w/v), about 1% (w/v) to about 3% (w/v), about 3%\n",
      "(w/v) to about 5% (w/v), about 5% (w/v) to about 7% (w/v),\n",
      "about 7% (w/v) to about 10% (w/v), about 10% (w/v) to\n",
      "about 15% (w/v), about 15% (w/v) to about 20% (w/v),\n",
      "about 20% (w/v) to about 30% (w/v), about 30% (w/v) to\n",
      "about 40% (w/v), or about 40% (w/v) to about 50% (w/v) of\n",
      "zoledronic acid.\n",
      "\n",
      "[0187] Some solid compositions may comprise at least\n",
      "about 5% (w/w), at least about 10% (w/w), at least about\n",
      "20% (w/w), at least about 50% (w/w), at least about 70%\n",
      "(w/w), at least about 80%, about 10% (w/w) to about 30%\n",
      "(w/w), about 10% (w/w) to about 20% (w/w), about 20%\n",
      "(w/w) to about 30% (w/w), about 30% (w/w) to about 50%\n",
      "(w/w), about 30% (w/w) to about 40% (w/w), about 40%\n",
      "(w/w) to about 50% (w/w), about 50% (w/w) to about 80%\n",
      "(w/w), about 50% (w/w) to about 60% (w/w), about 70%\n",
      "(w/w) to about 75% (w/w), about 70% (w/w) to about 80%\n",
      "(w/w), or about 80% (w/w) to about 90% (w/w) of zole-\n",
      "dronic acid.\n",
      "\n",
      "[0188] Any suitable amount of an osteoclast inhibitor,\n",
      "including a bisphosphonate, such as a nitrogen-containing\n",
      "bisphosphonate, e.g. zoledronic acid, minodronic acid, or\n",
      "ibandronic acid, may be used. Some solid or liquid oral\n",
      "dosage forms, or units of oral dosage forms (referred to\n",
      "collectively herein as oral dosage form(s)) may contain\n",
      "about 0.005 mg to about 20 mg, about 0.1 mg to about 10\n",
      "mg, about 0.5 mg to about 10 mg, about 0.2 mg to about 5\n",
      "mg, about 1 mg to about 500 mg, about 1 mg to about 50 mg,\n",
      "about 10 mg to about 250 mg, about 100 mg to about 300\n",
      "mg, about 20 mg to about 200 mg, about 20 mg to about 150\n",
      "mg, about 30 mg to about 100 mg, about 50 mg to about 200\n",
      "mg, about 1 mg to about 1,000 mg, about 10 mg to about 50\n",
      "mg, about 40 mg to about 60 mg, about 50 mg to about 60\n",
      "mg, about 55 mg, about 10 mg to about 300 mg, about 10\n",
      "mg to about 150 mg, about 10 mg to about 100 mg, about\n",
      "40 mg to about 150 mg, about 10 mg to about 600 mg, about\n",
      "40 mg to about 600 mg, about 40 mg to about 2000 mg,\n",
      "about 40 mg to about 800 mg, about 25 mg to about 800 mg,\n",
      "about 30 mg to about 800 mg, about 10 mg to about 500 mg,\n",
      "about 50 mg to about 150 mg, about 50 mg, about 100 mg,\n",
      "about 50 mg to about 500 mg, about 150 mg to about 200\n",
      "mg, about 100 mg to about 2000 mg, about 300 mg to about\n",
      "1500 mg, about 200 mg to about 1000 mg, about 100 mg to\n",
      "about 500 mg, about 160 mg, or about 150 mg of zoledronic\n",
      "acid in an acid form or in a salt form such as disodium salt\n",
      "form, or any amount of osteoclast inhibitor in a range\n",
      "bounded by, or between, any of these values. In some\n",
      "embodiments, the oral osteoclast inhibitor is administered\n",
      "daily, weekly, biweekly, monthly, every two or three months,\n",
      "once a year, or twice a year.\n",
      "\n",
      "[0189] Some oral dosage forms may contain about 0.005\n",
      "mg to about 20 mg, about 0.1 mg to about 10 mg, about 0.5\n",
      "mg to about 10 mg, about 0.2 mg to about 5 mg, about 1 mg\n",
      "to about 500 mg, about 1 mg to about 50 mg, about 10 mg\n",
      "to about 250 mg, about 100 mg to about 300 mg, about 20\n",
      "mg to about 200 mg, about 20 mg to about 150 mg, about\n",
      "30 mg to about 100 mg, about 1 mg to about 1,000 mg, about\n",
      "10 mg to about 50 mg, about 40 mg to about 60 mg, about\n",
      "50 mg to about 60 mg, about 55 mg, about 10 mg to about\n",
      "300 mg, about 10 mg to about 150 mg, about 10 mg to about\n",
      "100 mg, about 40 mg to about 150 mg, about 10 mg to about\n",
      "600 mg, about 40 mg to about 600 mg, about 40 mg to about\n",
      "2000 mg, about 40 mg to about 800 mg, about 25 mg to\n",
      "about 800 mg, about 30 mg to about 800 mg, about 10 mgDOSAGE FORMS FOR ORAL\n",
      "ADMINISTRATION OF ZOLEDRONIC ACID\n",
      "OR RELATED COMPOUNDS FOR\n",
      "TREATING DISEASE\n",
      "\n",
      "CROSS-REFERENCE TO RELATED\n",
      "APPLICATIONS\n",
      "\n",
      "[0001] This application is a continuation-in-part of U.S.\n",
      "patent application Ser. No. 15/432,777, filed Feb. 14, 2017;\n",
      "which is a continuation-in-part of U.S. patent application\n",
      "Ser. No. 15/136,092, filed Apr. 22, 2016, now U.S. Pat. No.\n",
      "9,616,078; which is a continuation-in-part of U.S. patent\n",
      "application Ser. No. 15/043,281, filed Feb. 12, 2016, now\n",
      "U.S. Pat. No. 9,517,242; which is a continuation of U.S.\n",
      "patent application Ser. No. 14/279,196, filed May 15, 2014,\n",
      "now U.S. Pat. No. 9,301,964; which is a continuation of U.S.\n",
      "patent application Ser. No. 14/063,979, filed Oct. 25, 2013,\n",
      "now U.S. Pat. No. 8,802,658; which is a continuation-in-part\n",
      "of U.S. patent application Ser. No. 13/894,274, filed May 14,\n",
      "2013, now abandoned; which claims the benefit of U.S.\n",
      "Prov. App. Nos. 61/646,538, filed May 14, 2012; 61/647,\n",
      "478, filed May 15, 2012; 61/654,292, filed Jun. 1, 2012;\n",
      "61/654,383, filed Jun. 1, 2012; 61/655,527, filed Jun. 5,\n",
      "2012; 61/655,541, filed Jun. 5, 2012; 61/764,563, filed Feb.\n",
      "14, 2013; 61/762,225, filed Feb. 7, 2013; 61/767,647, filed\n",
      "Feb. 21, 2013; 61/767,676, filed Feb. 21, 2013; and 61/803,\n",
      "721, filed Mar. 20, 2013; U.S. patent application Ser. No.\n",
      "15/136,092 also claims the benefit of U.S. Prov. App. No.\n",
      "62/150,871, filed Apr. 22, 2015; U.S. patent application Ser.\n",
      "No. 15/432,777 is also a continuation-in-part of U.S. patent\n",
      "application Ser. No. 15/352,461, filed Nov. 15, 2016; which\n",
      "is a continuation-in-part of International Pat. App. No.\n",
      "PCT/US2015/032739, filed May 27, 2015; which is a con-\n",
      "tinuation of International Pat. App. No. PCT/US2014/\n",
      "050427, filed Aug. 8, 2014; which is a continuation of U.S.\n",
      "patent application Ser. No. 14/279,241, filed May 15, 2014,\n",
      "now abandoned; any of the applications, U.S. patents issued\n",
      "from, or U.S. publications of any of the above applications\n",
      "are incorporated by reference in their entirety.\n",
      "\n",
      "SUMMARY\n",
      "\n",
      "[0002] Bisphosphonate compounds are potent inhibitors\n",
      "of osteoclast activity, and are used clinically to treat bone-\n",
      "related conditions such as osteoporosis and Pagets disease\n",
      "of bone; and cancer-related conditions including multiple\n",
      "myeloma, and bone metastases from solid tumors. They\n",
      "generally have low oral bioavailability.\n",
      "\n",
      "[0003] Patchy osteoporosis and bone marrow edema may\n",
      "result from osteoclast hyperactivity. Zoledronic acid is a\n",
      "potent inhibitor of bone resorption and osteoclast activity.\n",
      "Nitrogen containing bisphosphonates, such as zoledronic\n",
      "acid, also inhibit the mevalonate pathway in the osteoclast\n",
      "thereby interrupting normal osteoclast function.\n",
      "\n",
      "[0004] It has been discovered that oral dosage forms of\n",
      "bisphosphonate compounds, such as zoledronic acid, can be\n",
      "used to treat or alleviate pain or related conditions.\n",
      "\n",
      "[0005] Some embodiments include a method of enhancing\n",
      "the oral bioavailability of zoledronic acid comprising orally\n",
      "administering a dosage form containing zoledronic acid in\n",
      "the disodium salt form.\n",
      "\n",
      "[0006] Some embodiments include a dosage form com-\n",
      "prising zoledronic acid in the disodium salt form, wherein\n",
      "the bioavailability, in a mammal, of zoledronic acid in the\n",
      "\n",
      "disodium salt form is greater than the bioavailability of\n",
      "zoledronic acid in the diacid form would be in the same\n",
      "dosage form.\n",
      "\n",
      "[0007] Some embodiments include a dosage form com-\n",
      "prising zoledronic acid in an acid or a salt form, such as the\n",
      "disodium salt form, wherein the dosage form contains an\n",
      "amount of zoledronic acid in the disodium salt form that\n",
      "provides an area under the plasma concentration curve of\n",
      "zoledronic acid of about 4 ng-h/mL to about 2000 ng-h/mL\n",
      "to a human being to which the dosage form is administered.\n",
      "[0008] Some embodiments include a dosage form com-\n",
      "prising zoledronic acid in the disodium salt form, wherein\n",
      "the disodium salt form is present in a lower molar amount\n",
      "than would be present if the zoledronic acid were in the\n",
      "diacid form; and wherein the zoledronic acid in the disodium\n",
      "salt form has an improved bioavailability as compared to the\n",
      "zoledronic acid in the diacid form to the extent that the lower\n",
      "molar amount of the disodium salt in the dosage form does\n",
      "not reduce the amount of zoledronic acid delivered to the\n",
      "plasma of a mammal.\n",
      "\n",
      "[0009] Although an oral dosage form with enhanced bio-\n",
      "availability with respect to the bisphosphonate compound\n",
      "can be used, the treatment can also be effective using an oral\n",
      "dosage form that includes a bisphosphonate compound, such\n",
      "as zoledronic acid, wherein the bioavailability of the bis-\n",
      "phosphonate is unenhanced, or is substantially unenhanced.\n",
      "[0010] Some embodiments include a method of relieving\n",
      "inflammatory pain comprising administering an oral dosage\n",
      "form containing zoledronic acid to a mammal in need\n",
      "thereof, wherein the mammal experiences significant pain\n",
      "relief more than 3 hours after administration of the dosage\n",
      "form.\n",
      "\n",
      "[0011] Some embodiments include a method of relieving\n",
      "pain associated with an arthritis comprising administering an\n",
      "oral dosage form containing zoledronic acid to a human\n",
      "being in need thereof.\n",
      "\n",
      "[0012] Some embodiments include a method of treating\n",
      "complex regional pain syndrome comprising administering\n",
      "an oral dosage form containing zoledronic acid to a mammal\n",
      "in need thereof.\n",
      "\n",
      "[0013] Some embodiments include an oral dosage form\n",
      "comprising zoledronic acid, wherein the oral bioavailability\n",
      "of zoledronic acid is substantially unenhanced. For example,\n",
      "in some embodiments, the oral bioavailability in the dosage\n",
      "form is about 0.01% to about 4%.\n",
      "\n",
      "[0014] Some embodiments include a pharmaceutical prod-\n",
      "uct comprising more than one unit of an oral dosage form\n",
      "described herein. In some embodiments, each unit of the oral\n",
      "dosage form contains about 1 mg to about 50 mg of\n",
      "zoledronic acid.\n",
      "\n",
      "[0015] Some embodiments include a method of relieving\n",
      "inflammatory pain comprising administering an oral dosage\n",
      "form containing zoledronic acid to a mammal in need\n",
      "thereof.\n",
      "\n",
      "[0016] Insome embodiments, the mammal receives a total\n",
      "monthly dose of zoledronic acid that is about 800 mg/m? or\n",
      "less.\n",
      "\n",
      "[0017] In some embodiments, the dosage form contains\n",
      "about 10 mg/m? to about 20 mg/m? based upon the body\n",
      "surface area of the mammal.\n",
      "\n",
      "[0018] Some embodiments include a method of relieving\n",
      "inflammatory pain comprising orally administering zole-\n",
      "dronic acid to a mammal in need thereof.[0260] An incapacitance device (IITC Inc. Life Science,\n",
      "Woodland, Calif., USA) was used to measure hindpaw\n",
      "weight bearing, a postural effect of pain. The rats were\n",
      "manually held in a vertical position over the apparatus with\n",
      "the hindpaws resting on separate metal scale plates and the\n",
      "entire weight of the rat was supported on the hindpaws. The\n",
      "duration of each measurement was 6 seconds and 10 con-\n",
      "secutive measurements were taken at 60-second intervals.\n",
      "Eight readings (excluding the highest and lowest ones) were\n",
      "averaged to calculate the bilateral hindpaw weight-bearing\n",
      "values. Weight bearing data were analyzed as the ratio\n",
      "between right (fracture) and left hindpaw weight bearing\n",
      "values ((2R/(R+L))x100%).\n",
      "\n",
      "Edema Assessment\n",
      "\n",
      "[0261] Alaser sensor technique was used to determine the\n",
      "dorsal-ventral thickness of the hindpaw. Before baseline\n",
      "testing the bilateral hindpaws were tattooed with a 2 to 3 mm\n",
      "spot on the dorsal skin over the midpoint of the third\n",
      "metatarsal. For laser measurements each rat was briefly\n",
      "anesthetized with isoflurane and then held vertically so the\n",
      "hindpaw rested on a table top below the laser. The paw was\n",
      "gently held flat on the table with a small metal rod applied\n",
      "to the top of the ankle joint. Using optical triangulation, a\n",
      "laser with a distance measuring sensor was used to deter-\n",
      "mine the distance to the table top and to the top of the\n",
      "hindpaw at the tattoo site and the difference was used to\n",
      "calculate the dorsal-ventral paw thickness. The measure-\n",
      "ment sensor device used in these experiments (4381 Preci-\n",
      "cura, Limab, Goteborg, Sweden) has a measurement range\n",
      "of 200 mm with a 0.01 mm resolution.\n",
      "\n",
      "Hindpaw Temperature Measurement\n",
      "\n",
      "[0262] The temperature of the hindpaw was measured\n",
      "using a fine wire thermocouple (Omega, Stanford, Conn.,\n",
      "USA) applied to the paw skin. Six sites were tested per\n",
      "hindpaw. The six measurements for each hindpaw were\n",
      "averaged for the mean temperature.\n",
      "\n",
      "Results\n",
      "\n",
      "[0263] As illustrated in FIG. 3, treatment with orally\n",
      "administered zoledronic acid reversed pain, restored weight\n",
      "bearing, and prevented edema as compared to vehicle treated\n",
      "animals.\n",
      "\n",
      "[0264] As illustrated in FIG. 4, von Frey pain thresholds\n",
      "for the right (fracture) hindpaw were reduced by 72% versus\n",
      "the contralateral (normal) hindpaw in vehicle treated ani-\n",
      "mals. Zoledronate treatment reversed fracture induced pain\n",
      "by 77% as compared to vehicle treatment.\n",
      "\n",
      "[0265] As illustrated in FIG. 5, reduction in weight bear-\n",
      "ing, a postural effect of pain, was significantly higher in the\n",
      "vehicle treated group as compared to the zoledronic acid\n",
      "treated group. Weight bearing on the fracture hindlimb was\n",
      "reduced to 55% of normal in the vehicle treated group.\n",
      "Zoledronate treatment significantly restored hindlimb\n",
      "weight bearing as compared to vehicle treatment (86% of\n",
      "normal).\n",
      "\n",
      "[0266] As illustrated in FIG. 6, the expected increase in\n",
      "hindpaw thickness was greater in the vehicle treated group\n",
      "as compared to the zoledronic acid treated group, reflecting\n",
      "the development of edema. Zoledronate treatment reduced\n",
      "hindpaw edema by 60% versus vehicle treatment.\n",
      "\n",
      "[0267] Zoledronic acid reduced hindpaw warmth by 5%\n",
      "versus vehicle treatment.\n",
      "\n",
      "[0268] The daily dose in the above experiment was 18\n",
      "mg/m?/day. Under current FDA guidelines, the reference\n",
      "body surface area of a human adult is 1.62 m*. Thus, a daily\n",
      "\n",
      "dose of 18 mg/m? corresponds to a monthly dose of about\n",
      "500-560 mg/m? or a human dose of about 800-900 mg.\n",
      "\n",
      "Example 4. Solubility of Disodium Salt of\n",
      "Zoledronic Acid\n",
      "\n",
      "[0269] The aqueous solubility of zoledronic acid and\n",
      "disodium zoledronate tetrahydrate was determined. One\n",
      "gram of the test compound was measured in to a beaker.\n",
      "Demineralized water (pH 5.5) was then added in small\n",
      "increments to the test compound, and sonication was applied\n",
      "to the mixture. The procedure was continued until complete\n",
      "dissolution was achieved. Full dissolution was determined to\n",
      "have been reached when a clear solution was present with no\n",
      "visible material. The volume of water required to reach full\n",
      "dissolution was used to calculate a solubility value\n",
      "expressed in grams per 100 mL. The procedure was per-\n",
      "formed for each compound.\n",
      "\n",
      "Results\n",
      "\n",
      "[0270] As shown in FIG. 7, the aqueous solubility of\n",
      "disodium zoledronate tetrahydrate is approximately 50 times\n",
      "that of zoledronic acid. Disodium zoledronate tetrahydrate\n",
      "has a solubility of 12.5 g/100 mL compared to only 0.25\n",
      "2/100 mL for zoledronic acid.\n",
      "\n",
      "Example 5. Bioavailability of Orally Administered\n",
      "Zoledronic Acid and Disodium Zoledronate\n",
      "\n",
      "[0271] Tablets were manufactured containing either pure\n",
      "zoledronic acid or the disodium salt of zoledronic acid\n",
      "(disodium zoledronate tetrahydrate). Both types of tablets\n",
      "contained 50 mg of zoledronic acid equivalent per tablet.\n",
      "Identical excipients were used in both types of tablets, with\n",
      "amounts adjusted to account for the difference in molecular\n",
      "weights between the acid and the disodium salt.\n",
      "\n",
      "[0272] Beagle dogs were orally administered tablets con-\n",
      "taining 150 mg zoledronic acid equivalent either in the form\n",
      "of disodium zoledronate (Group 1) or pure zoledronic acid\n",
      "(Group 2). Each animal was given three 50 mg equivalent\n",
      "tablets (150 mg total), which were administered together.\n",
      "The animals oral cavity was wetted with water before\n",
      "placing the tablets on the back of the animals tongue.\n",
      "Animals were fasted before and after dosing. Animals were\n",
      "6 to 9 months of age and weighed 6 to 10 kg on the day of\n",
      "dosing. There were three dogs per group.\n",
      "\n",
      "[0273] Serial blood samples were collected from each\n",
      "animal by venipuncture of the jugular vein at various points\n",
      "after dosing for measurement of plasma concentrations of\n",
      "zoledronic acid. Blood samples were collected into chilled\n",
      "tubes containing K,EDTA as the anticoagulant. Samples\n",
      "were then centrifuged at approximately 3000 rpm at +4 C.\n",
      "for 10 minutes for plasma derivation. Plasma concentrations\n",
      "of zoledronic acid were measured using an LC/MS/MS\n",
      "method.\n",
      "\n",
      "Results\n",
      "\n",
      "[0274] The average plasma concentrations of zoledronic\n",
      "acid for each group of dogs is summarized in Table 1 andfive months, about six months, about seven months, about\n",
      "eight months, about nine months, about 10 months, about 11\n",
      "months, or about one year or more, after the administration\n",
      "of osteoclast inhibitor.\n",
      "\n",
      "[0084] With respect to use of oral zoledronic acid in a\n",
      "disodium salt form or in an acid form for relieving pain\n",
      "associated with an inflammatory condition or Pagets dis-\n",
      "ease of bone, relief of pain can be short-term, e.g. for a\n",
      "period of hours after administration of the dosage form,\n",
      "and/or relief of pain can be long-term, e.g. lasting for days,\n",
      "weeks, or even months after oral administration of zole-\n",
      "dronic acid. In some embodiments, a mammal, such as a\n",
      "human being, experiences significant pain relief at least\n",
      "about 3 hours, at least about 6 hours, at least about 12 hours,\n",
      "at least about 24 hours, at least about 48 hours, at least about\n",
      "one week, at least about 2 weeks, or at least about 3 weeks\n",
      "after administration of an oral dosage form comprising\n",
      "zoledronic acid. In some embodiments, a mammal, such as\n",
      "a human being, experiences significant pain relief during at\n",
      "least part of the time from about 3 hours to about 2 weeks,\n",
      "about 3 hours to about 3 weeks, about 3 hours to about 24\n",
      "hours, about 6 hours to about 2 weeks, or about 6 hours to\n",
      "about 24 hours, about 3 days to about 2 weeks, about 6 days\n",
      "to about 2 weeks, after administration of an oral dosage form\n",
      "comprising zoledronic acid. In some embodiments, a human\n",
      "being treated has significant pain relief at one month, three\n",
      "months, six months, nine months, one year, 5 years, or\n",
      "longer, after administration of the most recent dose of an\n",
      "osteoclast inhibitor such as zoledronic acid.\n",
      "\n",
      "[0085] With respect to the treatment of any condition\n",
      "recited herein, in some embodiments a first oral dosage form\n",
      "comprising zoledronic acid is administered and a second\n",
      "oral dosage form comprising oral zoledronic acid is admin-\n",
      "istered. The timing of the administration of the two dosage\n",
      "forms may be such that, with respect to the first oral dosage\n",
      "form, the second oral dosage with respect to the first oral\n",
      "dosage form, the second oral dosage form is administered at\n",
      "5xT 4x or greater (e.g., if T, 1s 1 hour, at 5 hours or later),\n",
      "at least 10xT,,,,,.. or greater, at least about 15xT,,.. or greater,\n",
      "at least about 20xT,. or greater, at least about 50xT,,. or\n",
      "greater, or at least about 200xT,,,. or greater, wherein T,,.,.\n",
      "is the time of maximum plasma concentration for the first\n",
      "oral dosage form.\n",
      "\n",
      "[0086] Some embodiments include treatment of a condi-\n",
      "tion recited herein, such as inflammatory pain, arthritis, or\n",
      "complex regional pain syndrome, wherein the treatment\n",
      "comprises either: administering only one dosage form to a\n",
      "mammal to treat the condition, or administering a first\n",
      "dosage form to the mammal, followed by administering a\n",
      "second dosage form to the mammal. If two or more dosage\n",
      "forms are administered, the second oral dosage form is\n",
      "administered before the maximum pain relieving effect of\n",
      "the first oral dosage form is achieved, or before a peak in the\n",
      "pain relieving effect of the first oral dosage form is experi-\n",
      "enced by a mammal, receiving the dosage form. In some\n",
      "embodiments, the second oral dosage form is administered\n",
      "before an observable pain relieving effect 1s achieved. In\n",
      "some embodiments, the second dosage form is administered\n",
      "about 12 hours to about 60 days, about 24 hours to about 28\n",
      "days, about 24 hours to about 7 days, about 24 hours to about\n",
      "14 days, or about 24 hours to about 21 days, after the first\n",
      "dosage form is administered.\n",
      "\n",
      "[0087] Some embodiments include treatment of a condi-\n",
      "tion recited herein, such as inflammatory pain, arthritis, or\n",
      "\n",
      "complex regional pain syndrome, wherein the treatment\n",
      "comprises administering a first dosage form to the mammal,\n",
      "followed by administering a second dosage form to the\n",
      "mammal, wherein the second dosage form is administered\n",
      "after the maximum pain relieving effect of the first oral\n",
      "dosage form is achieved, and the second oral dosage form is\n",
      "administered while the mammal is still experiencing pain\n",
      "relief from the first oral dosage form, or while the pain\n",
      "relieving effect from the first oral dosage form is observable.\n",
      "In some embodiments, the second dosage form 1s adminis-\n",
      "tered about 12 hours to about 60 days, about 24 hours to\n",
      "about 28 days, about 24 hours to about 7 days, about 24\n",
      "hours to about 14 days, or about 24 hours to about 21 days,\n",
      "after the first dosage form is administered.\n",
      "\n",
      "[0088] Zoledronic acid or another bisphosphonate may\n",
      "also be administered orally to relieve cancer-related pain,\n",
      "including pain associated with multiple myeloma and bone\n",
      "metastases from solid tumors. In some embodiments, zole-\n",
      "dronic acid is used to treat pain that is not cancer-related\n",
      "pain. For example, zoledronic acid may be used to treat pain\n",
      "that is not associated with multiple myeloma, bone metas-\n",
      "tasis from solid tumors, hypercalcemia of malignancy, giant\n",
      "cell tumor of bone, blood cancers or leukemias, or solid\n",
      "tumors or cancers. In some embodiments, enhanced bio-\n",
      "availability of the zoledronic acid may be achieved in\n",
      "treating one of these conditions by administering a dosage\n",
      "form comprising zoledronic acid in the form of a disodium\n",
      "salt. This may allow a reduced molar amount of the diso-\n",
      "dium salt to be used as compared to what would be used with\n",
      "the diacid form.\n",
      "\n",
      "[0089] In addition to relieving pain, oral administration of\n",
      "zoledronic acid or another bisphosphonate may also be\n",
      "useful to treat diseases or conditions that may or may not\n",
      "include a pain component. For example, zoledronic acid or\n",
      "another bisphosphonate may be useful to treat any of the\n",
      "pain conditions or types of conditions listed above, includ-\n",
      "ing treatment that does not simply relieve the pain of those\n",
      "conditions, and treatment that is carried out in such a way\n",
      "that the condition 1s treated without pain relief occurring. In\n",
      "addition to any pain relief zoledronic acid or another bis-\n",
      "phosphonate may or may not provide, zoledronic acid or\n",
      "another bisphosphonate may be used to treat a disease or\n",
      "condition such as a metabolic disease or condition; an\n",
      "inflammatory disease or condition, including an inflamma-\n",
      "tory disease or condition that is not associated with pain; a\n",
      "cancer disease or condition; a neurological disease or con-\n",
      "dition; etc. In some embodiments, enhanced bioavailability\n",
      "of the zoledronic acid may be achieved in treating one of\n",
      "these conditions by administering a dosage form comprising\n",
      "zoledronic acid in the form of a disodium salt. This may\n",
      "allow a reduced molar amount of the disodium salt to be\n",
      "used as compared to what would be used with the diacid\n",
      "form.\n",
      "\n",
      "[0090] In some embodiments, oral administration of zole-\n",
      "dronic acid or another bisphosphonate may also be useful to\n",
      "treat complex regional pain syndrome, rheumatoid arthritis,\n",
      "osteoarthritis, erosive osteoarthritis, axial spondyloarthritis\n",
      "including ankylosing spondylitis, acute vertebral crush frac-\n",
      "ture, fibrous dysplasia, SAPHO syndrome, osteoporosis,\n",
      "transient osteoporosis, or transient osteoporosis of the hip. In\n",
      "some embodiments, enhanced bioavailability of the zole-\n",
      "dronic acid may be achieved in treating one of these con-\n",
      "ditions by administering a dosage form comprising zole-\n",
      "dronic acid in the form of a disodium salt. This may allowe\n",
      "\n",
      "oO\n",
      "gO.\n",
      "8 \n",
      "a\n",
      "\n",
      "a\n",
      "\n",
      "-100.0\n",
      "\n",
      " \n",
      "\n",
      "~20.0\n",
      "\n",
      "a Change\n",
      "\n",
      " \n",
      "\n",
      "BML Are\n",
      "\n",
      "-160.0\n",
      "\n",
      "-180.0\n",
      "\n",
      "-200.0\n",
      "\n",
      "  \n",
      "\n",
      "OARSI Grade 0\n",
      "\n",
      "  \n",
      "  \n",
      " \n",
      "  \n",
      "\n",
      "  \n",
      "  \n",
      "\n",
      "  \n",
      " \n",
      "   \n",
      " \n",
      " \n",
      " \n",
      "\n",
      "  \n",
      "\n",
      "      \n",
      " \n",
      "\n",
      " \n",
      " \n",
      "\n",
      "    \n",
      "       \n",
      "     \n",
      "    \n",
      "         \n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "   \n",
      "\n",
      "oo tat ate on, bo alates\n",
      "peesessneneereceesenenees bs ectatatate! nace\n",
      "eralata aes ess see waren on eaaneaeeee\n",
      "Wels ets eas ahate an Noses e,\n",
      "\n",
      " \n",
      "\n",
      "watatere, RS\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "  \n",
      "\n",
      "   \n",
      " \n",
      "\n",
      " \n",
      "\n",
      "Change in BML Lesion Size Compared to Placebo\n",
      "with Zoledronic Acid Treatment\n",
      "\n",
      "OARSI Grade 1-2\n",
      "\n",
      "ae\n",
      "*\n",
      "\n",
      "   \n",
      " \n",
      "  \n",
      "\n",
      " \n",
      " \n",
      "\n",
      "nennrernomneneenennne\n",
      "senna peeeraes a ata! aceehehrenh. he\n",
      "wereearsenere  staat rate! oath, HS oe X\n",
      "seseciesensenetet Be ee as Re\n",
      "sees % ae saree seceterenenes\n",
      "saaeaneteeaeaenareeae se seseereeee\n",
      "serieeneaeetes eens Ba\n",
      "secret rear anatetate see seeeetete\n",
      "graeareeee, rate isha atatatates e otate. aha onnes,\n",
      "acetate enanaeee on, bs tatats ae gS ae, shatete e tas rs\n",
      "istatat '. Bee et seaseeseeeeeeseseeatee ee aera\n",
      "188 SSS 8S See eee eS onanaceewssesaneane aes Oeatatatatate\n",
      "ies Reerecesen eanareeeresananarereeer ane  secs atarecee ot SS anes \n",
      "Petatatetatattatatetatatetataiettatat ean sadaaunnnntateresesessensarannunnneeateee\n",
      "Pee Bea meee aes seaneeeee ee Neeson ie aa\n",
      "seeetenes a ee ee pau\n",
      "aeaaaeeeee MY? ate ate water the\n",
      "stateless\n",
      "\n",
      "     \n",
      "\n",
      "ie\n",
      "iof a time from about 3 hours to about 24 hours after\n",
      "administration of the dosage form.\n",
      "\n",
      "Embodiment 12\n",
      "\n",
      "[0321] The method of embodiment 10, wherein the mam-\n",
      "mal experiences significant pain relief during at least a part\n",
      "of a time from about 3 hours to about 3 weeks after\n",
      "administration of the dosage form.\n",
      "\n",
      "Embodiment 13\n",
      "\n",
      "[0322] A method of relieving inflammatory pain compris-\n",
      "ing administering an oral dosage form containing zoledronic\n",
      "acid to a mammal in need thereof, wherein the oral dosage\n",
      "form contains about 10 mg/m* to about 20 mg/m? of zole-\n",
      "dronic acid based upon the body surface area of the mam-\n",
      "mal.\n",
      "\n",
      "Embodiment 14\n",
      "\n",
      "[0323] The method of embodiment 13, wherein the oral\n",
      "dosage form contains about 15 mg/m? to about 20 mg/m? of\n",
      "zoledronic acid based upon the body surface area of the\n",
      "mammal.\n",
      "\n",
      "Embodiment 15\n",
      "\n",
      "[0324] A method of relieving inflammatory pain compris-\n",
      "ing orally administering to a mammal in need thereof, about\n",
      "300 mg/m? to about 600 mg/m? of zoledronic acid per month\n",
      "to the mammal, based upon the body surface area of the\n",
      "mammal.\n",
      "\n",
      "Embodiment 16\n",
      "\n",
      "[0325] The method of embodiment 15, comprising orally\n",
      "administering about 450 mg/m* to about 600 mg/m* of\n",
      "zoledronic acid per month to the mammal, based upon the\n",
      "body surface area of the mammal.\n",
      "\n",
      "Embodiment 17\n",
      "\n",
      "[0326] The method of any preceding embodiment,\n",
      "wherein the mammal is not suffering from bone metastasis.\n",
      "\n",
      "Embodiment 18\n",
      "\n",
      "[0327] The method of any preceding embodiment,\n",
      "wherein the mammal is not suffering from cancer.\n",
      "\n",
      "Embodiment 19\n",
      "\n",
      "[0328] The method of any preceding embodiment,\n",
      "wherein the zoledronic acid is administered as a salt of a\n",
      "dianion of zoledronic acid.\n",
      "\n",
      "Embodiment 20\n",
      "\n",
      "[0329] A method of relieving pain associated with an\n",
      "arthritis comprising administering an oral dosage form con-\n",
      "taining zoledronic acid to a human being in need thereof.\n",
      "\n",
      "Embodiment 21\n",
      "\n",
      "[0330] The method of embodiment 20, wherein the human\n",
      "being receives a total monthly dose of zoledronic acid that\n",
      "is about 40 mg to about 2000 mg.\n",
      "\n",
      "Embodiment 22\n",
      "\n",
      "[0331] The method of embodiment 21, wherein the total\n",
      "monthly dose is administered in 4 or 5 weekly doses.\n",
      "\n",
      "Embodiment 23\n",
      "\n",
      "[0332] The method of embodiment 21, wherein the total\n",
      "monthly dose is administered in 28 to 31 daily doses.\n",
      "\n",
      "Embodiment 24\n",
      "\n",
      "[0333] The method of embodiment 21, wherein the total\n",
      "monthly dose is administered in 5 to 10 individual doses\n",
      "during the month.\n",
      "\n",
      "Embodiment 25\n",
      "\n",
      "[0334] The method of embodiment 20, wherein the human\n",
      "being receives a total weekly dose of zoledronic acid that is\n",
      "about 100 mg to about 300 mg.\n",
      "\n",
      "Embodiment 26\n",
      "\n",
      "[0335] The method of embodiment 25, wherein the total\n",
      "weekly dose is a single dose, administered once a week.\n",
      "\n",
      "Embodiment 27\n",
      "\n",
      "[0336] The method of embodiment 25, wherein the total\n",
      "weekly dose is administered in 2 to 7 individual doses during\n",
      "the week.\n",
      "\n",
      "Embodiment 28\n",
      "\n",
      "[0337] The method of embodiment 20, wherein the human\n",
      "being receives a total weekly dose of zoledronic acid that is\n",
      "about 10 mg to about 100 mg.\n",
      "\n",
      "Embodiment 29\n",
      "\n",
      "[0338] The method of any of embodiments 20-28, wherein\n",
      "the human being experiences significant pain relief more\n",
      "than 3 hours after administration of the dosage form.\n",
      "\n",
      "Embodiment 30\n",
      "\n",
      "[0339] The method of embodiment 29, wherein the human\n",
      "being experiences significant pain relief during at least a part\n",
      "of a time from about 3 hours to about 24 hours after\n",
      "administration of the dosage form.\n",
      "\n",
      "Embodiment 31\n",
      "\n",
      "[0340] The method of embodiment 29, wherein the human\n",
      "being experiences significant pain relief during at least a part\n",
      "of a time from about 3 hours to about 3 weeks after\n",
      "administration of the dosage form.\n",
      "\n",
      "Embodiment 32\n",
      "\n",
      "[0341] The method of any of embodiments 20-31, wherein\n",
      "the dosage form contains about 10 mg/m to about 20 mg/m\n",
      "of zoledronic acid based upon the body surface area of the\n",
      "human being.TABLE E-continued\n",
      "\n",
      "Electrolytic Iron\n",
      "\n",
      "Ferric ammonium citrate\n",
      "Ferric chloride\n",
      "\n",
      "Ferric citrate\n",
      "\n",
      "Ferric oxide\n",
      "\n",
      "Ferric phosphate\n",
      "\n",
      "Ferric pyrophosphate\n",
      "Ferric sodium pyrophosphate\n",
      "Ferric sulfate\n",
      "\n",
      "Ferrous ascorbate\n",
      "\n",
      "Ferrous carbonate\n",
      "\n",
      "Ferrous citrate\n",
      "\n",
      "Ferrous fumarate\n",
      "\n",
      "Ferrous gluconate\n",
      "\n",
      "Ferrous lactate\n",
      "\n",
      "Ferrous sulfate\n",
      "\n",
      "Ferrous sulfate\n",
      "\n",
      "Iron caprylate\n",
      "\n",
      "Iron linoleate\n",
      "\n",
      "Iron naphthenate\n",
      "\n",
      "Iron oxides\n",
      "\n",
      "Iron peptonate\n",
      "\n",
      "Iron polyvinylpyrrolidone\n",
      "Iron tallate\n",
      "\n",
      "Sodium ferric EDTA\n",
      "Sodium ferricitropyrophosphate\n",
      "Dietary Iron\n",
      "\n",
      "Ferric oxide\n",
      "\n",
      "Potassium carbonate\n",
      "Calcium glycerophosphate\n",
      "Cellulose, such as microcrystalline cellulose\n",
      "Titanium dioxide\n",
      "\n",
      "[0227] Some compositions or dosage forms may be a\n",
      "liquid, or may comprise a solid phase dispersed in a liquid.\n",
      "[0228] An osteoclast inhibitor, such as zoledronic acid,\n",
      "minodronic acid, or ibandronic acid may be formulated for\n",
      "parental or intraperitoneal administration. Solutions of the\n",
      "active compounds as free acids or pharmacologically accept-\n",
      "able salts can be prepared in water suitably mixed with a\n",
      "surfactant, such as hydroxypropylcellulose. A dispersion can\n",
      "also have an oil dispersed within, or dispersed in, glycerol,\n",
      "liquid polyethylene glycols, and mixtures thereof. Under\n",
      "ordinary conditions of storage and use, these preparations\n",
      "may contain a preservative to prevent the growth of micro-\n",
      "organisms.\n",
      "\n",
      "[0229] In some embodiments, an oral dosage form may\n",
      "comprise a silicified microcrystalline cellulose such as\n",
      "PROSLOV. For example, about 20% (wt/wt) to about\n",
      "70% (wt/wt), about 10% (wt/wt) to about 20% (wt/wt),\n",
      "about 20% (wt/wt) to about 40% (wt/wt), about 25% (wt/wt)\n",
      "to about 30% (wt/wt), about 40% (wt/wt) to about 50%\n",
      "(wt/wt), or about 45% (wt/wt) to about 50% (wt/wt) silici-\n",
      "fied microcrystalline cellulose may be present in an oral\n",
      "dosage form or a unit of an oral dosage form.\n",
      "\n",
      "[0230] In some embodiments, an oral dosage form may\n",
      "comprise a crosslinked polyvinylpyrrolidone such as\n",
      "crospovidone. For example, about 1% (wt/wt) to about 10%\n",
      "(wt/wt), about 1% (wt/wt) to about 5% (wt/wt), or about 1%\n",
      "(wt/wt) to about 3% (wt/wt) crosslinked polyvinylpyrroli-\n",
      "done may be present in an oral dosage form or a unit of an\n",
      "oral dosage form.\n",
      "\n",
      "[0231] In some embodiments, an oral dosage form may\n",
      "comprise a fumed silica such as AEROSIL. For example,\n",
      "about 0.1% (wt/wt) to about 10% (wt/wt), about 0.1%\n",
      "(wt/wt) to about 1% (wt/wt), or about 0.4% (wt/wt) to about\n",
      "0.6% (wt/wt) fumed silica may be present in an oral dosage\n",
      "form or a unit of an oral dosage form.\n",
      "\n",
      "[0232] In some embodiments, an oral dosage form may\n",
      "comprise magnesium stearate. For example, about 0.1%\n",
      "(wt/wt) to about 10% (wt/wt), about 0.1% (wt/wt) to about\n",
      "1% (wt/wt), or about 0.4% (wt/wt) to about 0.6% (wt/wt)\n",
      "magnesium stearate may be present in an oral dosage form\n",
      "or a unit of an oral dosage form.\n",
      "\n",
      "[0233] An oral dosage form comprising zoledronic acid or\n",
      "another bisphosphonate or osteoclast inhibitor may be\n",
      "included in a pharmaceutical product comprising more than\n",
      "one unit of the oral dosage form.\n",
      "\n",
      "[0234] A pharmaceutical product containing oral dosage\n",
      "forms for daily use can contain 28, 29, 30, or 31 units of the\n",
      "oral dosage form for a monthly supply. An approximately 6\n",
      "week daily supply can contain 40 to 45 units of the oral\n",
      "dosage form. An approximately 3 month daily supply can\n",
      "contain 85 to 95 units of the oral dosage form. An approxi-\n",
      "mately six month daily supply can contain 170 to 200 units\n",
      "of the oral dosage form. An approximately one year daily\n",
      "supply can contain 350 to 380 units of the oral dosage form.\n",
      "[0235] A pharmaceutical product containing oral dosage\n",
      "forms for weekly use can contain 4 or 5 units of the oral\n",
      "dosage form for a monthly supply. An approximately two\n",
      "month weekly supply can contain 8 or 9 units of the oral\n",
      "dosage form. An approximately six week weekly supply can\n",
      "contain about 6 units of the oral dosage form. An approxi-\n",
      "mately three month weekly supply can contain 12, 13 or 14\n",
      "units of the oral dosage form. An approximately six month\n",
      "weekly supply can contain 22 to 30 units of the oral dosage\n",
      "form. An approximately one year weekly supply can contain\n",
      "45 to 60 units of the oral dosage form.\n",
      "\n",
      "[0236] A pharmaceutical product may accommodate other\n",
      "dosing regimes. For example, a pharmaceutical product may\n",
      "comprise 5 to 10 units of the oral dosage form, wherein each\n",
      "unit of the oral dosage form contains about 40 mg to about\n",
      "150 mg of zoledronic acid, minodronic acid, or ibandronic\n",
      "acid. Some pharmaceutical products may comprise 1 to 10\n",
      "units of the oral dosage form, wherein the product contains\n",
      "about 200 mg to about 2000 mg of zoledronic acid, mino-\n",
      "dronic acid, or ibandronic acid. For such a product, each unit\n",
      "of the oral dosage form may be taken daily for 1 to 10 days\n",
      "or 5 to 10 days during a month, such as at the beginning of\n",
      "a month.\n",
      "\n",
      "[0237] Some oral dosage forms comprising an osteoclast\n",
      "inhibitorsuch as suitable bisphosphonates like zoledronic\n",
      "acid, minodronic acid, or ibandronic acid or salts thereof\n",
      "may have enteric coatings or film coatings. In some embodi-\n",
      "ments, an oral dosage form of an osteoclast inhibitor com-\n",
      "prises a tablet having an enteric coating. In some\n",
      "embodiments, an oral dosage form of an osteoclast inhibitor\n",
      "comprises a capsule having an enteric coating. In some\n",
      "embodiments, an oral dosage form of an osteoclast inhibitor\n",
      "comprises a tablet having a film coating. In some embodi-\n",
      "ments, an oral dosage form of an osteoclast inhibitor com-\n",
      "prises a capsule having a film coating.\n",
      "\n",
      "[0238] Useful doses for an antibody against RANK or\n",
      "RANKL, such as denosumab, may range from about 0.1\n",
      "mg/kg to about 20 mg/kg, about 0.75 mg/kg to about 7.5\n",
      "mg/kg, about 0.1 mg/kg to about 5 mg/kg, about 1 mg/kg to\n",
      "about 2 mg/kg, about 10 mg/kg to about 20 mg/kg, about 12\n",
      "to about 17 mg/kg, about 15 mg/kg to about 20 mg/kg, about\n",
      "1 mg/kg, about 1 mg/kg to about 10 mg/kg, or any value\n",
      "bounded by or in between these ranges based on the body\n",
      "weight of the mammal. The chosen dose may be adminis-\n",
      "tered repeatedly, particularly for chronic conditions, or the(dasatinib), alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5- -continued\n",
      "bromophenyl) propenamide (LFM-A13), and ONO-WG-\n",
      "\n",
      "| O\n",
      "307. NZ? nN\n",
      "ARO Vs\n",
      "O\n",
      "\n",
      "CGI-1746\n",
      "F\n",
      "webevonas\n",
      "S\n",
      "KK, N Ny\n",
      "H H H\n",
      "CC-292\n",
      "O\n",
      "| H\n",
      "N\n",
      "w. . SA ~\n",
      "H H H\n",
      "CNX-774\n",
      "\n",
      " \n",
      "\n",
      "[0043] Inhibitors of osteoclast activity may be used for a\n",
      "\n",
      "number of medical purposes, such as treatment of undesir-\n",
      "\n",
      "Ibrutinib able conditions or diseases, including pain relief. This may\n",
      "\n",
      "Br be accomplished in many instances by administration of oral\n",
      "\n",
      "O OH dosage forms. Generally, an oral dosage form comprising a\n",
      "\n",
      "bisphosphonate such as zoledronic acid is administered\n",
      "\n",
      "Br N a orally to a mammal, such as a human being, at least once, to\n",
      "H treat a disease or condition, or to relieve pain.\n",
      "\n",
      "|\n",
      "\n",
      "[0044] The compounds containing Ion 1 or Ion 2 may also\n",
      "be osteoclast inhibitors:\n",
      "\n",
      "LMF-A13\n",
      "0 oN _ Ion 1\n",
      "CDH par\n",
      "S HN O A Aine H\n",
      "3H2\n",
      "HO YY \\ a\n",
      "f N Ion 2\n",
      "+\n",
      "\\ NH PO3H> PO3H)\n",
      "N\n",
      "/ H503P Ny WN PO3H)\n",
      "O 203 YY\n",
      "GDC-0834 HO OH\n",
      "\n",
      "oZ,\n",
      "\n",
      "ees 6\n",
      "LN N S [0045] The term treating or treatment broadly\n",
      "Yr Y j includes any kind of treatment activity, including the diag-\n",
      "\n",
      "nosis, cure, mitigation, or prevention of disease in man or\n",
      "\n",
      "NAN N Cl other animals, or any activity that otherwise affects the\n",
      "\n",
      "y structure or any function of the body of man or other\n",
      "animals.\n",
      "\n",
      "Dasatinib [0046] An oral dosage form of a bisphosphonate such as\n",
      "\n",
      "zoledronic acid may be used to treat, or provide relief of, any\n",
      "type of pain including, but not limited to, inflammatory pain,\n",
      "arthritis pain, complex regional pain syndrome, lumbosacral\n",
      "\n",
      "HN pain, musculoskeletal pain, neuropathic pain, chronic pain,\n",
      "cancer-related pain, acute pain, postoperative pain, etc. In\n",
      "\n",
      "na NN some instances, pain relief may be palliative, or pain relief\n",
      "> may be provided independent of improvement of the disease\n",
      "\n",
      "SY UN h or condition or the underlying cause of the disease or\n",
      "condition. For example, although the underlying disease\n",
      "\n",
      "Zo\n",
      "\n",
      "may not improve, or may continue to progress, an individual\n",
      "suffering from the disease may experience pain relief. In\n",
      "CGI-560 some embodiments, enhanced bioavailability of the zole-\n",
      "dronic acid may be achieved in treating one of these con-Embodiment 357\n",
      "\n",
      "[0686] The method of Embodiment 316 or 317, compris-\n",
      "ing treating ankylosing spondylitis.\n",
      "\n",
      "Embodiment 358\n",
      "\n",
      "[0687] The method of Embodiment 316, 317, 318, 319,\n",
      "320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331,\n",
      "332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343,\n",
      "344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355,\n",
      "356, or 357, wherein the dosage form is administered about\n",
      "every three months, or more frequently.\n",
      "\n",
      "Embodiment 359\n",
      "\n",
      "[0688] The method of Embodiment 316, 317, 318, 319,\n",
      "320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331,\n",
      "332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343,\n",
      "344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355,\n",
      "356, 357, or 358, wherein the mammal experiences pain\n",
      "relief at least 24 hours after the dosage form is administered\n",
      "to the mammal.\n",
      "\n",
      "Embodiment 360\n",
      "\n",
      "[0689] The method of Embodiment 316, 317, 318, 319,\n",
      "320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331,\n",
      "332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343,\n",
      "344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355,\n",
      "356, 357, 358, or 359, wherein the mammal experiences\n",
      "pain relief three months after the dosage form is adminis-\n",
      "tered.\n",
      "\n",
      "Embodiment 361\n",
      "\n",
      "[0690] The method of Embodiment 316, 317, 318, 319,\n",
      "320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331,\n",
      "332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343,\n",
      "344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355,\n",
      "356, 357, 358, 359, or 360, wherein the human being\n",
      "experiences pain relief that lasts for a duration of at least 48\n",
      "hours after administration of the dosage form.\n",
      "\n",
      "Embodiment 362\n",
      "\n",
      "[0691] The method of Embodiment 316, 317, 318, 319,\n",
      "320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331,\n",
      "332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343,\n",
      "344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355,\n",
      "356, 357, 358, 359, 360, or 361, wherein the human being\n",
      "receives the dosage form no more often than once daily.\n",
      "\n",
      "Embodiment 363\n",
      "\n",
      "[0692] The method of Embodiment 316, 317, 318, 319,\n",
      "320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331,\n",
      "332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343,\n",
      "344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355,\n",
      "356, 357, 358, 359, 360, or 361, wherein there is a period of\n",
      "about 24 hours to about 7 days between administration of\n",
      "dosage forms.\n",
      "\n",
      "Embodiment 364\n",
      "\n",
      "[0693] The method of Embodiment 363, wherein the\n",
      "dosage form is administered weekly.\n",
      "\n",
      "Embodiment 365\n",
      "\n",
      "[0694] The method of Embodiment 316, 317, 318, 319,\n",
      "320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331,\n",
      "332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343,\n",
      "344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355,\n",
      "356, 357, 358, 359, 360, or 361, wherein there is a period of\n",
      "about 14 days to about 28 days between administration of\n",
      "dosage forms.\n",
      "\n",
      "Embodiment 366\n",
      "\n",
      "[0695] The method of Embodiment 316, 317, 318, 319,\n",
      "320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331,\n",
      "332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343,\n",
      "344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355,\n",
      "356, 357, 358, 359, 360, or 361, wherein there is a period of\n",
      "at least one month between administration of dosage forms.\n",
      "\n",
      "Embodiment 367\n",
      "\n",
      "[0696] The method of Embodiment 316, 317, 318, 319,\n",
      "320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331,\n",
      "332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343,\n",
      "344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355,\n",
      "356, 357, 358, 359, 360, or 361, wherein there is a period of\n",
      "about 7 days to about 14 days between administration of\n",
      "dosage forms.\n",
      "\n",
      "Embodiment 368\n",
      "\n",
      "[0697] The method of Embodiment 316, 317, 318, 319,\n",
      "320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331,\n",
      "332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343,\n",
      "344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355,\n",
      "356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, or\n",
      "367, wherein the compound is administered more than once.\n",
      "\n",
      "Embodiment 369\n",
      "\n",
      "[0698] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity and/or CTX serum levels.\n",
      "\n",
      "Embodiment 370\n",
      "\n",
      "[0699] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 5%.\n",
      "\n",
      "Embodiment 371\n",
      "\n",
      "[0700] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 10%.\n",
      "\n",
      "Embodiment 372\n",
      "\n",
      "[0701] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 15%.Pain Threshold (g)\n",
      "\n",
      "190 +Embodiment 101\n",
      "\n",
      "[0410] A method of treating inflammatory pain, compris-\n",
      "ing administering olpadronic acid to a human being in need\n",
      "thereof.\n",
      "\n",
      "Embodiment 102\n",
      "\n",
      "[0411] A method of treating inflammatory pain, compris-\n",
      "ing administering alendronic acid to a human being in need\n",
      "thereof.\n",
      "\n",
      "Embodiment 103\n",
      "\n",
      "[0412] A method of treating inflammatory pain, compris-\n",
      "ing administering incadronic acid to a human being in need\n",
      "thereof.\n",
      "\n",
      "Embodiment 104\n",
      "\n",
      "[0413] A method of treating inflammatory pain, compris-\n",
      "ing administering ibandronic acid to a human being in need\n",
      "thereof.\n",
      "\n",
      "Embodiment 105\n",
      "\n",
      "[0414] A method of treating inflammatory pain, compris-\n",
      "ing administering risedronic acid to a human being 1n need\n",
      "thereof.\n",
      "\n",
      "Embodiment 106\n",
      "\n",
      "[0415] A method of treating complex regional pain syn-\n",
      "drome, comprising administering etidronic acid to a human\n",
      "being in need thereof.\n",
      "\n",
      "Embodiment 107\n",
      "\n",
      "[0416] A method of treating pain, comprising administer-\n",
      "ing etidronic acid to a human being in need thereof.\n",
      "\n",
      "Embodiment 108\n",
      "\n",
      "[0417] A method of treating arthritis pain, comprising\n",
      "administering etidronic acid to a human being in need\n",
      "thereof.\n",
      "\n",
      "Embodiment 109\n",
      "\n",
      "[0418] A method of treating inflammatory pain, compris-\n",
      "ing administering etidronic acid to a human being in need\n",
      "thereof.\n",
      "\n",
      "Embodiment 110\n",
      "\n",
      "[0419] A method of treating complex regional pain syn-\n",
      "drome, comprising administering clodronic acid to a human\n",
      "being in need thereof.\n",
      "\n",
      "Embodiment 111\n",
      "\n",
      "[0420] A method of treating pain, comprising administer-\n",
      "ing clodronic acid to a human being in need thereof.\n",
      "\n",
      "Embodiment 112\n",
      "\n",
      "[0421] A method of treating arthritis pain, comprising\n",
      "administering clodronic acid to a human being in need\n",
      "thereof.\n",
      "\n",
      "Embodiment 113\n",
      "\n",
      "[0422] A method of treating inflammatory pain, compris-\n",
      "ing administering clodronic acid to a human being in need\n",
      "thereof.\n",
      "\n",
      "Embodiment 114\n",
      "\n",
      "[0423] A method of treating complex regional pain syn-\n",
      "drome, comprising administering tiludronic acid to a human\n",
      "being in need thereof.\n",
      "\n",
      "Embodiment 115\n",
      "\n",
      "[0424] A method of treating pain, comprising administer-\n",
      "ing tiludronic acid to a human being in need thereof.\n",
      "\n",
      "Embodiment 116\n",
      "\n",
      "[0425] A method of treating arthritis pain, comprising\n",
      "administering tiludronic acid to a human being in need\n",
      "thereof.\n",
      "\n",
      "Embodiment 117\n",
      "\n",
      "[0426] A method of treating inflammatory pain, compris-\n",
      "ing administering tiludronic acid to a human being in need\n",
      "thereof.\n",
      "\n",
      "Embodiment 118\n",
      "\n",
      "[0427] The method of any of embodiments 78-117,\n",
      "wherein the active compound is orally administered.\n",
      "\n",
      "Embodiment 119\n",
      "\n",
      "[0428] The method of any of embodiments 78-117,\n",
      "wherein the active compound is parenterally administered.\n",
      "\n",
      "Embodiment 120\n",
      "\n",
      "[0429] A method of enhancing the oral bioavailability of\n",
      "zoledronic acid comprising orally administering a dosage\n",
      "form containing zoledronic acid in the disodium salt form.\n",
      "\n",
      "Embodiment 121\n",
      "\n",
      "[0430] The method of embodiment 120, wherein the zole-\n",
      "dronic acid in the disodium salt form provides an enhance-\n",
      "ment to bioavailability, as compared to zoledronic acid in the\n",
      "diacid form, which adds to any enhancement to bioavail-\n",
      "ability provided by any bioavailability-enhancing agents in\n",
      "the dosage form.\n",
      "\n",
      "Embodiment 122\n",
      "\n",
      "[0431] The method of embodiment 120, wherein the dos-\n",
      "age form is substantially free of bioavailability-enhancing\n",
      "agents.\n",
      "\n",
      "Embodiment 123\n",
      "\n",
      "[0432] The method of embodiment 120, wherein the zole-\n",
      "dronic acid in the disodium salt form is administered to a\n",
      "mammal in an amount that provides an area under the\n",
      "plasma concentration curve of zoledronic acid of about 4\n",
      "ng-h/mL to about 2000 ng-h/mL to the mammal each time\n",
      "the zoledronic acid in the disodium salt is administered.Pain Edema Warmth Weight\n",
      "Bearing.\n",
      "\n",
      " \n",
      "\n",
      "*\n",
      "\n",
      "os\n",
      "\n",
      "he\n",
      "Ne\n",
      "\n",
      "a\n",
      "ja\n",
      "s2\n",
      "@\n",
      "\n",
      "VAS Change vs. Placebo (mm)\n",
      ". bi\n",
      "Q\n",
      "\n",
      "~16.8\n",
      "-18.0\n",
      "\n",
      "~20.0\n",
      "\n",
      "iG. 12\n",
      "\n",
      " \n",
      "\n",
      "Ail patients\n",
      "\n",
      "Baseline VAS 2 50\n",
      "\n",
      "go aia Hate\n",
      "ecseeaeesesesens\n",
      "eae beeae tet\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "OARS! Grade 0\n",
      "\n",
      " \n",
      "\n",
      "Baseline VAS 2 50+\n",
      "CARS! Grade 0referred to as vertebral endplate signal changes (VESC).\n",
      "Modic changes, can be classified into various types includ-\n",
      "ing type 1 (M1), type 2 (M2), and type 3 (M3) lesions or\n",
      "changes, any of which may be treated using an osteoclast\n",
      "inhibitor, such as a nitrogen-bisphosphonate, including, e.g.\n",
      "zoledronic acid, minodronic acid, etc. Different types of\n",
      "Modic changes may occur in the same patient, for example\n",
      "type 1 and type 2 Modic changes (M1/2). In some cases, M1\n",
      "changes are related to lower back pain than other types of\n",
      "Modic change.\n",
      "\n",
      "[0120] VESCs may be found in patients with different\n",
      "types of low back pain including but not limited to spon-\n",
      "dylitis, trauma, spondyloarthropathies including ankylosing\n",
      "spondylitis, Schmorls nodes, fracture, tumor, and spinal\n",
      "cord infarction. Lesions in ankylosing spondylitis include\n",
      "osteitis and spondylodiscitis, which can be detected using\n",
      "MRI or another medical imaging instrument.\n",
      "\n",
      "[0121] Modic changes may be found in the cervical,\n",
      "thoracic, lumbar, and sacral spine. Modic changes may be\n",
      "found at various spinal levels such as at C1/2, C2/3, C3/4,\n",
      "C4/5, C5/6, C6/7, C7/T1, T1/2, T2/3, T3/4, T4/5, T5/6, T6/7,\n",
      "T7/8, T8/9, T9/10, T10/11, T11/12, T12/L1, L1/2, L2/3,\n",
      "L3/4, L4/5, L5/S1, etc., any of which may be treated using\n",
      "an osteoclast inhibitor, such as a nitrogen-bisphosphonate,\n",
      "including, e.g. zoledronic acid, minodronic acid, etc.\n",
      "\n",
      "[0122] In some embodiments, the Modic change being\n",
      "treated is located at L2/3. In some embodiments, the Modic\n",
      "change being treated is located at L3/4. In some embodi-\n",
      "ments, the Modic change being treated is located at L4/5. In\n",
      "some embodiments, the Modic change being treated is\n",
      "located at L5/S1.\n",
      "\n",
      "[0123] In some embodiments, the Modic change being\n",
      "treated is located at C3/4. In some embodiments, the Modic\n",
      "change being treated is located in at C4/5. In some embodi-\n",
      "ments, the Modic change being treated is located in at C5/6.\n",
      "In some embodiments, the Modic change being treated is\n",
      "located in at C6/7.\n",
      "\n",
      "[0124] In some embodiments, the Modic change being\n",
      "treated is located at T5/6. In some embodiments, the Modic\n",
      "change being treated is located in at T6/7. In some embodi-\n",
      "ments, the Modic change being treated is located in at T7/8.\n",
      "In some embodiments, the Modic change being treated is\n",
      "located in at T8/9. In some embodiments, the Modic change\n",
      "being treated is located at T9/10.\n",
      "\n",
      "[0125] In some embodiments, the patient being treated has\n",
      "predominantly M1. In some embodiments, the patient being\n",
      "treated has predominantly M1/M2. In some embodiments,\n",
      "the patient being treated has predominantly M2. In some\n",
      "embodiments, the patient being treated has predominantly\n",
      "M3.\n",
      "\n",
      "[0126] In some embodiments, the worst type of lesion that\n",
      "the patient being treated has is M1. In some embodiments,\n",
      "the worst type of lesion that the patient being treated has is\n",
      "M1/2. In some embodiments, the worst type of lesion that\n",
      "the patient being treated has is M2.\n",
      "\n",
      "[0127] In some embodiments, the patient being treated has\n",
      "Modic changes at more two or more levels. In some embodi-\n",
      "ments the patient being treated has Modic changes at three\n",
      "or more levels. In some embodiments greater pain relief is\n",
      "obtained when treating a patient with Modic changes at two\n",
      "levels, or three or more levels, than is obtained when treating\n",
      "a patient with Modic changes at a single level or at two\n",
      "levels.\n",
      "\n",
      "[0128] In some embodiments greater pain relief is\n",
      "obtained when treating a patient with Modic changes at two\n",
      "levels than is obtained when treating a patient with Modic\n",
      "changes at a single level.\n",
      "\n",
      "[0129] In some embodiments greater pain relief is\n",
      "obtained when treating a patient with Modic changes at three\n",
      "or more levels than is obtained when treating a patient with\n",
      "Modic changes at a single level.\n",
      "\n",
      "[0130] In some embodiments greater pain relief is\n",
      "obtained when treating a patient with Modic changes three\n",
      "or more levels than is obtained when treating a patient with\n",
      "Modic changes at two levels.\n",
      "\n",
      "[0131] In some embodiments, the inhibitor of osteoclast\n",
      "activity may be used to effect a reduction in the levels of\n",
      "pro-inflammatory cytokines in the patient with low back\n",
      "pain or any other type of pain or condition recited herein. In\n",
      "some embodiments greater pain relief may be obtained in\n",
      "patients with greater baseline levels of pro-inflammatory\n",
      "cytokines when treated with an inhibitor of osteoclast activ-\n",
      "ity, such as a nitrogen-containing bisphosphonate, including\n",
      "e.g. zoledronic acid, minodronic acid, etc. In some embodi-\n",
      "ments, greater pain relief may be obtained in patients who\n",
      "experience a reduction or a greater reduction 1n the levels of\n",
      "pro-inflammatory cytokines when treated with an inhibitor\n",
      "of osteoclast activity, such as a nitrogen-containing bispho-\n",
      "sphonate, including e.g. zoledronic acid, minodronic acid,\n",
      "etc. Pro-inflammatory cytokines include but are not limited\n",
      "to IL-1, IL-2, IL-3, IL-6, IL-8, IL-10, IL-12, tumor necrosis\n",
      "alpha (TNF-alpha), interferon gamma, etc.\n",
      "\n",
      "[0132] In some embodiments, the use of an inhibitor of\n",
      "osteoclast activity, such as a nitrogen-containing bisphos-\n",
      "phonate, including e.g. zoledronic acid, minodronic acid,\n",
      "etc., to a patient or mammal in need thereof, achieves a\n",
      "reduction relative to baseline in the size of Modic changes\n",
      "or VESCs of at least about 5%, at least about 10%, at least\n",
      "about 15%, at least about 20%, at least about 25%, at least\n",
      "about 30%, at least about 40%, at least about 50%, at least\n",
      "about 60%, at least about 70% at least about 80%, at least\n",
      "about 90%, or about 100%. In some embodiments, the\n",
      "reduction the size of Modic changes or VESCs represents an\n",
      "improvement relative to placebo of at least about 10%, at\n",
      "least about 15%, at least about 20%, at least about 25%, at\n",
      "least about 30%, at least about 40%, at least about 50%, at\n",
      "least about 60%, at least about 70%, at least about 80%, at\n",
      "least about 90%, at least about 100%, at least about 120%,\n",
      "at least about 150%, at least about 170%, at least about\n",
      "200%, at least about 250%, at least about 300%, at least\n",
      "about 350%, at least about 400%, or at least about 450%. In\n",
      "some embodiments, the use of an inhibitor of osteoclast\n",
      "activity inhibits an increase 1n the size of Modic changes or\n",
      "VESCs over time.\n",
      "\n",
      "[0133] The oral bioavailability of zoledronic acid may be\n",
      "enhanced by orally administering the zoledronic acid in the\n",
      "disodium salt form. For example, the bioavailability of\n",
      "zoledronic acid may be improved by at least about 10%, at\n",
      "least about 20%, at least about 30%, at least about 50%,\n",
      "and/or up to about 100%, or up to about 200%, as compared\n",
      "to administration of zoledronic acid in the diacid form.\n",
      "[0134] Because of the improved bioavailability of the\n",
      "disodium salt a dosage form may contain, or a mammal,\n",
      "such as a human being, may receive, on a molar basis, less\n",
      "of the disodium salt form of zoledronic acid than would\n",
      "otherwise be administered of the diacid form of zoledronic\n",
      "acid. For example, a dosage form may contain, or a mammal-continued\n",
      "PO3H- M*\n",
      "OH\n",
      "Ny .ogN PO3H-\n",
      "\n",
      "AD SH\n",
      "\n",
      "OH\n",
      "\n",
      "O PO 4M*\n",
      "A s .4N PO;*\n",
      "\n",
      "Fe\n",
      "\n",
      "OH\n",
      "\n",
      "wherein X~ is any suitable anion, e.g. F-, Br-, Cl, IT, OH,\n",
      "acetate, etc.; and M* is any suitable cation, e.g. Na*, K,\n",
      "NH,,, etc. Many other salt forms are also possible.\n",
      "\n",
      "[0108] In some embodiments, a compound containing Ion\n",
      "1 may be further represented by a formula,\n",
      "\n",
      "O PO3Na>\n",
      "\n",
      "PO3Nap.\n",
      "OH\n",
      "\n",
      "[0109] In some embodiments, a compound containing Ion\n",
      "1 may be in a hydrate form.\n",
      "\n",
      "[0110] In some embodiments, a compound containing Ion\n",
      "1 is administered in a dosage form comprising a salt form,\n",
      "such as a zwitterionic form, or a salt of a cation, a mono-\n",
      "anion, a dianion, a trianion, etc.\n",
      "\n",
      "[0111] Acompound containing Ion 1 can be present 1n any\n",
      "amount, such as less than about 100% w/w, less than about\n",
      "50% w/w, less than about 20% w/w, less than about 10%\n",
      "w/w, less than about 1% w/w, less than 0.1% w/w, less than\n",
      "about 0.07% w/w, less than about 0.05% w/w, less than\n",
      "about 0.04% w/w, less than about 0.03% w/w, less than\n",
      "about 0.02% w/w; and/or greater than 0% w/w, at least about\n",
      "0.00000001% w/w, at least about 0.000001 % w/w, or at least\n",
      "about 0.00001% w/w, based upon the total amount of\n",
      "zoledronic acid, a compound containing Ion 1, and a com-\n",
      "pound containing Ion 2 present in the composition.\n",
      "\n",
      "[0112] Examples of salts of compounds containing Ion 2\n",
      "are shown below:\n",
      "\n",
      "xX\n",
      "PO3H\n",
      "PO3H> i 3H\n",
      "Nag POs\n",
      "PO3H>\n",
      "POs\n",
      "Nae\n",
      "PO3H>\n",
      ". M\n",
      "PO3H FO3H\n",
      "HO AP.\n",
      "PO3H, OH\n",
      "\n",
      "-continued\n",
      "\n",
      "oe x POsH 2M*\n",
      "PO3H, OH\n",
      "PO3H > PO3H \n",
      "wh Sa of Avo\n",
      "PO3H\" OH\n",
      "+\n",
      "PO3H pee POSH on\n",
      "we Sot of esos\n",
      "OH\n",
      "\n",
      "PO3H-\n",
      "\n",
      "wherein X~ is any suitable anion, e.g. F-, Br-, Cl, IT, OH,\n",
      "acetate, etc.; and M is any suitable cation, e.g. Na, K*,\n",
      "NH,, etc. Many other salt forms are also possible.\n",
      "\n",
      "[0113] In some embodiments, a salt of a compound con-\n",
      "taining Ion 2 may be further represented by a formula,\n",
      "\n",
      "Neus N PO3HNa\n",
      "HO v OH\n",
      "\n",
      "PO3HNa Qy\n",
      "\n",
      "[0114] In some embodiments, a compound containing Ion\n",
      "2 may be in a hydrate form.\n",
      "\n",
      "[0115] In some embodiments, a compound containing Ion\n",
      "2 is administered in a dosage form comprising a salt form,\n",
      "such as a zwitterionic form, or a salt of a cation, a mono-\n",
      "anion, a dianion, a trianion, etc.\n",
      "\n",
      "[0116] Acompound containing Ion 2 can be present in any\n",
      "amount, such as less than about 100% w/w, less than about\n",
      "50% w/w, less than about 20% w/w, less than about 10%\n",
      "w/w, less than about 1% w/w, less than about 0.3%, less than\n",
      "about 0.2%, less than 0.1% w/w, less than about 0.08% w/w,\n",
      "less than about 0.07% w/w, less than about 0.05% w/w, less\n",
      "than about 0.04% w/w, less than about 0.03% w/w, less than\n",
      "about 0.02% w/w; and/or greater than 0% w/w, at least about\n",
      "0.00000001% w/w, at least about 0.000001 % w/w, or at least\n",
      "about 0.00001% w/w, based upon the total amount of\n",
      "zoledronic acid, a compound containing Ion 1, and a com-\n",
      "pound containing Jon 2 present in the composition.\n",
      "\n",
      "[0117] In some embodiments, a compound containing Ion\n",
      "1 and a compound containing Jon 2 are present in an amount\n",
      "that is less than 0.1% w/w.\n",
      "\n",
      "[0118] In some embodiments, the administration of an\n",
      "osteoclast inhibitor, such as a nitrogen-containing bisphos-\n",
      "phonate, including, e.g. zoledronic acid, minodronic acid,\n",
      "etc., to a patient or mammal in need thereof affects Modic\n",
      "changes (MCs). For example, any of the above compounds\n",
      "could be used to treat Modic changes, or vertebral endplate\n",
      "signal changes (VESC) and bone marrow changes visible\n",
      "using magnetic resonance imaging (MRI), or neck pain or\n",
      "back pain associated with Modic changes.\n",
      "\n",
      "[0119] Modic changes, as used herein, includes its ordi-\n",
      "nary meaning in the art and refers to pathological vertebral\n",
      "endplate and bone marrow changes visible using magnetic\n",
      "resonance imaging (MRI). Modic changes may also beamount per dose may be increased or decreased as treatment\n",
      "progresses. The chosen dose may be administered one or\n",
      "more times per week, monthly, every two months, every\n",
      "three months, every six months, or every year.\n",
      "\n",
      "[0239] In some embodiments, 60 mg of denosumab is\n",
      "administered subcutaneously to patient in need of treatment.\n",
      "In some embodiments, the administration is repeated every\n",
      "six months.\n",
      "\n",
      "[0240] There are a number of ways that some part of\n",
      "Compound 1 and/or Compound 2 may be removed from a\n",
      "zoledronic acid product. For example, HPLC, preparative\n",
      "TLC, crystallization, sublimation, or zone purification may\n",
      "be employed. Solvents that may be useful in HPLC, TLC, or\n",
      "crystallization, may include, but are not limited to, water or\n",
      "organic solvents, such as hexanes, diethyl ether, ethyl\n",
      "acetate, methyl acetate, acetone, acetic acid, acetonitrile,\n",
      "tetrahydrofuran, ethanol, methanol, isopropyl alcohol, chlo-\n",
      "roform, diethyl ether, toluene, dimethylformamide, benzene,\n",
      "etc. Gradients, or two solvent systems may be employed as\n",
      "well. For example, an HPLC separation may begin by\n",
      "elution with water, after some time eluting with water, an\n",
      "organic solvent, such as acetonitrile, methanol, ethanol,\n",
      "ethyl acetate, acetone, acetic acid, methyl acetate, or another\n",
      "solvent could gradually be added to the water, or may\n",
      "replace the water entirely. Similarly, crystallization or\n",
      "recrystallization may employ a single solvent, or a combi-\n",
      "nation of solvents. For example, zoledronic acid or a salt\n",
      "thereof, such as a disodium salt, might be recrystallized from\n",
      "water, ethanol, methanol, diethyl ether, methyl acetate, ace-\n",
      "tic acid, etc., or a combination of these solvents or others. In\n",
      "some embodiments, zoledronic acid or a salt thereof, such as\n",
      "a disodium salt, may be dissolved in one solvent, such as\n",
      "water or acetic acid, and crystallized by a second solvent or\n",
      "solvent system, such as hexane, diethyl ether, chloroform,\n",
      "dichloromethane, ethyl acetate, methyl acetate, acetic acid,\n",
      "ethanol, methanol, or a combination thereof. In some\n",
      "embodiments, a disodium salt of zoledronic acid is dissolved\n",
      "in water, and then crystallized by adding hexane. In some\n",
      "embodiments, a disodium salt of zoledronic acid is dissolved\n",
      "in water, and then crystallized by adding diethyl ether. In\n",
      "some embodiments, a disodium salt of zoledronic acid is\n",
      "dissolved in water, and then crystallized by adding chloro-\n",
      "form. In some embodiments, a disodium salt of zoledronic\n",
      "acid is dissolved in water, and then crystallized by adding\n",
      "dichloromethane. In some embodiments, a disodium salt of\n",
      "zoledronic acid is dissolved in water, and then crystallized\n",
      "by adding ethyl acetate. In some embodiments, a disodium\n",
      "salt of zoledronic acid is dissolved in water, and then\n",
      "crystallized by adding methyl acetate. In some embodi-\n",
      "ments, a disodium salt of zoledronic acid is dissolved in\n",
      "water, and then crystallized by adding acetic acid. In some\n",
      "embodiments, a disodium salt of zoledronic acid is dissolved\n",
      "in water, and then crystallized by adding ethanol. In some\n",
      "embodiments, a disodium salt of zoledronic acid is dissolved\n",
      "in water, and then crystallized by adding methanol. For\n",
      "embodiments employing water and a second solvent, the\n",
      "ratio of water to the second solvent (water:second solvent)\n",
      "may be about 1:100 to about 100:1, about 1:10 to about 1:5,\n",
      "about 1:5 to about 1:4, about 1:4 to about 1:3, about 1:3 to\n",
      "about 1:2, about 1:2 to about 1:1, about 1:1 to about 2:1,\n",
      "about 2:1 to about 3:1, about 3:1 to about 4:1, about 4:1 to\n",
      "about 5:1, or about 1:1 to about 10:1.\n",
      "\n",
      "[0241] Insome embodiments, a combination of two meth-\n",
      "ods recited in the paragraph above may be employed, such\n",
      "\n",
      "as HPLC or TLC and crystallization. In some embodiments,\n",
      "a method may be repeated, such as HPLC, preparative TLC,\n",
      "crystallization, sublimation, or zone purification. In some\n",
      "embodiments, a purification method recited in the paragraph\n",
      "above may be performed twice. In some embodiments, a\n",
      "purification method recited in the paragraph above may be\n",
      "performed three or four times.\n",
      "\n",
      "[0242] Some oral dosage forms comprising zoledronic\n",
      "acid or a salt thereof may have enteric coatings or film\n",
      "coatings.\n",
      "\n",
      "[0243] Inthe examples below, zoledronic acid was admin-\n",
      "istered in the disodium salt form as disodium zoledronate\n",
      "tetrahydrate. No bioavailability enhancing agents were used\n",
      "in the test compositions.\n",
      "\n",
      "Example 1\n",
      "\n",
      "Effect of Orally Administered Zoledronic Acid in Rat Model\n",
      "of Inflammatory Pain\n",
      "\n",
      "Method:\n",
      "\n",
      "[0244] The effect of orally administered zoledronic acid\n",
      "on inflammatory pain was examined using the rat complete\n",
      "Freunds adjuvant (CFA) model. Inflammatory pain was\n",
      "induced by injection of 100% CFA in a 75 uL volume into\n",
      "the left hind paws of Sprague-Dawley rats on day 0,\n",
      "followed by assessments on days 1-3. Animals were orally\n",
      "administered vehicle (control), zoledronic acid 18 mg/m? (or\n",
      "3 mg/kg), zoledronic acid 120 mg/m? (or 20 mg/kg), or\n",
      "zoledronic acid 900 mg/m* (or 150 mg/kg) daily on days\n",
      "1-3. Drug was dissolved in distilled water and prepared fresh\n",
      "daily. Animals were fasted prior to dosing. Under current\n",
      "FDA guidelines for extrapolating starting dosages from\n",
      "animals to humans, dosages expressed in mg/m? are con-\n",
      "sidered equivalent between mammalian species. Thus, for\n",
      "example, 18 mg/m? in a rat is considered equivalent to 18\n",
      "mg/m in a human being, while 3 mg/kg in a rat may not be\n",
      "equivalent to 3 mg/kg in a human being.\n",
      "\n",
      "[0245] Values for inflammatory pain (mechanical hyper-\n",
      "algesia) in the vehicle and drug-treated animals were\n",
      "obtained on day 0 prior to CFA injection, and at baseline and\n",
      "post-treatment on days 1-3. Pain was assessed using a digital\n",
      "Randall-Selitto device (dRS; IITC Life Sciences, Woodland\n",
      "Hills, Calif.). Animals were placed in a restraint sling that\n",
      "suspended the animal, leaving the hind limbs available for\n",
      "testing. Paw compression threshold was measured by apply-\n",
      "ing increasing pressure to the plantar surface of the hind paw\n",
      "with a dome-shaped tip placed between the 3rd and 4th\n",
      "metatarsus. Pressure was applied gradually over approxi-\n",
      "mately 10 seconds. Measurements were taken from the first\n",
      "observed nocifensive behavior of vocalization, struggle or\n",
      "withdrawal. A cut-off value of 300 g was used to prevent\n",
      "injury to the animal.\n",
      "\n",
      "[0246] Reversal of inflammatory pain was calculated\n",
      "according to the formula:\n",
      "\n",
      "% reversal=(Post-treatment-Post-CFA baseline)/(Pre-\n",
      "CFA baselinePost-CFA baseline)x100.\n",
      "\n",
      "[0247] The experiment was carried out using 9-10 animals\n",
      "per group.\n",
      "Results:\n",
      "\n",
      "[0248] Oral administration of zoledronic acid significantly\n",
      "improved inflammatory pain thresholds compared toEmbodiment 413\n",
      "\n",
      "[0742] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 80%.\n",
      "\n",
      "Embodiment 414\n",
      "\n",
      "[0743] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 85%.\n",
      "\n",
      "Embodiment 415\n",
      "\n",
      "[0744] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by about 80%-85%.\n",
      "\n",
      "Embodiment 416\n",
      "\n",
      "[0745] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 90%.\n",
      "\n",
      "Embodiment 417\n",
      "\n",
      "[0746] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by about 80%-90%.\n",
      "\n",
      "Embodiment 418\n",
      "\n",
      "[0747] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by about 85%-90%.\n",
      "\n",
      "Embodiment 419\n",
      "\n",
      "[0748] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by about 85%-95%.\n",
      "\n",
      "Embodiment 420\n",
      "\n",
      "[0749] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by about 90%-95%.\n",
      "\n",
      "Embodiment 421\n",
      "\n",
      "[0750] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 95%.\n",
      "\n",
      "Embodiment 422\n",
      "\n",
      "[0751] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 99%.\n",
      "\n",
      "Embodiment 423\n",
      "\n",
      "[0752] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases CTX\n",
      "serum levels by at least about 100%.\n",
      "\n",
      "Embodiment 424\n",
      "\n",
      "[0753] The method, dosage form, or product, of any\n",
      "preceding embodiment, wherein the zoledronic acid 1s orally\n",
      "administered in a manner that results in a 24 hour sustained\n",
      "plasma level factor that is at least 1.5 times that of 4 mg of\n",
      "zoledronic acid administered intravenously.\n",
      "\n",
      "[0754] Unless otherwise indicated, all numbers expressing\n",
      "quantities of ingredients, properties such as molecular\n",
      "weight, reaction conditions, and so forth used in the speci-\n",
      "fication and claims are to be understood in all instances as\n",
      "indicating both the exact values as shown and as being\n",
      "modified by the term about. Accordingly, unless indicated\n",
      "to the contrary, the numerical parameters set forth in the\n",
      "specification and attached claims are approximations that\n",
      "may vary depending upon the desired properties sought to be\n",
      "obtained. At the very least, and not as an attempt to limit the\n",
      "application of the doctrine of equivalents to the scope of the\n",
      "claims, each numerical parameter should at least be con-\n",
      "strued in light of the number of reported significant digits\n",
      "and by applying ordinary rounding techniques.\n",
      "\n",
      "[0755] The terms a, an, the and similar referents\n",
      "used 1n the context of describing the invention (especially in\n",
      "the context of the following claims) are to be construed to\n",
      "cover both the singular and the plural, unless otherwise\n",
      "indicated herein or clearly contradicted by context. All\n",
      "methods described herein can be performed in any suitable\n",
      "order unless otherwise indicated herein or otherwise clearly\n",
      "contradicted by context. The use of any and all examples, or\n",
      "exemplary language (e.g., such as) provided herein is\n",
      "intended merely to better illuminate the invention and does\n",
      "not pose a limitation on the scope of any claim. No language\n",
      "in the specification should be construed as indicating any\n",
      "non-claimed element essential to the practice of the inven-\n",
      "tion.\n",
      "\n",
      "[0756] Groupings of alternative elements or embodiments\n",
      "disclosed herein are not to be construed as limitations. Each\n",
      "group member may be referred to and claimed individually\n",
      "or in any combination with other members of the group or\n",
      "other elements found herein. It is anticipated that one or\n",
      "more members of a group may be included in, or deleted\n",
      "from, a group for reasons of convenience and/or patentabil-\n",
      "ity. When any such inclusion or deletion occurs, the speci-\n",
      "fication is deemed to contain the group as modified thus\n",
      "fulfilling the written description of all Markush groups used\n",
      "in the appended claims.\n",
      "\n",
      "[0757] Certain embodiments are described herein, includ-\n",
      "ing the best mode known to the inventors for carrying out the\n",
      "invention. Of course, variations on these described embodi-\n",
      "ments will become apparent to those of ordinary skill in the\n",
      "art upon reading the foregoing description. The inventor\n",
      "expects skilled artisans to employ such variations as appro-\n",
      "priate, and the inventors intend for the invention to be\n",
      "practiced otherwise than specifically described herein.\n",
      "Accordingly, the claims include all modifications and\n",
      "equivalents of the subject matter recited in the claims as\n",
      "permitted by applicable law. Moreover, any combination of\n",
      "the above-described elements in all possible variationso'a'e'e eee -\n",
      "\n",
      "nie lelelele\\e\\e\\e'e|e'e'e'e ee\\e\\|e\\0/a\\e/0a\\e [aaa ele eennnnnnnnne\n",
      "\n",
      " \n",
      "\n",
      "rr i i in i it 0 ie I INN NNN NNN\n",
      "\n",
      "100 : sseeccoceee fil\n",
      "\n",
      "w=iS Vehicle\n",
      "\n",
      "sepow Zoladranic Acid\n",
      "\n",
      " \n",
      "\n",
      "Weight Bearing (5)\n",
      "\n",
      "6a 4\n",
      "\n",
      " \n",
      "\n",
      "Time after Fracture\n",
      "\n",
      "FIG. 15about 45%, at least about 50%, at least about 55%, at least\n",
      "about 60%, at least about 70%, at least about 75%, at least\n",
      "about 80%, at least about 85%, at least about 90%, at least\n",
      "about 95%, at least about 99%, at least about 100%, about\n",
      "60%-70%, about 70%-80%, about 80%-90%, about\n",
      "85-95%, about 80%-85%, about 85%-90%, about 90%-\n",
      "95%, or any other reduction in osteoclast activity or CTX\n",
      "serum levels in a range bounded by, or between, any of these\n",
      "values.\n",
      "\n",
      "[0164] In some embodiments, zoledronic acid in a diso-\n",
      "dium salt or an acid form and other bisphosphonates includ-\n",
      "ing salt or acid form may be used to treat Pagets disease of\n",
      "Bone or treat pain associated with Pagets disease of bone\n",
      "and/or lower serum alkaline phosphatase (ALP) levels. For\n",
      "example, the reduction of ALP levels by at least about 20%,\n",
      "at least about 40%, at least about 50%, at least about 60%,\n",
      "at least about 80%, about 50-60%, about 60-80%, about\n",
      "80-90%, about 90-95%, or any other reduction in ALP levels\n",
      "in a range bounded by, or between, any of these values from\n",
      "baseline, within 12 months, 18 months, or up to at least 5\n",
      "years from the time of the last oral administration of\n",
      "zoledronic acid or other bisphosphonates. In some embodi-\n",
      "ments, when zoledronic acid in a disodium salt or an acid\n",
      "form, or other bisphosphonate is administered to treat the\n",
      "Pagets disease of bone or pain associated with the Pagets\n",
      "disease of bone, the Pagets disease or the pain associated\n",
      "with the Pagets disease has recurrence rate of less than\n",
      "20%, less than 10%, less than 5%, less than 1%, or does not\n",
      "return within 12 months, 18 months, or 5 years, or more,\n",
      "from the time of the last oral administration of zoledronic\n",
      "acid, or other bisphosphonates.\n",
      "\n",
      "[0165] In some embodiments, a dosage form comprising a\n",
      "disodium salt of zoledronic acid is a solid.\n",
      "\n",
      "[0166] In some embodiments, a dosage form comprising a\n",
      "disodium salt of zoledronic acid is used to treat an inflam-\n",
      "matory condition.\n",
      "\n",
      "[0167] Insome embodiments, a dosage form comprising a\n",
      "disodium salt of zoledronic acid is used to treat arthritis.\n",
      "[0168] In some embodiments, a dosage form comprising a\n",
      "disodium salt of zoledronic acid is used to treat complex\n",
      "regional pain syndrome.\n",
      "\n",
      "[0169] Insome embodiments, zoledronic acid is in a form\n",
      "that has an aqueous solubility, meaning the solubility in\n",
      "water, greater than 1% (w/v), about 5% (w/v) to about 50%\n",
      "(w/v), about 5% (w/v) to about 20% (w/v), about 10% (w/v)\n",
      "to about 15% (w/v), or about 12% (w/v) to about 13% (w/v).\n",
      "[0170] The disodium salt form of zoledronic acid can be\n",
      "more compressible than the diacid form of zoledronic acid.\n",
      "This can make it easier for a dosage form to have a desired\n",
      "hardness. It can also make it easier to increase the drug load,\n",
      "so that a smaller tablet can be given for a given dosage\n",
      "strength. In some embodiments, a solid dosage form of\n",
      "zoledronic acid, such as the diacid form of zoledronic acid\n",
      "or the disodium salt form of zoledronic acid, can have a\n",
      "hardness of about 5 kPa to about 20 kPa or about 5 kPa to\n",
      "about 14 kPa.\n",
      "\n",
      "[0171] Zoledronic acid or another bisphosphonate may be\n",
      "combined with a pharmaceutical carrier selected on the basis\n",
      "of the chosen route of administration and standard pharma-\n",
      "ceutical practice as described, for example, in Remingtons\n",
      "Pharmaceutical Sciences, 2005, the disclosure of which is\n",
      "hereby incorporated herein by reference, in its entirety. The\n",
      "relative proportions of active ingredient and carrier may be\n",
      "determined, for example, by the solubility and chemical\n",
      "\n",
      "nature of the compounds, chosen route of administration and\n",
      "standard pharmaceutical practice.\n",
      "\n",
      "[0172] Zoledronic acid or another bisphosphonate may be\n",
      "administered by any means that may result in the contact of\n",
      "the active agent(s) with the desired site or site(s) of action in\n",
      "the body of a patient. The compounds may be administered\n",
      "by any conventional means available for use in conjunction\n",
      "with pharmaceuticals, either as individual therapeutic agents\n",
      "or in a combination of therapeutic agents. For example, they\n",
      "may be administered as the sole active agents in a pharma-\n",
      "ceutical composition, or they can be used in combination\n",
      "with other therapeutically active ingredients.\n",
      "\n",
      "[0173] In some embodiments, an osteoclast inhibitor is\n",
      "co-administered with a steroid. Suitable steroids include, for\n",
      "example, hydrocortisone, hydrocortisone acetate, cortisone\n",
      "acetate, tixocortol pivalate, prednisolone, methylpredniso-\n",
      "lone, prednisone, triamcinolone acetonide, triamcinolone\n",
      "alcohol, mometasone, amcinonide, budesonide, desonide,\n",
      "fluocinonide, fluocinolone acetonide, halcinonide, betame-\n",
      "thasone, betamethasone sodium phosphate, dexamethasone,\n",
      "dexamethasone sodium phosphate, fluocortolone, hydrocor-\n",
      "tisone-17-valerate, acleometasone dipropionate, betametha-\n",
      "sone valerate, betamethasone dippropionate, prednicarbate,\n",
      "clobetasone-17-butyrate, clobetasol-17-propionate,  fluo-\n",
      "cortilone caproate, fluocortolone pivalate, and fluprednidene\n",
      "acetate, hydrocortisone-17-butyrate, 17-aceponate, 17-bute-\n",
      "prate, and prednicarbate.\n",
      "\n",
      "[0174] Any effective dose of steroid can be administered\n",
      "to a person. In some embodiment, the dose of a steroid may\n",
      "be about 1-500 mg, 5-25 mg, about 1-3 mg, about 2-4 mg,\n",
      "about 3-5 mg, about 4-6 mg, about 5-7 mg, about 6-8 mg,\n",
      "about 7-9 mg, about 8-10 mg, about 10-15 mg, about 10-20\n",
      "mg, about 20-50 mg, about 50-100 mg, about 100-200 mg,\n",
      "about 200-300 mg, about 300-400 mg, 400-500 mg 1-20 mg,\n",
      "about 10-30 mg, about 20-40 mg, about 30-50 mg, about\n",
      "40-60 mg, about 50-70 mg, about 60-80 mg, about 70-90\n",
      "mg, about 80-100 mg, about 90-110 mg, about 100-120 mg,\n",
      "\n",
      "about 110-130 mg,\n",
      "about 140-160 mg,\n",
      "about 170-190 mg,\n",
      "about 200-220 mg,\n",
      "about 230-250 mg,\n",
      "about 260-280 mg,\n",
      "about 290-310 mg,\n",
      "about 320-340 mg,\n",
      "about 350-370 mg,\n",
      "about 380-300 mg,\n",
      "about 410-430 mg,\n",
      "about 440-460 mg,\n",
      "\n",
      "about 120-140 mg,\n",
      "about 150-170 mg,\n",
      "about 180-200 mg,\n",
      "about 210-230 mg,\n",
      "about 240-260 mg,\n",
      "about 270-290 mg,\n",
      "about 300-320 mg,\n",
      "about 330-350 mg,\n",
      "about 360-380 mg,\n",
      "about 390-410 mg,\n",
      "about 420-440 mg,\n",
      "about 450-470 mg,\n",
      "\n",
      "about 130-150 mg,\n",
      "about 160-180 mg,\n",
      "about 190-210 mg,\n",
      "about 220-240 mg,\n",
      "about 250-270 mg,\n",
      "about 280-300 mg,\n",
      "about 310-330 mg,\n",
      "about 340-360 mg,\n",
      "about 370-390 mg,\n",
      "about 400-420 mg,\n",
      "about 430-450 mg,\n",
      "about 460-480 mg,\n",
      "\n",
      "about 470-490 mg, about 480-300 mg, about 490-510 mg of\n",
      "the steroid, or any amount in a range bounded by any of\n",
      "these values.\n",
      "\n",
      "[0175] The steroid can be given orally (for example, 7.5\n",
      "mg of prednisone), by a separate infusion (for example, 7.5\n",
      "mg of methyl! prednisolone), mixed in with zoledronic acid\n",
      "in the same infusion, or be administered intramuscularly,\n",
      "subcutaneously, by rectal suppository, by inhalation, or\n",
      "injected directly into a joint.\n",
      "\n",
      "[0176] Zoledronic acid or another bisphosphonate may be\n",
      "administered to a human patient in a variety of forms\n",
      "adapted to the chosen route of administration, e.g., orally,\n",
      "rectally, or parenterally. Parenteral administration in this\n",
      "respect includes, but is not limited to, administration by the\n",
      "following routes: pulmonary, intrathecal, intravenous, intra-that is combined with the excipient is such that the oral\n",
      "dosage form comprises more than about 10% zoledronic\n",
      "acid by weight.\n",
      "\n",
      "Embodiment 270\n",
      "\n",
      "[0592] The method of any preceding embodiment, such as\n",
      "embodiment 268 or 269, wherein the amount of zoledronic\n",
      "acid that is combined with the excipient is such that zole-\n",
      "dronic acid is present in the oral dosage form in an amount\n",
      "that is 0.4 mg/kg to about 3 mg/kg based upon the weight of\n",
      "the mammal.\n",
      "\n",
      "Embodiment 271\n",
      "\n",
      "[0593] The method of any preceding embodiment, such as\n",
      "embodiment 270, wherein the amount of zoledronic acid\n",
      "that is combined with the excipient is such that zoledronic\n",
      "acid is present in the oral dosage form in an amount that is\n",
      "0.4 mg/kg to about 1.5 mg/kg based upon the weight of the\n",
      "mammal.\n",
      "\n",
      "Embodiment 272\n",
      "\n",
      "[0594] The method of any preceding embodiment, such as\n",
      "embodiment 270, wherein the amount of zoledronic acid\n",
      "that is combined with the excipient is such that zoledronic\n",
      "acid is present in the oral dosage form in an amount that is\n",
      "0.6 mg/kg to about 0.9 mg/kg based upon the weight of the\n",
      "mammal.\n",
      "\n",
      "Embodiment 273\n",
      "\n",
      "[0595] The method of any preceding embodiment, such as\n",
      "embodiment 268, 269, 270, 271, or 272, wherein the oral\n",
      "dosage form is safe for once daily administration of the oral\n",
      "dosage form for about 3 to about 10 days.\n",
      "\n",
      "Embodiment 274\n",
      "\n",
      "[0596] The method of any preceding embodiment, such as\n",
      "embodiment 268, 269, 270, 271, or 272, wherein the oral\n",
      "dosage form is safe for once weekly administration of the\n",
      "oral dosage form for about 3 to about 10 weeks.\n",
      "\n",
      "Embodiment 275\n",
      "\n",
      "[0597] A method of safely delivering zoledronic acid to\n",
      "the blood of a mammal through repeated oral administration\n",
      "comprising:\n",
      "[0598] orally administering about 0.05 mg/kg to about\n",
      "4 mg/kg of zoledronic acid to the mammal no more\n",
      "frequently than once a day and more frequently than\n",
      "once a week; or\n",
      "[0599] orally administering about 0.1 mg/kg to about 10\n",
      "mg/kg to the mammal once a week, or less frequently\n",
      "[0600] wherein zoledronic acid is orally administered at\n",
      "least 5 times.\n",
      "\n",
      "Embodiment 276\n",
      "\n",
      "[0601] The method of any preceding embodiment, such as\n",
      "embodiment 275, wherein zoledronic acid is orally admin-\n",
      "istered about 5 to about 10 times.\n",
      "\n",
      "Embodiment 277\n",
      "\n",
      "[0602] The method of any preceding embodiment, such as\n",
      "embodiment 275 or 276, wherein zoledronic acid is orally\n",
      "\n",
      "administered in a dosage form comprising more than about\n",
      "10% zoledronic acid by weight.\n",
      "\n",
      "Embodiment 278\n",
      "\n",
      "[0603] The method of any preceding embodiment, such as\n",
      "embodiment 259, 260, 261, 262, 263, 264, 265, 266, 267,\n",
      "268, 269, 270, 271, 272, 273, 274, 275, 276, or 277, wherein\n",
      "the mammal is a human being.\n",
      "\n",
      "Embodiment 279\n",
      "\n",
      "[0604] The method of any preceding embodiment, such as\n",
      "embodiment 259, 260, 261, 262, 263, 264, 265, 266, 267,\n",
      "268, 269, 270, 271, 272, 273, 274, 275, 276, 277, or 278,\n",
      "wherein about 50 mg to about 350 mg of oral zoledronic acid\n",
      "is administered to the mammal per month.\n",
      "\n",
      "Embodiment 280\n",
      "\n",
      "[0605] An oral dosage form prepared by the method of any\n",
      "preceding embodiment, such as embodiment 259, 260, 261,\n",
      "262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273,\n",
      "274, 275, 276, 277, 278, or 279.\n",
      "\n",
      "Embodiment 281\n",
      "\n",
      "[0606] An oral dosage form prepared by the method of any\n",
      "preceding embodiment, wherein an osteoclast inhibitor,\n",
      "including a bisphosphonate, such as zoledronic acid,\n",
      "neridronic acid, etc., is in a dosage form containing one of,\n",
      "or a combination of, the ingredients in the Table E.\n",
      "\n",
      "Embodiment 282\n",
      "\n",
      "[0607] A molecular complex comprising zoledronic acid\n",
      "or neridronic acid in an acid or a salt form.\n",
      "\n",
      "Embodiment 283\n",
      "\n",
      "[0608] The molecular complex of Embodiment 282, fur-\n",
      "ther comprising a basic or a salt form of a) an amine, b) an\n",
      "amide, or c) ammonium.\n",
      "\n",
      "Embodiment 284\n",
      "\n",
      "[0609] The molecular complex of Embodiment 283,\n",
      "wherein the molecular complex comprises ammonia in a salt\n",
      "form.\n",
      "\n",
      "Embodiment 285\n",
      "\n",
      "[0610] The molecular complex of Embodiment 283,\n",
      "wherein the amine is an amino acid.\n",
      "\n",
      "Embodiment 286\n",
      "\n",
      "[0611] The molecular complex of Embodiment 285,\n",
      "wherein the amino acid is a lysine.\n",
      "\n",
      "Embodiment 287\n",
      "\n",
      "[0612] The molecular complex of Embodiment 285,\n",
      "wherein the amino acid is L-lysine.\n",
      "\n",
      "Embodiment 288\n",
      "\n",
      "[0613] The molecular complex of Embodiment 285,\n",
      "wherein the amino acid is D-lysine.(54)\n",
      "\n",
      "(71)\n",
      "\n",
      "(72)\n",
      "\n",
      "(21)\n",
      "(22)\n",
      "\n",
      "(63)\n",
      "\n",
      "(60)\n",
      "\n",
      "DOSAGE FORMS FOR ORAL\n",
      "ADMINISTRATION OF ZOLEDRONIC ACID\n",
      "OR RELATED COMPOUNDS FOR\n",
      "TREATING DISEASE\n",
      "\n",
      "Applicant: ANTECIP BIOVENTURES IT LLC,\n",
      "New York, NY (US)\n",
      "\n",
      "Inventor: Herriot Tabuteau, New York, NY (US)\n",
      "Appl. No.: 16/144,916\n",
      "Filed: Sep. 27, 2018\n",
      "\n",
      "Related U.S. Application Data\n",
      "\n",
      "Continuation-in-part of application No. 15/432,777,\n",
      "filed on Feb. 14, 2017, now Pat. No. 10,111,837,\n",
      "which is a continuation-in-part of application No.\n",
      "15/136,092, filed on Apr. 22, 2016, now Pat. No.\n",
      "9,616,078, which is a continuation-in-part of appli-\n",
      "cation No. 15/043,281, filed on Feb. 12, 2016, now\n",
      "Pat. No. 9,517,242, which is a continuation of appli-\n",
      "cation No. 14/279,196, filed on May 15, 2014, now\n",
      "Pat. No. 9,301,964, which is a continuation of appli-\n",
      "cation No. 14/063,979, filed on Oct. 25, 2013, now\n",
      "Pat. No. 8,802,658, which is a continuation-in-part of\n",
      "application No. 13/894,274, filed on May 14, 2013,\n",
      "now abandoned, said application No. 15/432,777 is a\n",
      "continuation-in-part of application No. 15/352,461,\n",
      "filed on Nov. 15, 2016, now abandoned, which is a\n",
      "continuation-in-part of application No. PCT/US2015/\n",
      "032739, filed on May 27, 2015, which is a continu-\n",
      "ation of application No. PCT/US2014/050427, filed\n",
      "on Aug. 8, 2014, which is a continuation of applica-\n",
      "tion No. 14/279,241, filed on May 15, 2014, now\n",
      "abandoned.\n",
      "\n",
      "Provisional application No. 61/646,538, filed on May\n",
      "14, 2012, provisional application No. 61/647,478,\n",
      "\n",
      "filed on May 15, 2012, provisional application No.\n",
      "61/654,292, filed on Jun. 1, 2012, provisional appli-\n",
      "cation No. 61/654,383, filed on Jun. 1, 2012, provi-\n",
      "sional application No. 61/655,527, filed on Jun. 5,\n",
      "2012, provisional application No. 61/655,541, filed\n",
      "on Jun. 5, 2012, provisional application No. 61/764,\n",
      "563, filed on Feb. 14, 2013, provisional application\n",
      "No. 61/762,225, filed on Feb. 7, 2013, provisional\n",
      "application No. 61/767,647, filed on Feb. 21, 2013,\n",
      "provisional application No. 61/767,676, filed on Feb.\n",
      "21, 2013, provisional application No. 61/803,721,\n",
      "filed on Mar. 20, 2013, provisional application No.\n",
      "62/150,871, filed on Apr. 22, 2015.\n",
      "\n",
      "Publication Classification\n",
      "\n",
      "(51) Int. CL.\n",
      "AIK 31/675 (2006.01)\n",
      "AG6IK 9/00 (2006.01)\n",
      "AGIK 9/20 (2006.01)\n",
      "AGIK 47/12 (2006.01)\n",
      "AGIK 45/06 (2006.01)\n",
      "AGIK 9/28 (2006.01)\n",
      "AGIK 31/663 (2006.01)\n",
      "(52) U.S. CL.\n",
      "CPC vee A6IK 31/675 (2013.01); A61K 9/0053\n",
      "\n",
      "(2013.01); A61K 9/2054 (2013.01); A6IK\n",
      "9/2027 (2013.01); A6IK 9/2013 (2013.01):\n",
      "A61K 9/2009 (2013.01); A61K 9/2004\n",
      "(2013.01); A6IK 47/12 (2013.01); A61K 9/20\n",
      "(2013.01); A61K 45/06 (2013.01); A61K 9/28\n",
      "(2013.01); A61K 31/663 (2013.01)\n",
      "\n",
      "(57) ABSTRACT\n",
      "\n",
      "Oral dosage forms of osteoclast inhibitors, such as zole-\n",
      "dronic acid, in an acid or a salt form can be used to treat or\n",
      "alleviate pain or related conditions, such as arthritis.TABLE E-continued\n",
      "\n",
      "Mustard or Oil of Mustard (Brown and Yellow)\n",
      "Glveyrrhiza\n",
      "\n",
      "Ammoniated Glycyrrhizin\n",
      "Licorice\n",
      "\n",
      "Caprylic Acid\n",
      "\n",
      "Stannous Chloride\n",
      "\n",
      "Ammonium bicarbonate\n",
      "Ammonium carbonate\n",
      "Ammonium chloride\n",
      "Ammonium hydroxide\n",
      "Ammonium phosphate, such as ammonium phosphate dibasic or\n",
      "Ammonium phosphate monobasic\n",
      "Ammonium sulfate\n",
      "\n",
      "Calcium iodate\n",
      "\n",
      "Potassium iodate\n",
      "\n",
      "Potassium iodide\n",
      "\n",
      "Aconitic Acid\n",
      "\n",
      "Calcium carbonate\n",
      "\n",
      "Potassium bicarbonate\n",
      "\n",
      "Sodium bicarbonate\n",
      "\n",
      "Sodium carbonate\n",
      "\n",
      "Sodium sesquicarbonate\n",
      "Glycerin and Glycerides\n",
      "Dextran\n",
      "\n",
      "Dextrins\n",
      "\n",
      "Corn dextrins\n",
      "\n",
      "Calcium acetate\n",
      "\n",
      "Calcium chloride\n",
      "\n",
      "Calcium gluconate\n",
      "\n",
      "Calcium phytate\n",
      "\n",
      "Calcium hydroxide\n",
      "\n",
      "Calcium oxide\n",
      "\n",
      "Succinic acid\n",
      "\n",
      "Butylated Hydroxytoluene (BHT)\n",
      "Calcium hexametaphosphate\n",
      "Calcium phosphate dibasic\n",
      "Calcium phosphate monobasic\n",
      "Calcium phosphate tribasic\n",
      "Calcium pyrophosphate\n",
      "Phosphoric acid\n",
      "\n",
      "Potassium phosphate dibasic\n",
      "Potassium phosphate monobasic\n",
      "Potassium phosphate tribasic\n",
      "Potassium polymetaphosphate\n",
      "Potassium pyrophosphate\n",
      "Potassium tripolyphosphate\n",
      "Sodium acid pyrophosphate\n",
      "Sodium hexametaphosphate\n",
      "Sodium metaphosphate\n",
      "\n",
      "Sodium phosphate dibasic\n",
      "Sodium phosphate monobasic\n",
      "Sodium phosphate tribasic\n",
      "Sodium pyrophosphate, tetrabasic\n",
      "Sodium tetrametaphosphate\n",
      "Sodium tetraphosphate\n",
      "\n",
      "Sodium trimetaphosphate\n",
      "Sodium tripolyphosphate\n",
      "Sulfuric Acid\n",
      "\n",
      "alpha-Tocopherol acetate\n",
      "Tocopherols\n",
      "\n",
      "Choline Bitartrate\n",
      "\n",
      "Choline Chloride\n",
      "\n",
      "Aluminum ammonium sulfate\n",
      "Aluminum hydroxide\n",
      "Aluminum oleate\n",
      "\n",
      "Aluminum palmitate\n",
      "\n",
      "Aluminum potassium sulfate\n",
      "Aluminum sodium sulfate\n",
      "Aluminum sulfate\n",
      "\n",
      "Sodium aluminate\n",
      "\n",
      "Sodium aluminum phosphate, acidic\n",
      "Sodium aluminum phosphate, basic\n",
      "Sodium phosphoaluminate\n",
      "Beeswax (yellow or white)\n",
      "Japan wax\n",
      "\n",
      "Carnauba wax\n",
      "\n",
      "Corn Sugar (Dextrose)\n",
      "\n",
      "TABLE E-continued\n",
      "\n",
      "Corn Syrup\n",
      "\n",
      "Invert Sugar\n",
      "\n",
      "Inositol\n",
      "\n",
      "Calcium stearate\n",
      "Hydrogenated tallow\n",
      "Stearic acid\n",
      "\n",
      "Tallow\n",
      "\n",
      "Malic acid\n",
      "\n",
      "L-Malic acid\n",
      "\n",
      "Calcium sorbate\n",
      "Potassium sorbate\n",
      "Sodium sorbate\n",
      "\n",
      "Sorbic acid\n",
      "\n",
      "Sulfamic acid\n",
      "\n",
      "Sodium hydrosulfite\n",
      "\n",
      "Zinc hydrosulfite\n",
      "\n",
      "Tall oil\n",
      "\n",
      "Fish oil, hydrogenated\n",
      "Sucrose\n",
      "\n",
      "Agar-agar\n",
      "\n",
      "Ammonium alginate\n",
      "Calcium alginate\n",
      "Potassium alginate\n",
      "Propylene glycol alginate\n",
      "Sodium alginate\n",
      "Propylene Glycol\n",
      "Propylene glycol monostearate\n",
      "Brown algae\n",
      "\n",
      "Red algae\n",
      "\n",
      "Calcium glycerophosphate\n",
      "Manganese glycerophosphate\n",
      "Magnesium glycerophosphate\n",
      "Potassium glycerophosphate\n",
      "Potassium hydroxide\n",
      "Sodium hydroxide\n",
      "Potassium metabisulfite\n",
      "Sodium bisulfite\n",
      "\n",
      "Sodium metabisulfite\n",
      "Sodium sulfite\n",
      "\n",
      "Sulfur dioxide\n",
      "Magnesium phosphate, dibasic\n",
      "Magnesium carbonate\n",
      "Magnesium chloride\n",
      "Magnesium hydroxide\n",
      "Magnesium oxide\n",
      "Magnesium stearate\n",
      "Magnesium sulfate\n",
      "Magnesium phosphate, tribasic\n",
      "Adipic acid\n",
      "\n",
      "Hydrogenated soybean oil\n",
      "Ethyl formate\n",
      "\n",
      "Formic acid\n",
      "\n",
      "Sodium formate\n",
      "Carrageenan\n",
      "\n",
      "Nutmeg and Mace\n",
      "\n",
      "Zinc acetate\n",
      "\n",
      "Zinc carbonate\n",
      "\n",
      "Zine chloride\n",
      "\n",
      "Zinc oxide\n",
      "\n",
      "Zinc sulfate\n",
      "\n",
      "Caramel\n",
      "\n",
      "Lard\n",
      "\n",
      "Lard oil\n",
      "\n",
      "Papain\n",
      "\n",
      "Gum guaiac\n",
      "\n",
      "Coconut oil\n",
      "\n",
      "Linoleic acid\n",
      "\n",
      "Oleic acid\n",
      "\n",
      "Peanut oil\n",
      "\n",
      "Calcium hypophosphite\n",
      "Manganous hypophosphite\n",
      "Potassium hypophosphite\n",
      "Sodium hypophosphite\n",
      "Pectin, amidated\n",
      "\n",
      "Pectin, high ester\n",
      "\n",
      "Pectin, low acid\n",
      "PectinatesEmbodiment 373\n",
      "\n",
      "[0702] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 20%.\n",
      "\n",
      "Embodiment 374\n",
      "\n",
      "[0703] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 25%.\n",
      "\n",
      "Embodiment 375\n",
      "\n",
      "[0704] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 30%.\n",
      "\n",
      "Embodiment 376\n",
      "\n",
      "[0705] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 35%.\n",
      "\n",
      "Embodiment 377\n",
      "\n",
      "[0706] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 40%.\n",
      "\n",
      "Embodiment 378\n",
      "\n",
      "[0707] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 45%.\n",
      "\n",
      "Embodiment 379\n",
      "\n",
      "[0708] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 50%.\n",
      "\n",
      "Embodiment 380\n",
      "\n",
      "[0709] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 55%.\n",
      "\n",
      "Embodiment 381\n",
      "\n",
      "[0710] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 60%.\n",
      "\n",
      "Embodiment 382\n",
      "\n",
      "[0711] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at about 60%-70%.\n",
      "\n",
      "Embodiment 383\n",
      "\n",
      "[0712] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by about 70%-80%.\n",
      "\n",
      "Embodiment 384\n",
      "\n",
      "[0713] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 70%.\n",
      "\n",
      "Embodiment 385\n",
      "\n",
      "[0714] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at about 75%.\n",
      "\n",
      "Embodiment 386\n",
      "\n",
      "[0715] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by about 80%-90%.\n",
      "\n",
      "Embodiment 387\n",
      "\n",
      "[0716] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 80%.\n",
      "\n",
      "Embodiment 388\n",
      "\n",
      "[0717] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 85%.\n",
      "\n",
      "Embodiment 389\n",
      "\n",
      "[0718] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by about 80%-85%.\n",
      "\n",
      "Embodiment 390\n",
      "\n",
      "[0719] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by at least about 90%.\n",
      "\n",
      "Embodiment 391\n",
      "\n",
      "[0720] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by about 85%-90%.\n",
      "\n",
      "Embodiment 392\n",
      "\n",
      "[0721] The method, composition, molecular complex,\n",
      "dosage form, or product, of any preceding embodiment,\n",
      "wherein zoledronic acid or neridronic acid decreases osteo-\n",
      "clast activity by about 85%-95%.Embodiment 124\n",
      "\n",
      "[0433] The method of embodiment 123, wherein the zole-\n",
      "dronic acid in the disodium salt form is administered at an\n",
      "interval of about 3 to about 4 weeks in an amount that\n",
      "provides an area under the plasma concentration curve of\n",
      "zoledronic acid of about 100 ng-h/mL to about 2000 ng-h/\n",
      "mL to the mammal each time the zoledronic acid in the\n",
      "disodium salt form is administered.\n",
      "\n",
      "Embodiment 125\n",
      "\n",
      "[0434] The method of embodiment 123, wherein the zole-\n",
      "dronic acid 1n the disodium salt form is administered weekly,\n",
      "or 3 to 5 times in a month, in an amount that provides an area\n",
      "under the plasma concentration curve of zoledronic acid of\n",
      "about 20 ng-h/mL to about 700 ng-h/mL to the mammal each\n",
      "time the zoledronic acid in the disodium salt form is admin-\n",
      "istered.\n",
      "\n",
      "Embodiment 126\n",
      "\n",
      "[0435] The method of embodiment 123, wherein the zole-\n",
      "dronic acid in the disodium salt form is administered daily\n",
      "in an amount that provides an area under the plasma con-\n",
      "centration curve of zoledronic acid of about 4 ng-h/mL to\n",
      "about 100 ng-h/mL to the mammal each time the zoledronic\n",
      "acid in the disodium salt form is administered.\n",
      "\n",
      "Embodiment 127\n",
      "\n",
      "[0436] The method of embodiment 120, wherein the dos-\n",
      "age form is a solid.\n",
      "\n",
      "Embodiment 128\n",
      "\n",
      "[0437] The method of embodiment 120, 121, 122, 123,\n",
      "124, 125, 126, or 127, wherein the bioavailability of zole-\n",
      "dronic acid is improved by at least about 20% as compared\n",
      "to administration of zoledronic acid in the diacid form.\n",
      "\n",
      "Embodiment 129\n",
      "\n",
      "[0438] The method of embodiment 120, 121, 122, 123,\n",
      "124, 125, 126, 127, or 128, further comprising administer-\n",
      "ing, on a molar basis, less of the zoledronic acid in the\n",
      "disodium salt form than would be administered of zole-\n",
      "dronic acid in the diacid form in order to achieve the same\n",
      "plasma levels of zoledronic acid.\n",
      "\n",
      "Embodiment 130\n",
      "\n",
      "[0439] The method of embodiment 129, wherein at least\n",
      "about 10 mole % less of the disodium salt form is admin-\n",
      "istered as compared the amount of zoledronic acid in the\n",
      "diacid form that would be administered in order to achieve\n",
      "the same plasma levels of zoledronic acid.\n",
      "\n",
      "Embodiment 131\n",
      "\n",
      "[0440] The method of embodiment 129, wherein the diso-\n",
      "dium salt form is administered in an amount, on a molar\n",
      "basis, that has a value of about 0.8n,, to about 1.2n,,, wherein:\n",
      "\n",
      "ng-(b/ba)(Na)\n",
      "\n",
      "wherein b, is the bioavailability of the diacid form, b, is the\n",
      "bioavailability of the disodium salt form, and n, is the\n",
      "\n",
      "number of moles of zoledronic acid in the diacid form that\n",
      "would be administered in order to achieve the same plasma\n",
      "levels of zoledronic acid.\n",
      "\n",
      "Embodiment 132\n",
      "\n",
      "[0441] The method of embodiment 131, wherein the diso-\n",
      "dium salt is administered in an amount that has a value of\n",
      "about n_,.\n",
      "\n",
      "Embodiment 133\n",
      "\n",
      "[0442] The method of any of embodiments 120-132,\n",
      "wherein the zoledronic acid is used to treat an inflammatory\n",
      "condition.\n",
      "\n",
      "Embodiment 134\n",
      "\n",
      "[0443] The method of embodiment 133, wherein the zole-\n",
      "dronic acid is used to treat arthritis.\n",
      "\n",
      "Embodiment 135\n",
      "\n",
      "[0444] The method of embodiment 133, wherein the zole-\n",
      "dronic acid is used to treat complex regional pain syndrome.\n",
      "\n",
      "Embodiment 136\n",
      "\n",
      "[0445] The method of any of embodiments 1-39, 62-77,\n",
      "and 120-135, wherein:\n",
      "\n",
      "[0446] a first oral dosage form is administered; and\n",
      "[0447] a second oral dosage form is administered;\n",
      "[0448] wherein, with respect to the first oral dosage form,\n",
      "\n",
      "the second oral dosage form is administered at 10xT,,,. or\n",
      "greater, wherein T, 1s the time of maximum plasma\n",
      "concentration for the first oral dosage form.\n",
      "\n",
      "Embodiment 137\n",
      "\n",
      "[0449] A dosage form comprising zoledronic acid in the\n",
      "disodium salt form, wherein the bioavailability, in a mam-\n",
      "mal, of zoledronic acid in the disodium salt form is greater\n",
      "than the bioavailability of zoledronic acid in the diacid form\n",
      "would be in the same dosage form.\n",
      "\n",
      "Embodiment 138\n",
      "\n",
      "[0450] A dosage form comprising zoledronic acid in the\n",
      "disodium salt form, wherein the dosage form contains an\n",
      "amount of zoledronic acid in the disodium salt form that\n",
      "provides an area under the plasma concentration curve of\n",
      "zoledronic acid of about 4 ng-h/mL to about 2000 ng-h/mL\n",
      "to a human being to which the dosage form is administered.\n",
      "\n",
      "Embodiment 139\n",
      "\n",
      "[0451] The dosage form of embodiment 138, wherein the\n",
      "dosage form contains an amount of zoledronic acid in the\n",
      "disodium salt form that provides an area under the plasma\n",
      "concentration curve of zoledronic acid of about 100 ng-h/mL\n",
      "to about 2000 ng-h/mL to a human being to which the dosage\n",
      "form is administered.\n",
      "\n",
      "Embodiment 140\n",
      "\n",
      "[0452] The dosage form of embodiment 138, wherein the\n",
      "dosage form contains an amount of zoledronic acid in the\n",
      "disodium salt form that provides an area under the plasmathe zoledronic acid is administered does not eat food or drink\n",
      "beverage for at least 1 hour before the zoledronic acid is\n",
      "administered.\n",
      "\n",
      "Embodiment 158\n",
      "\n",
      "[0474] The method of embodiment 157, wherein the mam-\n",
      "mal or human being to which the zoledronic acid is admin-\n",
      "istered does not eat food or drink beverage for at least 2\n",
      "hours before the zoledronic acid is administered.\n",
      "\n",
      "Embodiment 159\n",
      "\n",
      "[0475] The method of embodiment 158, wherein the mam-\n",
      "mal or human being to which the zoledronic acid is admin-\n",
      "istered does not eat food or drink beverage for at least 4\n",
      "hours before the zoledronic acid is administered.\n",
      "\n",
      "Embodiment 160\n",
      "\n",
      "[0476] The method of embodiment 159, wherein the mam-\n",
      "mal or human being to which the zoledronic acid is admin-\n",
      "istered does not eat food or drink beverage for at least 6\n",
      "hours before the zoledronic acid is administered.\n",
      "\n",
      "Embodiment 161\n",
      "\n",
      "[0477] The method of any of embodiments 157-160,\n",
      "wherein the mammal or human being to which the zole-\n",
      "dronic acid is administered does not eat food or drink\n",
      "beverage for at least 30 minutes after the zoledronic acid is\n",
      "administered.\n",
      "\n",
      "Embodiment 162\n",
      "\n",
      "[0478] The method of embodiment 161, wherein the mam-\n",
      "mal or human being to which the zoledronic acid is admin-\n",
      "istered does not eat food or drink beverage for at least 1 hour\n",
      "after the zoledronic acid is administered.\n",
      "\n",
      "Embodiment 163\n",
      "\n",
      "[0479] The method of embodiment 161, where in the\n",
      "mammal or human being to which the zoledronic acid is\n",
      "administered does not eat food or drink beverage for at least\n",
      "2 hours after the zoledronic acid is administered.\n",
      "\n",
      "Embodiment 164\n",
      "\n",
      "[0480] The method, dosage form, or product, of any\n",
      "preceding embodiment, wherein the zoledronic acid in the\n",
      "oral dosage form has a 24 hour sustained plasma level factor\n",
      "of about 1 or higher.\n",
      "\n",
      "Embodiment 165\n",
      "\n",
      "[0481] The method, dosage form, or product, of any\n",
      "preceding embodiment, wherein the zoledronic acid in the\n",
      "oral dosage form has a 24 hour sustained plasma level factor\n",
      "that is higher than that of intravenously administered zole-\n",
      "dronic acid.\n",
      "\n",
      "Embodiment 166\n",
      "\n",
      "[0482] The method, dosage form, or product, of any\n",
      "preceding embodiment, wherein the oral dosage form is a\n",
      "solid that has a hardness of about 5 kPa to about 20 kPa.\n",
      "\n",
      "Embodiment 167\n",
      "\n",
      "[0483] A method of treating bone marrow lesions com-\n",
      "prising: selecting a patient having a bone marrow lesion and\n",
      "OARSI grade 0 of joint space narrowing, and administering\n",
      "an inhibitor of osteoclast activity to the patient for the\n",
      "treatment of the bone marrow lesion.\n",
      "\n",
      "Embodiment 168\n",
      "\n",
      "[0484] The method of embodiment 167, wherein the\n",
      "inhibitor of osteoclast activity is administered at least twice.\n",
      "\n",
      "Embodiment 169\n",
      "\n",
      "[0485] The method of embodiment 167, wherein the\n",
      "inhibitor of osteoclast activity is administered about every\n",
      "three months, or more frequently.\n",
      "\n",
      "Embodiment 170\n",
      "\n",
      "[0486] The method of embodiment 167, wherein the\n",
      "inhibitor of osteoclast activity comprises a nitrogen-contain-\n",
      "ing bisphosphonate.\n",
      "\n",
      "Embodiment 171\n",
      "\n",
      "[0487] The method of any one of embodiments 167-170,\n",
      "wherein the inhibitor of osteoclast activity is or comprises\n",
      "zoledronic acid.\n",
      "\n",
      "Embodiment 172\n",
      "\n",
      "[0488] The method of any one of embodiments 167-170,\n",
      "wherein the inhibitor of osteoclast activity is or comprises\n",
      "pamidronic acid.\n",
      "\n",
      "Embodiment 173\n",
      "\n",
      "[0489] The method of any one of embodiments 167-170,\n",
      "wherein the inhibitor of osteoclast activity is or comprises\n",
      "neridronic acid.\n",
      "\n",
      "Embodiment 174\n",
      "\n",
      "[0490] The method of any one of embodiments 167-170,\n",
      "wherein the inhibitor of osteoclast activity is or comprises\n",
      "olpadronic acid.\n",
      "\n",
      "Embodiment 175\n",
      "\n",
      "[0491] The method of any one of embodiments 167-170,\n",
      "wherein the inhibitor of osteoclast activity is or comprises\n",
      "alendronic acid.\n",
      "\n",
      "Embodiment 176\n",
      "\n",
      "[0492] The method of any one of embodiments 167-170,\n",
      "wherein the inhibitor of osteoclast activity is or comprises\n",
      "incadronic acid.\n",
      "\n",
      "Embodiment 177\n",
      "\n",
      "[0493] The method of any one of embodiments 167-170,\n",
      "wherein the inhibitor of osteoclast activity is or comprises\n",
      "ibandronic acid.Weight Bearing (%)Embodiment 249\n",
      "\n",
      "[0569] The method of embodiment 240, wherein the\n",
      "inhibitor of osteoclast activity is neridronic acid.\n",
      "\n",
      "Embodiment 250\n",
      "\n",
      "[0570] The method of embodiment 240, wherein the\n",
      "inhibitor of osteoclast activity is olpadronic acid.\n",
      "\n",
      "Embodiment 251\n",
      "\n",
      "[0571] The method of embodiment 240, wherein the\n",
      "inhibitor of osteoclast activity is alendronic acid.\n",
      "\n",
      "Embodiment 252\n",
      "\n",
      "[0572] The method of embodiment 240, wherein the\n",
      "inhibitor of osteoclast activity is incadronic acid.\n",
      "\n",
      "Embodiment 253\n",
      "\n",
      "[0573] The method of embodiment 240, wherein the\n",
      "inhibitor of osteoclast activity is ibandronic acid.\n",
      "\n",
      "Embodiment 254\n",
      "\n",
      "[0574] The method of embodiment 240, wherein the\n",
      "inhibitor of osteoclast activity is risedronic acid.\n",
      "\n",
      "Embodiment 255\n",
      "\n",
      "[0575] The method of embodiment 240, wherein the\n",
      "patient experiences a reduction in pain intensitywhen\n",
      "using a 100 mm visual analog scaleof at least about 5.\n",
      "\n",
      "Embodiment 256\n",
      "\n",
      "[0576] The method of embodiment 240, wherein the\n",
      "inhibitor of osteoclast activity is administered at least twice\n",
      "over a period of at least four weeks.\n",
      "\n",
      "Embodiment 257\n",
      "\n",
      "[0577] The method of embodiment 240, wherein the\n",
      "inhibitor of osteoclast activity is administered once weekly\n",
      "for a period of six weeks.\n",
      "\n",
      "Embodiment 258\n",
      "\n",
      "[0578] The method of embodiment 257, wherein the\n",
      "inhibitor of osteoclast activity comprises zoledronic acid,\n",
      "and the weekly dose is between about 25 mg and about 75\n",
      "mg.\n",
      "\n",
      "Embodiment 259\n",
      "\n",
      "[0579] A method of safely delivering zoledronic acid to\n",
      "the blood of a mammal through repeated oral administration\n",
      "comprising:\n",
      "\n",
      "[0580] orally administering about 0.4 mg/kg to about 4\n",
      "mg/kg of zoledronic acid to the mammal no more\n",
      "frequently than once a day and more frequently than\n",
      "once a week; or\n",
      "\n",
      "[0581] orally administering about 0.4 mg/kg to about 10\n",
      "mg/kg to the mammal once a week, or less frequently.\n",
      "\n",
      "Embodiment 260\n",
      "\n",
      "[0582] The method of any preceding embodiment, such as\n",
      "embodiment 259, wherein about 0.5 mg/kg to about 2 mg/kg\n",
      "is orally administered to the mammal daily.\n",
      "\n",
      "Embodiment 261\n",
      "\n",
      "[0583] The method of any preceding embodiment, such as\n",
      "embodiment 260, wherein about 0.6 mg/kg to about 0.9\n",
      "mg/kg is orally administered to the mammal daily.\n",
      "\n",
      "Embodiment 262\n",
      "\n",
      "[0584] The method of any preceding embodiment, such as\n",
      "embodiment 259, wherein about 0.5 mg/kg to about 2 mg/kg\n",
      "is orally administered to the mammal weekly.\n",
      "\n",
      "Embodiment 263\n",
      "\n",
      "[0585] The method of any preceding embodiment, such as\n",
      "embodiment 263, wherein about 0.6 mg/kg to about 0.9\n",
      "mg/kg is orally administered to the mammal weekly.\n",
      "\n",
      "Embodiment 264\n",
      "\n",
      "[0586] The method of any preceding embodiment, such as\n",
      "embodiment 259, 260, 261, 262, or 263, wherein zoledronic\n",
      "acid is orally administered about 3 to about 10 times.\n",
      "\n",
      "Embodiment 265\n",
      "\n",
      "[0587] The method of any preceding embodiment, such as\n",
      "embodiment 259, 260, 261, 262, 263, or 264, wherein\n",
      "zoledronic acid is orally administered in a dosage form\n",
      "comprising more than about 10% zoledronic acid by weight.\n",
      "\n",
      "Embodiment 266\n",
      "\n",
      "[0588] The method of any preceding embodiment, such as\n",
      "embodiment 259, 260, 261, 262, 263, 264, or 265, wherein\n",
      "zoledronic acid is administered in a manner and amount that\n",
      "results in the mammal having an AUC, _,, of zoledronic acid\n",
      "that is about 50 ng-h/mL to about 500 ng-h/mL with each\n",
      "administration of zoledronic acid.\n",
      "\n",
      "Embodiment 267\n",
      "\n",
      "[0589] The method of any preceding embodiment, such as\n",
      "embodiment 266, wherein zoledronic acid is administered in\n",
      "a manner and amount that results in the mammal having an\n",
      "AUC,.5, of zoledronic acid that is about 100 ng-h/mL to\n",
      "about 500 ng-h/mL with each administration of zoledronic\n",
      "acid.\n",
      "\n",
      "Embodiment 268\n",
      "\n",
      "[0590] A method of preparing an oral dosage form that is\n",
      "safe for repeated administration to a mammal comprising\n",
      "combining zoledronic acid with an excipient that is phar-\n",
      "maceutically acceptable to the mammal, wherein the amount\n",
      "of zoledronic acid that is combined with the excipient is such\n",
      "that zoledronic acid 1s present in the oral dosage form in an\n",
      "amount that is 0.4 mg/kg to about 10 mg/kg based upon the\n",
      "weight of the mammal.\n",
      "\n",
      "Embodiment 269\n",
      "\n",
      "[0591] The method of any preceding embodiment, such as\n",
      "embodiment 268, wherein the amount of zoledronic acida reduced molar amount of the disodium salt to be used as\n",
      "compared to what would be used with the diacid form.\n",
      "[0091] In some embodiments, oral administration of zole-\n",
      "dronic acid or another bisphosphonate may also be useful to\n",
      "treat hypercalcemia of malignancy, multiple myeloma, bone\n",
      "metastases from solid tumors, Pagets disease of bone, giant\n",
      "cell tumor of bone, blood cancers or leukemias, or solid\n",
      "tumors or cancers. In some embodiments, enhanced bio-\n",
      "availability of the zoledronic acid may be achieved in\n",
      "treating one of these conditions by administering a dosage\n",
      "form comprising zoledronic acid in the form of a disodium\n",
      "salt. This may allow a reduced molar amount of the diso-\n",
      "dium salt to be used as compared to what would be used with\n",
      "the diacid form.\n",
      "\n",
      "[0092] Some nitrogen-containing bisphosphonates may be\n",
      "represented by Formula A:\n",
      "\n",
      "Formula A\n",
      "RI R\n",
      "O O\n",
      "Sy\n",
      "\\ / on\n",
      "OH HO\n",
      "\n",
      "HO\n",
      "\n",
      "[0093] With respect to Formula A, R' is F, Cl, Br, H, or\n",
      "OH. In some embodiments, R* is OH.\n",
      "\n",
      "[0094] With respect to Formula A, R* is aminoalkyl, such\n",
      "as aminoethyl, aminopropyl, aminopentyl, dimethylamino-\n",
      "ethyl, methylpentylaminoethyl, etc; or optionally substituted\n",
      "heterocyclyl alkyl, such as optionally substituted imida-\n",
      "zolylmethyl, optionally substituted pyridinylmethyl, etc. In\n",
      "some embodiments R? is optionally substituted imidazoly-\n",
      "lalkyl.\n",
      "\n",
      "[0095] Unless otherwise indicated, when a compound or\n",
      "chemical structural feature such as heterocyclyl alkyl is\n",
      "referred to as being optionally substituted, it includes a\n",
      "feature that has no substituents G.e. unsubstituted), or a\n",
      "feature that is substituted, meaning that the feature has one\n",
      "or more substituents. The term substituent has the broadest\n",
      "meaning known to one of ordinary skill in the art, and\n",
      "includes a moiety that replaces one or more hydrogen atoms\n",
      "in a parent compound or structural feature. The term\n",
      "replaces is merely used herein for convenience, and does\n",
      "not require that the compound be formed by replacing one\n",
      "atom with another. In some embodiments, a substituent may\n",
      "be any ordinary organic moiety known in the art, which may\n",
      "have a molecular weight (e.g. the sum of the atomic masses\n",
      "of the atoms of the substituent) of 15 g/mol to 50 g/mol, 15\n",
      "g/mol to 100 g/mol, 15 g/mol to 150 g/mol, 15 g/mol to 200\n",
      "g/mol, 15 g/mol to 300 g/mol, or 15 g/mol to 500 g/mol. In\n",
      "some embodiments, a substituent comprises, or consists of:\n",
      "0-30, 0-20, 0-10, or O-5 carbon atoms; and 0-30, 0-20, 0-10,\n",
      "or 0-5 heteroatoms, wherein each heteroatom may indepen-\n",
      "dently be: N, O, P, S, Si, F, Cl, Br, or I; provided that the\n",
      "substituent includes one C, N, O, P, S, Si, F, Cl, Br, or atom.\n",
      "In some embodiments, substituents can independently have\n",
      "a molecular weight of about 15 Da to about 600 Da and can\n",
      "consist of 2 to 5 chemical elements, wherein the chemical\n",
      "elements are independently C, H, O, N, P, S, Si, F, Cl, or Br.\n",
      "In some embodiments, a substituent 1s optionally substituted\n",
      "alkyl, O-alkyl (e.g. OCH3, OC,H;, -OC,H,,\n",
      "OC,H,,  etc.), S-alkyl (e.g. SCH3, SC,H.,\n",
      "SC,H,, SC,Hp, etce.), NR'R\", OH, SH, CN,\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "CF,, NO., perfluoroalkyl, optionally substituted aryl,\n",
      "optionally substituted heteroaryl, optionally substituted\n",
      "amine or a halogen, wherein R' and R\" are independently H\n",
      "or optionally substituted alkyl. Wherever a substituent is\n",
      "described as optionally substituted, that substituent can be\n",
      "substituted with the above substituents.\n",
      "\n",
      "[0096] For convenience, the term molecular weight is\n",
      "used with respect to a moiety or part of a molecule to\n",
      "indicate the sum of the atomic masses of the atoms in the\n",
      "moiety or part of a molecule, even though it may not be a\n",
      "complete molecule.\n",
      "\n",
      "[0097] Examples of nitrogen-containing bisphosphonates\n",
      "include but are not limited to pamidronic acid, incadronic\n",
      "acid, ibandronic acid, risedronic acid, minodronic acid,\n",
      "cimadronic acid, neridronic acid, alendronic acid, olpad-\n",
      "ronic acid, zoledronic acid, etc.\n",
      "\n",
      "O\n",
      "\n",
      "\\ LOH\n",
      "a NH O\n",
      "HO xX |\n",
      "\n",
      "POH\n",
      "Ho \\, 08 DT\n",
      "UP PON\n",
      "Ho~ \\ / ~ouH\n",
      "O HO\n",
      "\n",
      "incadronic acid\n",
      "\n",
      "pamidronic acid\n",
      "\n",
      "HO OH\n",
      "\\\n",
      "P OH\n",
      "Y\n",
      "O HOP==O0O\n",
      "HO\n",
      "\n",
      " \n",
      "\n",
      "ibandronic acid\n",
      "\n",
      "O O\n",
      "\n",
      "i | A>\n",
      "OH\n",
      "HoT NN oe ~ wf W\n",
      "HN\n",
      "HO P=>0\n",
      "/\\\n",
      "HO OH\n",
      "\n",
      "cimadronic acid minodronic acid\n",
      "\n",
      "[0098] Zoledronic acid has the structure shown below, and\n",
      "is also referred to as zoledronate.\n",
      "\n",
      "OH\n",
      "Ox J\n",
      "ou\n",
      "\n",
      "lA\n",
      "\n",
      "HO OH\n",
      "N= eh\n",
      "\n",
      "OH\n",
      "\n",
      "Zoledronic acid\n"
     ]
    }
   ],
   "source": [
    "# Use pytesseract to extract text from images (scans) of documents\n",
    "text_array = []\n",
    "\n",
    "# Loop through all pages for a patent\n",
    "for image in glob.glob('sandbox/images/img_preprocessing/*.png'):\n",
    "    print('Reading from image', image[-6:-4])\n",
    "    text_array.append(pytesseract.image_to_string(Image.open(image)))\n",
    "\n",
    "# Convert array items to string\n",
    "text = ''.join(text_array)\n",
    "\n",
    "# Write to text file\n",
    "with open('sandbox/text/raw/patent.txt', 'w') as text_file:\n",
    "    text_file.write(text)\n",
    "\n",
    "print(text)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<hr>\n",
    "<br>\n",
    "\n",
    "<a id='section-5'></a>\n",
    "\n",
    "### - Text segmentation using RegEx"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
